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Abstract
The CD45 (leukocyte common) antigen is a haemopoietic cell specific tyrosine 
phosphatase essential for antigen receptor signalling in lymphocytes. Multiple isoforms 
of CD45 are expressed in a cell type and activation-specific manner, but the exact 
function of the different isoforms remains obscure. In humans, naive T cells express 
high molecular weight isoforms (containing CD45RA), but following activation switch 
to expression of low molecular weight (CD45R0 and CD45RB) isoforms. Human CD45 
variant alleles which alter CD45 isoform expression have been identified and associated 
with infectious and autoimmune diseases.
Two contrasting allelic variants have been analysed. The exon 4 77G allele is present at 
a low frequency in Caucasoids and prevents splicing from high to low molecular weight 
isoforms. An increased frequency of this allele is found in multiple sclerosis, HIV and 
Hepatitis C infected individuals. The exon 6 138G allele is found at a high frequency in 
Far Eastern populations and promotes splicing towards low molecular weight isoforms. 
This allele is protective in Graves’ disease and Hepatitis B infection. Both alleles are 
associated with altered phenotype and in vitro functional response of T cells. Similarly 
CD45 transgenic mice exhibit altered T cell phenotype and function. These data 
demonstrate that subtle changes in isoform expression lead to an alteration in cell 
phenotype and that both combinations of isoforms and the total level of expression are 
important for CD45 function.
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Outline of Thesis
The leukocyte common antigen, CD45 is a haemopoietic cell specific protein tyrosine
L
phosphatase, comprising up to 10% of the cell surface. CD45-deficient humans and 
mice are severely immunodeficient and it has been shown to be essential for efficient 
antigen receptor signalling in lymphocytes. Multiple isoforms of CD45 are expressed in 
a cell type and activation-specific manner. In humans, activation of naive T cells 
switches expression from high to low molecular weight isoforms. However, despite 
being tightly regulated the exact function of the different CD45 isoforms remains 
obscure.
The aim of this thesis is to investigate the function of the different CD45 isoforms, 
specifically focusing on how the expression of alternatively spliced isoforms affects the 
function of lymphocytes. We will utilise the existence of human CD45 variant alleles to 
determine the effects of altered isoform expression on T cell phenotype and function 
and investigate the mechanisms responsible for altered immune function.
This thesis is divided into eight chapters which are outlined as follows. Chapter one 
contains four sections, the first section being a brief overview of the human immune 
system with particular reference to the phenotype and function of naive and memory T 
cells. Section 1.2 provides an overview of the CD45 molecule, and our current 
understanding of its functional mechanisms. Section 1.3 focuses specifically on human 
CD45 polymorphisms and their disease associations, whilst section 1.4 outlines the 
detailed objectives of this study. The methods employed throughout this thesis are 
described in Chapter 2.
In Chapter 3, CD45 iso form expression on leukocytes and T cell phenotype is 
characterised in CD45 variant individuals. Functional responses, both proliferative 
responses and cytokine production of T cells from CD45 variant individuals to various 
stimuli are described in Chapter 4. Minigenes are used in Chapter 5 to analyse the 
molecular mechanisms responsible for altered isoform expression in 138G variant 
individuals. Chapter 6 briefly describes the CD45 isoform expression in HIV 
seropositive individuals with novel CD45 polymorphisms. A transgenic mouse model
15
has been created which approximates the abnormal CD45 splicing observed in humans 
with the C77G polymorphism. The T cell phenotype and function of these mice is 
described in Chapter 7. Finally the results of the whole investigation are brought 
together and discussed in Chapter 8 along with suggestions of areas for further study.
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CHAPTER 1
Introduction
1.1.0 The immune system
Our environment contains a large variety of infectious microbes including bacteria, 
viruses, fungi, protozoa and multi-cellular parasites. These can all cause infection, 
which if left uncontrolled may eventually kill the host. The body has therefore had to 
develop a defence system which is not only capable of fighting a variety of pathological 
invaders, but can distinguish these pathogens (referred to as non-self) from its own cells 
(self).
Micro-organisms exist in many different forms, requiring a wide variety of immune 
responses to deal with the various infections. As an exterior defence, skin epithelial 
cells provide a strong physical and chemical barrier to most organisms. However, many 
invaders gain access across the epethelia of the gastrointestinal or urogenital tracts, can 
infect the nasopharynx and lungs, or can even directly enter the blood. The site of 
infection and type of pathogen, whether it is intra- or extra-cellular, will largely 
determine which immune response will be effective.
1.1.1 The innate immune response
The first part of any immune response is the recognition of the pathogen. This is 
followed by a suitable reaction to eliminate it. Specificity and mechanism of response 
can be used to distinguish two different but interrelated types of immunity, that of the 
innate and adaptive immune systems. The innate system provides the first line of 
defence, a rapid but non-specific response to pathogens. These responses may be 
humoral, including the complement system, or cellular, such as NK cells and 
phagocytes (e.g. granulocytes, macrophages and dendritic cells).
17
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The innate system is able to recognise the pathogen as ‘foreign’ or ‘non-self. Cells of 
the innate system operate through germ-line encoded receptors called pattern 
recognition receptors (PRRs). These receptors recognise pathogen associated molecular 
patterns (PAMPS), conserved molecular structures shared by a variety of pathogens, 
which may include polysaccharides, proteins, lipids and nucleic acid motifs, such as 
bacterial CpG islands (Medzhitov and Janeway, 2000). A variety of innate receptors 
have been identified including the mannose receptor which recognizes structures on the 
surface of bacteria, yeasts and parasites, triggering phagocytosis and opsonisation and 
initiating inflammatory responses (Martinez-Pomares and Gordon, 1999b; Gordon, 
2002). Myeloid cells, including macrophages and dendritic cells, also express scavenger 
receptors, which recognise molecules such as lipoteichoic acid and LPS and facilitate 
the uptake and clearance of apoptotic cells.
Many cell types use a variety of Toll like receptors (TLRs) to recognise different 
features of bacterial and viral products. TLRs induce a range of defence mechanisms 
dependant upon the stimulus and receptor usage. There is a general induction of iNOS 
(inducible Nitric Oxide Synthase) and corresponding induction of Nitric Oxide (NO) 
which has antimicrobial properties. TLR signalling also induces the production of 
cytokines and co-stimulatory molecules including TNFa (Tumour necrosis factor a), 
which can activate macrophages, causing them to release defensins and facilitating the 
adaptive immune response.
The innate response is amplified through the release of various soluble factors, such as 
defensins, cytokines, chemokines and complement. The complement system is a group 
of about 20 serum proteins whose overall function is the control of inflammation. 
Activation of the complement cascade can result in; direct killing of micro-organisms, 
opsonization of target cells, activation of phagocytes and augmentation of antibody 
responses (Carroll, 1998).
NK cells, which can comprise up to 15% of peripheral blood lymphocytes, are an 
important link between the innate and adaptive immune responses. They have a role in 
controlling viral infections and tumours, by detecting cells expressing low or no MHC 
class 1, an evasion tactic employed by many viruses (Cerwenka and Lanier, 2001).
18
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Once activated they have direct cytolytic activity (using the same mechanisms as CD 8+ 
T cells) and release cytokines which selectively induce Thl T cell responses.
1.1.2 The adaptive immune response
The innate immune response provides a rapid, but non-specific response to pathogens. 
This is important, but limited, as it is not capable of recognising specific pathogen 
peptides and cannot generate immunological memory. However, activation of an innate 
response primes the adaptive immune response, which is capable of generating specific 
responses and can confer lifelong protection against previously encountered antigens.
Tissue resident and immature DCs are recruited to the site of an infection, where they 
take up and process antigen. They then mature and migrate to the lymphoid tissues, 
where they interact with both T cells and B cells. Some native antigen may also migrate 
through the lymphatic system to the lymph nodes, where it can be taken up by follicular 
DCs and presented to B cells. B cells recognise antigen via the B cell antigen receptor, 
the specificity of which is determined by recombination of germ line genes of the heavy 
and light chains during development. Some B cells will internalise the antigen and act 
as antigen presenting cells (APCs) for T cells. After activation and clonal expansion 
some B cells will differentiate into plasma cells and produce antibodies.
The specificity of the adaptive immune response is due to positive and negative 
selection events during T cell development, coupled with receptor rearrangement. This 
results in a variety of T cell clones, each characterised by a specific receptor. Activation 
of T cells requires two signals: One signal is provided by the antigen-MHC complex on 
the APCs, with the second signal provided by co-stimulatory molecules. Expansion of 
antigen specific T cell clones occurs after activation. Some of the cells from each clone 
will become effector cells, before dying by apoptosis, whilst others will become the 
memory cells which are responsible for secondary responses.
19
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1.1.3 Cells of the immune system
Leukocytes, the cellular components of the immune system, are derived from 
pluripotent haemopoietic stem cells in the bone marrow. These stem cells give rise to 
two lineages of cells in the blood via myeloid and lymphoid progenitors (Figure 1.1). 
Myeloid progenitors give rise to polymorphonuclear granulocytes (including basophils, 
neutrophils and eosinophils), erythroid progenitors and monocytes. Found in both blood 
and tissues, granulocytes are important in the phagocytosis of pathogens. Monocytes are 
found in the blood, but differentiate into macrophages in the tissues. These cells are 
important as both phagocytic cells and antigen presenting cells, displaying antigens to 
the adaptive immune response. Derived from both myeloid and lymphoid progenitors, 
dendritic cells are often referred to as professional antigen presenting cells. They are 
highly efficient in the uptake of antigen and presentation of it to cells of the adaptive 
immune system. Although also derived from the same haemopoietic stem cells, 
Erythrocyes (red blood cells) and platelets are not directly involved in the immune 
response, but platelets do have an important role in blood clotting and inflammation.
Lymphoid progenitors give rise to lymphocytes; T cells, B cells and NK cells. Unlike 
other lymphocytes, NK cells do not have antigen specific receptors. Lymphocytes fall 
into two major subgroups, T cells (thymus derived cells) and B cells.
B cells, named for their development in the Bursa of Fabricius in birds, mature in the 
foetal liver or bone marrow of humans. B cells migrate between the blood and lymphoid 
tissues and are responsible for mediating humoral responses. Activation of B cells 
through the B cell receptor (BCR) results in the generation of plasma cells, which 
produce antibodies (immunoglobulin molecules) that may inactivate bacteria by 
neutralisation, opsonisation or activating compliment. B cell receptors recognise native 
antigen, which can be protein or specific peptide, but may also be carbohydrates, lipids 
or synthetic molecules. T cell receptors are only capable of recognising specific 
antigenic peptides. Both B and T cells can form memory cells, which respond more 
efficiently on re-exposure to the same antigen.
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Figure 1.1 Schematic representation of the differentiation of cells of the immune system.
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T cells originate in the bone marrow, before migrating to the thymus where they 
develop and mature and differentiate into CD4+ and CD8+ T cells. During antigen 
recognition and activation, the CD4 extracellular domain binds the invariant part of the 
MHC class II molecules (Swain, 1983). The CD4 molecule can participate in signal 
transduction through the interaction of its cytoplasmic domain with the tyrosine kinase, 
Lck (Samelson et al., 1986; Hsi et al., 1989). The CD8 molecule also binds Lck, and so 
can also enhance TCR signalling, but the extracellular domain of CD8 binds to invariant 
parts of the of MHC class I molecules during activation.
Once mature, T cells circulate between the blood, lymphoid and non-lymphoid tissues 
and have a variety of functions. T cell subsets differ in both their phenotype and 
function. Upon activation, CD4+ T cells differentiate into Thl or Th2 cells depending 
upon their cellular environment. ThO cells are polarised to differentiate into Thl cells in 
the presence of IL12, IFNy or TGFp (transforming growth factor P) or Th2 cells in the 
presence of IL4. The selective production of Thl cells leads to cell mediated immunity, 
whilst production of predominantly Th2 cells provides humoral immunity.
Some Thl cells can act as mediators of inflammatory responses, releasing a range of 
cytokines, including IFNy and TNFp within an hour of stimulation. The release of IFNy 
has several effects, including the activation of macrophages, and inhibiting the 
polarisation of Th2 cells. Activated Thl cells can also up-regulate Fas-ligand 
expression, so are capable of directly triggering apoptosis of cells (Ju et al., 1994). Th2 
cells also release a range of cytokines, including IL-4, 5, 6, 9, 10 and 13. Via effects on 
APCs, IL-10 production inhibits Thl polarisation, providing a Th2 environment. Th2 
cells interact with B cells, helping them to divide, differentiate and make antibody 
(Mond et al., 1995).
Upon activation, naive CD8+ T cells can differentiate in to Tel or Tc2 cells. Tel cells, 
commonly referred to as cytolytic T cells (CTL) have direct cytolytic activity and 
release cytokines such as IL-2 and IFNy. Tc2 cells have a helper function similar to that 
of CD4+ T cells, and release cytokines such as IL-4, 5, 6 and 10 (Kelso et al., 1991; 
Seder et al., 1992). Both of these subsets become cytotoxic upon re-stimulation 
(Cerwenka et al., 1998). CTL are important mediators of cell cytotoxicity, killing cells
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infected with viruses or intracellular pathogens and tumour cells. These cells can 
directly kill the infected cells through a number of mechanisms, including the release of 
lytic granules into infected cells (such as perforin or granzyme) and the induction of Fas 
mediated apoptosis.
1.1.4 The T cell receptor
The structure of the TCR is highly conserved. It is a heterodimer of two transmembrane 
glycoproteins, either the a,p or y,5 chains (Figure 1.2). In humans, around 95% of 
peripheral T cells express the ocp TCR, whilst the remainder (1-10%) express the yd 
TCR. These cells differ in the way that they recognise antigen and are thought to have a 
role in the recognition of non-classical MHC molecules and heat shock proteins 
(Janeway et al., 1988; O'Brien et al., 1989; Moss et al., 1992).
The transmembrane glycoproteins of the TCR have an amino-terminal extracellular 
domain, containing variable and constant regions. They also have a short linker joining 
to the membrane spanning domain and a short cytoplasmic tail. The functional TCR 
complex which is expressed on the surface of cells is an association between these 
variant TCRap chains and the invariant TCR^ chain and CD3 (y,5 and s) chains. The 
TCR chains recognise the antigen, whilst the TCR<^  and CD3 subunits transduce the 
signal via immuno-receptor tyrosine-based motifs (ITAMS) in their cytoplasmic 
domains (Weiss and Littman, 1994).
The TCR chains only recognise specific peptides bound to self-MHC molecules. Each 
TCR chain comprises variable (V), diversity (D), joining (J) and constant (C) regions. 
Each of these regions is encoded by many genes, which can be rearranged during T cell 
development. This, along with the addition and removal of nucleotides during 
recombination, gives rise to a vast number of different apTCR combinations, 
generating the great diversity of TCR specificity.
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Figure 1.2 Schematic representation of the T cell receptor complex. The T-cell receptor complex 
is made up o f antigen-recognition proteins and invariant signalling proteins. The TCR a:P 
heterodimer recognises and binds peptide bound to MHC, but cannot signal to the cell directly. 
Signalling is carried out through the four CD3 signalling chains and the associated £ chains. Each 
CD3 chain has one ITAM (represented by the yellow segment), whilst each C, chain contains 3 
ITAMs.
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1.1.5 T cell development
T cell progenitors migrate from the bone marrow to the thymus, where they mature, 
undergoing TCR rearrangement and selection events (Figure 1.3). These precursor cells 
are HSA+, CD43+, CD44+, CD8 - and CD41ow (Michie et a l , 1998; Schwarzler et a l , 
2001). In the thymic cortex these precursors develop into triple negative cells with a 
CD3-, CD4-, CD8 - phenotype, but are also referred to as double negative cells due to 
their lack of CD4 and CD8 expression. At this stage the cells can be subdivided 
according to expression of CD25 and CD44 (Godfrey et a l, 1993). When the cells 
become CD25+ CD44-, rearrangement of the TCR p chain begins. It is expression of 
the pre TCR on the cell surface that leads to proliferation, a  chain rearrangement and 
the expression of CD4 and CD8  (von Boehmer et al., 1988). These are now double 
positive thymocytes, expressing both CD4 and CD8 , and account for 70-80% of all 
thymocytes.
T cells recognise peptide bound to self-MHC molecules, but must be able to do so 
without making response to self antigens. To establish such tolerance, thymocytes 
undergo positive and negative selection processes during development. Positive 
selection ensures that the TCR recognises self-MHC, only rescuing from apoptosis 
those cells which are capable of doing so. These successful cells will then lose 
expression of CD4 or CD8  and increase CD3 expression (Reinherz et a l, 1980; Roehm 
et a l, 1984; Lopez-Botet and Moretta, 1985; Saito and Watanabe, 1998). Some of these 
single positive cells may still bind self-peptides. Therefore the thymocytes are 
negatively selected, via Fas induced apopotosis (Goldrath and Bevan, 1999). Around 
95% of the double positive thymocytes die during development. The remaining 5% of 
cells are MHC restricted, self-tolerant, single positive cells, whose TCR has the 
appropriate affinity and avidity for peptide-MHC complexes. These cells can expand 
intrathymically to produce a repertoire of cells that will efficiently target foreign 
antigens without damaging the host. The T cells then leave the thymus, circulating 
between the blood and lymph tissues, until they encounter antigen in the lymph nodes.
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Figure 1.3 Schematic representation of the T cell development in the thymus. T cells progress through the triple negative stage, with varying 
expression o f CD25 and CD44. As the cells become CD25+ CD44-, TCR rearrangement begins, and is completed at the double positive stage, 
where the thymocytes express both CD4 and CD8. Cells which survive the negative and positive selection processes, become CD4+ or CD8+ T 
cells. Cells which are not successfully selected die by apoptosis.
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1.1.6 Activation of T cells.
After taking up antigen, changes in chemokine receptor expression cause DCs to 
migrate to the lymphoid tissues, including the lymph nodes, where they mature and can 
interact with circulating naive T cells.
During an infection, some of the cytokines and chemokines released by infected cells 
and APCs trigger the up-regulation of integrin molecules. Adhesion molecules, 
including integrins, initiate the interaction between an APC and T cell. CD2 and CD1 la 
(LFA-1) on T cells interact with LFA-3 and ICAM-1 on the APC, allowing subsequent 
contact between the TCR and MHC complex, and additional co-stimulatory molecules 
(Shaw and Dustin, 1997). The CD4 and CD8  co-receptors aid in this establishment of 
contact, as well as being required for initial T cell activation (Miceli et al., 1991).
The interaction between the TCR and MHC-peptide complex alone is not sufficient to 
activate T cells. Without additional co-stimulatory signals, the T cell will become 
anergic, becoming unresponsive and incapable of effector functions, such as IL-2 
production (Schwartz, 1990). For optimal stimulation of CD4+ and CD8 + T cell clones 
and isolated T cells, co-stimulation between CD28 on T cells and CD80 (B7.1) or CD8 6  
(B7.2) on APCs is required (Freeman et a l, 1989; Azuma et a l, 1993). This co­
stimulatory interaction also reduces the length of signalling required to commit the cell 
to proliferation. Both CD80 and CD8 6  interact with either CD28 which is constitutively 
expressed on T cells, or CTLA-4 which is expressed after activation. Interaction with 
CTLA-4 provides an inhibitory signal, and it is thought that it may have a role in 
switching off T cell proliferation once an infection is under control by preventing the 
positive CD28-CD80/86 interaction (Boussiotis et a l, 1996; Sperling and Bluestone, 
1996; Waterhouse et a l, 1996).
Signalling through CD40, which is expressed on most APCs, can upregulate 
CD80/CD86 expression (Caux et a l, 1994; Kiener et a l, 1995). CD40-CD40L 
engagement is essential for B cell growth, isotype switching and Ig-synthesis 
(Banchereau et a l, 1994). However, it can also lead to T cell activation, enhancing both 
Thl and Th2 type responses (van Essen et a l, 1995; Peng et a l, 1996). The interaction 
between CD40L on T cells and CD40 on DCs can result in an up-regulation of MHC
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and costimulatory molecule expression and cytokine production by the DCs. This can 
enable the DC to directly activate naive CD8 + T cells, in some circumstances 
overcoming the requirement for CD4+ T cell help (Lanzavecchia, 1998).
1.1.7 TCR signalling pathways
Binding of the TCR to the MHC-peptide complex mediates signalling (Figure 1.4) and 
can result in activation, anergy or apoptosis, depending on the state of T cell 
differentiation and the influence of co-receptors (Weiss, 1991; Miller and Morahan, 
1992; Cohen et al., 2002). The TCR/CD3 complex does not have intrinsic kinase 
activity, but when bound to antigen it interacts with various membrane-bound proteins 
including CD4, CD8 and the protein tyrosine phosphatase, CD45. Aggregation of the T 
cell receptor complex with the appropriate co-receptors aids activation, bringing Lck 
tyrosine kinases associated with the cytoplasmic domains of the co-receptors together 
with the ITAMs and other targets associated with the cytoplasmic domains of the TCR 
complex.
In naive T cells the CD3c chain is associated with p59fyn (a Src family kinase) whilst 
the constitutively phosphorylated £ chain is associated with ZAP-70 via its ITAMS 
(Wange et al., 1993; Weiss and Littman, 1994). Upon TCR stimulation £ chain ITAMS 
are phosphorylated by Lck and fyn, which are activated by CD45. The phosphorylated £ 
chain activates ZAP70, which in turn activates LAT (linker of activation in T cells) and 
SLP-76 (Wardenburg et al., 1996; Zhang et al., 1998). The phosphorylation of LAT 
leads to an association with several SH2 domain-containing proteins, including growth 
factor receptor-bound protein 2 (GRB2), phospholipase Cyl (PLCyl), IL2-inducible T- 
cell kinase (ITK) and the p85 subunit of the lipid kinase phosphatidylinositol 3 kinase 
(PI3K). GRB2 can then associate with RAS, triggering signalling though the MAP 
(Mitogen activated protein) kinase cascade. MAPs are serine or threonine kinases, 
which become sequentially activated by phosphorylation. After activation ERK 
translocates into the nucleus, where it activates the transcription of the immediate early 
genes involved in cell division and the IL-2 gene (Cantrell, 1996). LAT also
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Figure 1.4 Schematic diagram of CD4+ T cell activation (not drawn to scale). The interactions 
between the antigen presenting cell and T cell are shown with the associated signalling events which 
lead to the activation o f the T cell.
29
Chapter 1
constitutively associates with the adaptor GADS, through which it indirectly binds SLP- 
76.
SLP-76 is a T cell adaptor protein, which activates phopholipase Cy (PLCy) and 
guanine-nucleotide exchange factors (GEFs) which activate Vav and Grb2, components 
of the Ras pathway. PLCy, cleaves phosphatidyl -inositol-4,5-bisphosphate (PIP2) into 
inositol triphosphate (IP3) and diacylglycerol (DAG) (Nishibe et al., 1990). DAG then 
activates protein kinase C (PKC), which in turn activates MAP kinase, and the 
subsequent signalling events. DAG also binds IkB, an inhibitor of NFkB, allowing the 
active form to translate to the nucleus, initiating gene transcription. The release of IP3 
causes intracellular stores of calcium ions to be released. In addition to this a calcium 
specific ion channel is opened on the T cell membrane, allowing the influx of 
extracellular calcium ions. These calcium ions activate calcineurine, a calcium binding 
protein, which subsequently activates transcription factors including NF-AT. Activation 
of NF-AT allows it to translocate to the nucleus where it can promote IL-2 expression, 
leading to IL-2 production, proliferation and differentiation.
Co-stimulatory signals, such as those provided by CD28, are essential for T cell 
activation. Phosphinositol-3 kinase (PI3K) associates with the intracellular domain of 
CD28. PI3K phosphorylates PI-4,5 -P 2 (phosphoinositol 4, 5 -  bisphosphate) to produce 
PI- 3,4,5- P3 (phosphoinositol 3,4,5 -trisphosphate). This lipid and its metabolite PI-3,4- 
P2 bind the pleckstrin homology (PH) domains of the proteins. This either induces 
relocation of the proteins to defined areas of the plasma membrane where activation can 
occur, or, it induces conformational changes that allow for allosteric modifications of 
activity.
1.1.8 T cell memory
In the lymph node, naive T cells which encounter antigen and the appropriate co­
stimulatory molecules undergo clonal expansion, before leaving as effector cells. The 
majority of cells in each clone (95%) will be short lived, migrating to the site of 
infection and dying by apoptosis after fulfilling their function. The remaining 5% of the 
cells will contribute to the maintenance of the memory population that circulate between
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the blood and lymph nodes in a relatively resting state until they re-encounter the same 
antigen. Alterations in these three phases, expansion, contraction (death by apoptosis) 
and maintenance of memory cells, will determine whether T cell immunity is long or 
short lived (Ahmed and Gray, 1996). On re-exposure to antigen, cells of the memory 
population respond more efficiently, with a faster, stronger and more prolonged 
response (Veiga-Femandes et al, 2000). This enhanced response is due to a reduced 
detection threshold and decreased dependency on CD28 mediated co-stimulation in 
memory cells compared to naive cells (Fujii et al., 1992; London et al., 2000).
For B cells, memory and effector cells are generated using different pathways, with 
different signals driving memory or plasma cell formation (Klinman, 1998). However, 
for T cells the differentiation of memory cells is less clearly understood. It is also 
complicated by the different methods of phenotypically defining different populations 
of memory cells. The conventional model of memory T cell generation is through linear 
differentiation from naive to effector to memory cells (Farber, 1998). Complementary to 
this idea is the decreasing potential hypothesis, where after several rounds of division, 
activated cells lose their potential to become memory cells and are driven to either the 
effector state or apoptosis. An alternative model to this is that the effector and memory 
T cells differentiate through different pathways, as observed with B cells and some 
studies have suggested that memory cells may be directly derived from a subset of naive 
cells (Liu et al., 2001b).
The maintenance of immunological memory is also a matter for debate. The contentious 
issue is whether persistent antigen is necessary for the maintenance of memory. Whilst 
there is some data supporting the idea that it is not necessary (Murali-Krishna et al., 
1999; Swain et al., 1999) most experimental models cannot rule out the presence of 
some persistent antigen. Antigen may be retained on follicular DCs as antigen-antibody 
complexes for long periods of time, and persistent antigen has been observed in some 
viral infections, such as Hepatitis B and LCMV (Rehermann et al., 1996; Klenerman et 
al., 1997). Regardless of the requirement for persistant antigen, homeostasis within the 
memory population is maintained by a variety of factors, including the presence of 
certain cytokines, ensuring that the numbers and proportions of the different T cell 
populations remain constant and the immune system can function normally.
31
Chapter 1
1.1.9 Markers for T cell memory
Upon activation T cells change the expression of some cell surface markers, including 
molecules involved in adhesion, co-stimulation and migration, as well as cytokine 
expression patterns. These changes in expression are related to the properties of the 
naive, effector and memory cell populations, and are often used to define them. 
Monoclonal antibodies to the leukocyte common antigen, CD45 have been used to 
define naive and memory cells. CD45 is a tyrosine phosphatase that is essential for T 
cell receptor signalling. Alternative splicing of exons 4, 5 and 6  (also known as A, B 
and C) in the extracellular region of the CD45 molecule leads to the expression of 
different isoforms.
After mitogenic activation in vitro, human T cells were found to lose expression of the 
high molecular weight isoforms, containing exon A, so termed CD45RA, and gain the 
expression of the lower molecular weight isoforms, including the 180 kDa null isoform, 
CD45R0 (Akbar et a l , 1988). In an oversimplified manner these subsets have been used 
to define naive and memory cells, which do posses very different properties. As both 
naive and memory T cells express multiple CD45 isoforms, the terms CD45RA and 
CD45R0 will be used from now on to describe cells which predominantly express high 
molecular weight (CD45RA containing) isoforms, and those expressing predominantly 
low molecular weight isoforms (CD45R0 and CD45RB low).
In the CD4+ cells, the CD45RA+ T cells are small resting cells, which have long 
telomeres and rarely divide. These CD45RA cells have a more diverse T cell receptor 
repertoire, and respond to neo-antigens (Young et al., 1997). The CD45R0 cells show 
evidence of activation, have shorter telomeres and divide quite frequently (Michie et al., 
1992; Maini, 1999). Functional studies have also shown that both CD4+ and CD8+ 
CD45R0+ populations respond to recall antigens (Merkenschlager et al., 1988; 
Merkenschlager and Beverley, 1989).
However, whilst naive CD8 + cells express the high molecular weight CD45RA 
isoforms, the phenotype of memory or activated cells can be variable (Hamann et al., 
1997). It has been shown that following prolonged in vitro stimulation CD8 + cells can
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re-express CD45RA (Warren and Skipsey, 1991), and antigen specific CD8 + 
CD45RA+ memory cells have been identified in viral infections (Wills et al., 1999; 
Faint et al., 2001; Dunne et al., 2002). These antigen-experienced cells can still be 
distinguished from naive cells, by other phenotypic markers, such as CD1 la, CD27 and 
CCR7. Naive CD8 + CD45RA+ cells are predominantly CD27+ and CD28+ and loss of 
these molecules correlates with repeated stimulation, as is often seen during viral 
infections. However, there are also some antigen-experienced CD45RA+ cells which 
express CD27 and not CD28 (Appay et al., 2002; Wills et al., 2002). Whilst CD lla 
expression is low on naive cells, a population of CD8 + C45RA+ CD lla high cells has 
been observed which has properties of memory cells and increases with both age and 
systemic viral infections (Hoflich et al., 1998).
T cells with different effector functions can be defined by alterations in phenotype, 
characterised by expression patterns of a variety of activation markers and cytokines. 
Whilst CD45 expression is an extremely useful marker of activation status, to better 
define naive and memory populations, other markers also need to be used. The 
expression levels of adhesion molecules such as CD lla (LFA-1) and isoforms of CD44 
are increased on activated T cells. Expression of co-stimulatory molecules, CD27 and 
CD28, also vary, with CD28 increasing on activation, whilst CD27 is down regulated 
on chronic activation, and is known to correlate with effector function (De Jong et al., 
1992; Hintzen et al., 1993; Hendriks et al., 2000).
Two different populations of memory T cells, central and effector memory, have been 
further defined by expression of CCR7, a chemokine receptor involved in homing of 
cells to secondary lymphoid organs, and the cellular adhesion molecule, CD62L (or L- 
selectin) (Campbell et al., 2001). Effector T cells have reduced CCR7 and CD62L 
expression. This reduces their ability to home to lymph nodes, although they have 
increased capacity to migrate to inflamed tissues, due to an increase in expression of 
chemokine receptors such as CCR5 and CCR2. Within the CCR7- CD62L- effector 
population there is also an enriched CD27- population (Campbell et al., 2001). Central 
memory T cells express CCR7 and CD62L, and therefore preferentially circulate 
through the lymphoid tissues (Mackay, 1999; Sallusto et al., 1999). These cells do not 
have immediate effector function and only secrete IL-2, although they can differentiate 
into effector cells. Naive cells are defined by the expression of CD45RA and high
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expression of CCR7, CD27 and CD62L. The expression of many of the markers used to 
define cell populations are largely overlapping, so a better definition of nai've and 
memory cell phenotype would be desirable.
1.2.0 The Leukocyte Common Antigen (CD45).
First described in 1977, the leukocyte common antigen, CD45, is a transmembrane 
protein tyrosine phosphatase that is known to be essential for T cell signalling. Also 
referred to as T200, B220 or Ly-5, this high molecular weight glycoprotein is expressed 
on nucleated haemopoetic cells and can comprise up to 1 0 % of the cell surface 
(Alexander, 1997).
Both CD45-deficient humans and mice are severely immunodeficient (Kishihara et al., 
1993; Tchilian et al., 2001c). Thymocyte development is blocked in CD45-deficient 
mice, where an inability to positively select T-cells, leads to severely reduced numbers 
of peripheral T-cells (Byth et al., 1996). The block in antigen receptor signal 
transduction in CD45 deficient cells is believed to be due to dysregulation of the Src 
family of tyrosine kinases. Src family members have been shown to be both positively 
and negatively regulated by CD45 phosphatase activity (Thomas and Brown, 1999; 
Alexander, 2000; Penninger et al., 2001). Recent evidence also suggests that CD45 
phosphatase activity can regulate Janus kinases (JAK) (Irie-Sasaki et al., 2001). JAKs 
are involved in the activation of type I and type II cytokine receptors, which have a role 
in the differentiation, proliferation and anti-viral activity of haemopoetic cells
1.2.1 The structure of CD45
The gene encoding human CD45, the protein tyrosine phosphatase receptor-type C gene 
(PTPRC), is located on chromosome 1 (Iq31-lq32) (Alexander, 1997). There are 
several other genes of immunological interest close to this region of the chromosome 
(such as those encoding the Fc IgGl/IgG2A receptors). The PTPRC gene is thought to 
be around 120Kb and contains 34 exons. Although little is known about the regulation 
of the gene, the highly conserved first intron of the gene has been found to have strong
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promotor activity (Timon and Beverley, 2001). Exon 1, encodes a 5’ untranslated 
sequence, and is spliced into two alternatively used exons, la  and lb, with exon la 
preferentially expressed. There are three sites for the initiation of transcription, PI a, Plb 
and P2 (Saga et al., 1987; Hall et al., 1988).
CD45 is a type 1 transmembrane protein, containing a large extracellular domain of 
391-552 amino acids (Hall et a l, 1988). The amino terminal of this domain contains the 
variable exons 4, 5 and 6 . The CD45 molecule is highly glycosylated, mostly attributed 
to N-glycosylation on the extracellular domain and O-glycosylation of the variable 
exons. This glycosylation pattern is not only dependant upon the variable exon usage, 
but also on the developmental stage, cell type and activation state, suggesting it is 
functionally important. The extracellular region also contains a cysteine rich domain 
and three fibronectin type III domains. The fibronectin domains are important for the 
structural integrity of the molecule as they serve as a platform for N-linked 
carbohydrate groups. The 700 amino acid cytoplasmic tail, contains two phospho- 
tyrosine phosphatase domains, the first of which has enzyme activity, whilst the second 
is thought to be important for protein folding and substrate binding (Alexander, 1997). 
Molecular modelling also indicates that the juxtamembrane region may form a putative 
wedge (Bilwes et al., 1996). These structural features are outline in figure 1.5.
Homologues of CD45 have been recognised in a range of species including the chicken, 
the homed shark (Heterodontus francisci) (Okumura et al., 1996), the puffer fish (Fugu 
rubripes) (Diaz del Pozo et al., 2000) and various mammals (Okumura et al., 1996; 
Ballingall et al., 2001). Interestingly CD45 has recently been described in the Pacific 
Hagfish (Eptatretus stoutii) (Nagata et al., 2002). This would be consistent with the role 
CD45 in signalling through cytokine receptors, as the jawless vertebrates are believed to 
lack the adaptive immune system. The cytoplasmic domain of CD45 is highly 
conserved between species (Okumura et al., 1996) suggesting an essential function for 
CD45 through divergent evolution of the vertebrate immune system.
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Figure 1.5 Schematic diagram of the structure of CD45. CD45 exists as multiple isoforms due to 
alternative splicing. Figures shows the largest (CD45RABC) and smallest (CD45R0) isoforms (not 
drawn to scale). The variable exons have multiple O-glycosylation sites. The remaining part o f the 
extracellular domain consists o f a cysteine rich region followed by three fibronectin type III repeats, 
and is heavily N-glycosylated. The large cytoplasmic tail contains two phosphatase domains, D1 and 
D2, although only D1 has enzymatic activity. Molecular modelling data indicates that the 
juxtamembrane region may form a structural wedge. (Adapted from Hermiston et al., 2002).
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1.2.2 Alternative splicing of CD45 
Splicing mechanisms
Unlike bacterial genes, those of eukaryotic organisms contain introns, non-coding 
sequences that range from 80 to 10,000 nucleotides or greater. Removal of the introns is 
essential for correct translation of the gene. The exact intron sequence is not usually 
important and they often acquire mutations. The only conserved sequences in introns 
are those which are required for their removal, either at or near to the end of the intron; 
namely the 5’ splice site (donor site) and the 3’ splice site (acceptor site). These intron 
sequences are removed from the mRNA sequence, though a mechanism known as 
splicing.
Occurring in the nucleolus, RNA splicing is a two step process (outlined in figure 1.6). 
The first step is the cleavage of the 5’ donor site, which results in an exon with a 3’ end 
and an RNA lariat. The 5’ end of the intron forms a phosphodiester bond with the 2’- 
OH of an adenosine residue which is near to the 3’ acceptor site. The second step of the 
reaction is the release of the RNA lariat and ligation of the exons. The splicing process 
is carried out by the spliceosome, a multicomponent, ribonuclear protein complex. The 
spliceosome comprises of five small ribonucloprotein complexes (snRNPs) U l, U2, 
U4/U6 and U5 and approximately 50-100 non-snRNP splice factors (Kramer, 1996).
During the first step of the process the spliceosome is assembled. The Ul snRNP binds 
to the 5’ splice site, guided by a nucleotide sequence in the Ul RNA that forms 
complementary base pairs to the nine-nucleotide splice site consensus sequence. Branch 
point A is then recognised by the branch point binding protein (BBP), which is then 
replaced by U2. The U2 snRNP binding also requires an auxiliary factor, U2AF, which 
binds to polypyrimidine tracts near to the 3’ splice site by RNA recognition motifs 
(RRM) and arginine-serine-rich (RS)-domains. This complex then binds U4-U6-U5, 
bringing the exons together. U4 snRNP then dissociates from U6 . Ul becomes 
destabilised at the 5’ splice site, and is replaced by U6  as it forms a helix with U2, 
moving the branch point close to the 5’ splice site. The exon is then excised at the 5’ 
splice site by a transesterification reaction, and the intron forms a lariat, where the 5 ’ 
end interacts with an adenosine at the branch point. The free 3’-OH at the end of the 5’
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Figure 1.6 Schematic diagram of the RNA splicing mechanism. RNA splicing is catalysed by a 
spliceosome formed from the assembly o f U l, U2, U5 and U4/U6 snRNPs (depicted as green circles) 
and other molecules (not shown). After spliceosome assembly the reaction occurs in two steps, firstly, 
lariat formation and cleavage o f the 5 ’ splice site, and secondly 3 ’ splice site cleavage and ligation o f 
the exon sequence. The exon sequences are therefore jointed together and intron sequence is released 
as a lariat and will subsequently degrade.
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exon interacts with the U5 snRNP and is positioned close to the 3’ splice site. After 
some conformational changes, the second step of the splicing process results in the 
joining of the two exons. After ligation the spliceosome complex dissociates, the 
snRNPs detach from the lariat RNA which is degraded by RNAases. The components of 
the spliceosome can be re-used in further splicing reactions.
Alternative Splicing
Recent genomic analysis has shown that whilst eurokaryoytes have a large proteomic 
diversity, they only have a limited number of genes. The human genome only consists 
of 31,000 to 39,000 genes (Venter et al., 2001; Cartegni et al., 2002), but because a 
single primary RNA transcript can have several alternatively spliced regions, the 
combinatorial effects of splicing can be very pronounced, and genes that code for tens 
of different isoforms are common. This demonstrates the importance of post- 
transcriptional mechanisms of gene regulation, which contribute to the increased 
generation of protein diversity. One of the most significant mechanisms is through 
alternative splicing of mRNA precursors, producing different protein isoforms from a 
single primary transcript. An extreme example of this is the Drosophila Dscam gene. 
This gene encodes a cell surface protein involved in neuronal connectivity, and 
alternative splicing of its pre-mRNA can potentially generate 38,016 different protein 
isoforms, almost double the number of genes in the Drosophila genome (Schmucker et 
al., 2000; Graveley, 2001).
The mechanisms of splice site selection are closely connected in both constitutive and 
alternative splicing, as many of the components of the essential machinery for 
constitutive splicing also have a role in the regulation of alternative splicing. Compared 
to constitutive exons, alternative exons are often found to have suboptimal splice sites 
and / or length. Splicing of alternative exons can be modulated by trans-acting factors, 
which recognise an arrangement of positive (splicing enhancers) and / or negative 
(splice silencers) or cA-acting sequence elements (either exonic of intronic). Differences 
in the amounts or activities of a variety of splicing factors during development or in 
different tissues can cause differential patterns of splicing.
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Alternative splicing can occur as a result of a variety of factors, such as alternative 
promoter usage (Nabeshima et al., 1984), alternative poly(A) site usage (Early et al., 
1980) or transcriptional factors, such as the protein-recruiting and elongating properties 
of the transcription machinery. Some of the major trans-acting splice factors known to 
have a role in alternative splicing include the SR protein family, the polypyrimidine 
tract binding protein (PTB), and the CELF protein family. The CELF family of proteins 
(CUG-BP and ETR3-like factors) are involved in cell-specific and developmentally 
regulated alternative splicing in the striated muscle and brain. They promote the 
inclusion of exon 5 of the cardiac troponin-T gene (cTNT) by binding muscle specific 
enhancers. PTB, also known as hnRNP 1, is an RNA binding protein which recognises 
polypyrimidine tracts preceding the 3 ’ splice site. It has a role as a negative regulator of 
splicing, mainly by competing with U2AF in binding to the polyprimidine tract.
A group of highly conserved proteins, required for constitutive splicing, the SR family 
proteins, also have a role in alternative splicing. These proteins have a modular 
structure, consisting of an RNA-recognition motif (RRM) and a C-terminal domain, the 
RS domain, which is rich in alternating serine and arginine residues. RNA binding 
specificity is determined by the RRM’s, whilst the RS domain mediates protein-protein 
interactions. These interactions are thought to be necessary for the recruitment of the 
splicing apparatus and for splice site pairing (Wu and Maniatis, 1993; Tacke and 
Manley, 1999). The SR related protein (SRrps) are another class of RS domain 
containing proteins, which may contain RRM’s and are involved in splicing. These 
proteins include U1-70K and U2AF, as well as regulators of alternative splicing, such as 
Tra and Tra2. Both the SR family and SR-related proteins function by recognising 
exonic splicing enhancers (ESEs) and leading to the activation of suboptimal adjacent 3’ 
splice sites (Blencowe, 2000).
Around 15% of the mutations which cause genetic disease affect pre-mRNA splicing. 
Hereditary disease is frequently caused by mutations in no-coding regions, such as those 
affecting 5’ and 3’ splice sites, branch sites or polyadenylations signals (Krawczak et 
al., 1992). Analysis of 50 single base substitutions causing exon skipping in human 
genes (including missense, nonsense and translationally silent mutations) showed that at 
least one of the target motifs for the SR proteins SF2/ASF, SRp40, SRp55 and SC35, 
found in ESEs were disrupted (Liu et al., 2001a). This is interesting as it would suggest
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that one of the main causes of exon skipping is single base alterations in ESEs, the 
splicing enhancer sequences.
CD45 alternative splicing
Alternative splicing of exons 4, 5 and 6  (also referred to as exons A, B and C) at the N- 
terminus of the extracellular domain of CD45, could potentially generate 8 different 
isoforms (figure 1.7) although only 5 of these have been identified at the protein level in 
humans (Streuli et al., 1987). The highest molecular weight isoform, CD45RABC 
contains all three variable exons (4, 5 and 6 ). In the lowest molecular weight null 
isoform, CD45R0 all three exons have been spliced out (Penninger et al., 2001). In 
murine T cells and cell lines, there is some evidence that exons 7, 8  and 10 can also be 
alternatively spliced (Chang et al., 1991; Virts et al., 1998). So far this has only been 
demonstrated at the mRNA level and protein expression has not been established. A 
smaller CD45 isoform, CD45iota, has been described in murine Thl cells, which has 
exons, 4, 5, 6  and 7 spliced out (Tsujikawa et al., 2000). CD45iota mRNA has been 
found present in the foetal thymus and splenic T cells of mice and in murine Thl but not 
Th2 clones. The observed difference in the expression pattern of the CD45iota isoform 
could be a method of modulating the T helper cell activation threshold, selectively 
controlling lymphocytes and modulating cytokine signalling. However, this isoform has 
not been identified in humans so is very unlikely to have a role in human T cells.
The expression of CD45 isoforms is highly regulated and dependent upon the activation 
and differentiation states of haemopoietic cells (Akbar et al., 1988; Mackay, 1990; 
Novak et al., 1994). The cell surface expression pattern of the major isforms, in 
different cell types, in humans is outlined in figure 1.8. In some species, such as 
humans and mice, it has been used to distinguish between different functional subsets of 
lymphocytes. B cells express the high molecular weight (220kD) isoform CD45RABC 
(also called B220), whilst immature CD4+CD8+ T cells express mainly the low 
molecular weight isoforms. Mature CD4+ and CD8 + thymocytes and peripheral T cells 
can express multiple isoforms. Additionally, isoform expression may alter during T cell 
activation. Natural Killer (NK) cells are also known to express both the high and low 
molecular weight isoforms of CD45 (Mysliwski et al., 2001), although little is known
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Figure 1.7 Schematic representation of the CD45 alternatively spliced region and the eight 
possible mRNA transcripts generated by alternative splicing. Exons are represented as boxes and 
introns represented as lines (not to scale). The molecular weight o f the various proteins isoforms are 
given in kilodaltons.
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Figure 1.8 Cell surface Expression patterns of CD45 isoforms. Schematic representation, only 
predominant isoforms depicted. Less abundant isoforms are denoted in smaller font. Triangles 
represent increasing expression o f the protein during development o f T, B and myeloid cells and 
decreasing expression during erythroid differentiation, with the exception o f plasma cells, which have 
decreased total CD45 expression (adapted from Hermiston et al., 2002).
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about the function of CD45 in NK cell responses. However, the exact function of the 
different CD45 isoforms remains obscure. The variable exons are heavily O- 
glycosylated, and alternative splicing of this region appears to be a conserved feature of 
CD45 observed in a variety of species (Okumura et al., 1996). This could suggest that 
the length of the region and alterations in the glycosylation pattern may be important for 
the function of CD45 and its interaction with other molecules.
Several studies have begun to identify potential cis- and trans-acting factors which 
govern the alternative splicing of CD45. Many of these studies have focused on the ex­
acting elements for tissue specific alternative splicing. Minigene experiments and linker 
scanning analysis has shown that sequences both within and flanking exons 4 and 6  are 
essential for cell type specific splicing. Whilst exons 4, 5, and 6  are all variably spliced, 
it is only the inclusion of exons 4 and 6  which are tightly regulated. These same 
regulatory elements have also been shown to control the isoform switching that occurs 
during T cell activation (Streuli and Saito, 1989; Lynch and Weiss, 2001).
During T cell activation, the protein expression of the larger CD45RA containing 
isoforms is transiently increased. This increase, reflecting alterations in the mRNA 
levels, is observed during the first day, and then decreases as it is replaced by 
expression of the small CD45R0 isoform over the next 3 days. During the first four 
hours post activation the expression of mRNA for the larger CD45RA containing 
isoforms is increased. This then rapidly decreases, disappearing by 24 hours, as mRNA 
for the CD45R0 isoform increases. Studies using minigenes in a model T cell system 
have also shown that the activation of PKC, Ras and de novo protein synthesis is also 
essential for this switch in isoform expression (Birkeland et al., 1989; Deans et al., 
1989; Lynch and Weiss, 2000).
Tissue specific splicing of different CD45 iso forms is thought to be controlled by both 
positively and negatively regulatory trans-acting factors which allow the exons to be 
spliced out (Rothstein et al., 1991 1994; Trowbridge and Thomas, 1994). One candidate 
for mediating tissue-specific splicing of CD45 is the SR proteins previously mentioned. 
These are regulated by phosphorylation and expressed in a tissue specific manner. In 
model systems expressing CD45 minigenes and over expressing various SR proteins, it 
has been shown that SRp20 and 9G8 can facilitate exon inclusion, whilst SF2/ASF,
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SC35, SRp30c, SRp40 and SRp70 promote exon exclusion (Sarkissian et a l, 1996; 
Lemaire et al., 1999; ten Dam et al., 2000).
1.2.3 Role of CD45 in development and signalling
Initial studies using CD45-deficient cell lines identified CD45 as an obligate positive 
regulator of antigen receptor signalling (Pingel and Thomas, 1989; Koretzky et al., 
1990; Hovis et al., 1993; Volarevic et al., 1993; Desai et al., 1994). It was subsequently 
observed that both CD45-deficient humans and mice are severely immunodeficient 
(Kishihara et a l, 1993; Byth et al, 1996; Mee et al., 1999; Kung et al., 2000; Tchilian 
et al., 2001c). CD45-deficient mice have been made by several different groups, by 
targeting exons 6 , 9 or 12. All of these mice have profound defects in thymic 
development, due to increased apoptosis and dysfunctional signalling through both the 
pre-TCR and TCR complexes. These mice were found to have reduced numbers of both 
single and double positive thymocytes. Despite proceeding normally until the final stage 
in development, B cell maturation is also affected in CD45-/- mice. There is a two-fold 
increase in the total number of B cells, but there are decreased numbers of mature (IgM 
low, IgD high) cells in both the spleen and periphery; the remaining cells are mainly 
immature IgM high, IgD low cells in the spleen (Kishihara et al., 1993; Benatar et al., 
1996; Byth et al., 1996). CD45 is an essential modulator of signalling threshold in B 
cells. Although the function of CD45 is less well defined in B cells, it is thought to be 
similar for BCR signalling as TCR signalling, regulating phosphorylation of Src family 
kinases.
One of the earliest events in TCR signalling is initiated by Lck and Fyn, which are both 
Src family kinases (SFK). P56Lck is constitutively associated with the co-receptor 
molecules, CD4 and CD8 . Upon receptor clustering, p59fyn associates with the 
cytoplasmic domains of the C, and CD3e chains. Therefore antigen recognition allows 
both Fyn and Lck to phosphorylate specific ITAMS on the accessory chains of the TCR 
complex. The enzyme activity of the SFKs is regulated by phosphorylation of the 
regulatory tyrosine residues at amino acids 394 and 505 in the kinase domain and 
carboxy-terminal region. Phosphorylation of tyrosine 394 in the kinase domain is
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activatory, whilst that of tyrosine 505 in the carboxy-terminal domain is inhibitory. 
Upon antigen-specific activation, the inhibitory tyrosine (505) is dephosphorylated, 
allowing autophosphorylation of the activatory tyrosine (394), and restoring catalytic 
activity.
However, even after phosphorylation of the activatory tyrosine the SFKs can still be 
kept inactive by Csk (C-terminal SRC kinase), a protein tyrosine kinase. In resting cells, 
Csk activity is constitutive, so the Src proteins are usually inactive. CD45 counteracts 
this effect as it can remove phosphates from phosphotyrosine, particularly from the 
inhibitory tyrosine reside of SFKs. Signalling activity of the SFKs in response to 
receptor aggregation is therefore determined by the balance between Csk, which 
prevents their activation, and CD45 which restores their potential to be activated.
This idea is supported by the fact that in most CD45-deficient cell lines and CD45-/- 
thymocytes, both lyn and fyn are hyperphosphorylated at their negative regulatory 
tyrosine, and the TCR is completely uncoupled from intracellular signals. In addition to 
this it has been demonstrated that thymic development can be rescued in CD45-/- mice 
by expression of a constructively active Lck Y505F mutant. This shows that this 
negatively regulatory tyrosine is a physiologically relevant substrate for CD45 (Pingel 
and Thomas, 1989; Koretzky et al., 1990; Cahir McFarland et a l, 1993; Sieh et al., 
1993; Stone et al., 1997; Pingel et al., 1999; Seavitt et al., 1999). However, it has also 
been observed that despite hyperphosphorylation of the negatively regulatory tyrosine, 
cellular SFK activity is actually increased in CD45-/- thymocytes and some CD45 
deficient cells lines (Biffen et al., 1994; Ashwell and D'Oro, 1999; D'Oro and Ashwell, 
1999). This is thought to be due to an increased phosphorylation of the autocatalytic site 
in these cells, suggesting that this autocatalytic activatory tyrosine could also function 
as a CD45 substrate.
Therefore, CD45 can modulate the signal transduction thresholds by functioning not 
only as a positive, but also as a negative regulator of SFKs. It is plausible that the use of 
different regulatory mechanisms is cell state dependant, corresponding with 
accessibility of substrate. In resting T cells, CD45 dephosphorylates the negative 
regulatory tyrosine and to some extent the autocatalytic activatory tyrosine, resulting in 
signal competent Lck. TCR clustering during antigen recognition may functionally
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segregate CD45 from its substrate by exclusion from lipid rafts and the immunological 
synapse. This will lead to sustained Lck activity whilst the signal transduction cascades 
are being initiated (Dustin, 2002).
In T cells p59fyn is associated with the T cell receptor. It has two isoforms, p59fynT 
and p59fynB, generated by alternative splicing of one exon. The p59fynT isoform is 
present in lymphocytes. As with Lck, fyn has two tyrosine phosphorylation sites, which 
are regulated in a similar manner. CD45 dephosphorylates the negative regulatory 
residue (position 528). Subsequent autophosphorylation of the tyrosine residue (417) 
located within the catalytic domain results in PTK activity (Cooke and Perlmutter, 
1989; Koch et al., 1991; Shiroo et al., 1992).
More recently it has been suggested that CD45 may also have a role in negatively 
regulating cytokine and interferon receptor activation by dephosphorylating Janus 
Kinases (JAKs) (Irie-Sasaki et al., 2001; Penninger et al., 2001; Yamada et al., 2002). 
JAKs are positive regulators of cytokine signalling, which function by phosphorylating 
the signal transducers and activators of transcription (STATs) family of transcription 
factors. Phosphorylated STATs translocate to the nucleus where they regulate the 
expression of genes involved in chemokine and cytokine responses.
It is not clear if different CD45 isoforms have equal roles in the regulation of T cell 
signalling. In vitro, different CD45 isoforms have been shown to have the same 
phosphatase activity and the cytoplasmic tail is sufficient to restore TCR signalling 
(Trowbridge, 1991; Hovis et al., 1993; Volarevic et al., 1993; Desai et a l, 1994). But, 
further studies with CD45-deficient cell lines or transgenic mice expressing single 
CD45 isoforms on a knockout background have yielded inconsistent results, with the 
expression of different isoforms having different effects on signalling. (Chui et al., 
1994; Novak et al., ; Leitenberg et al., 1996; Onodera et a l, 1996; Kozieradzki et al., 
1997; Doman et al., 2002). The interpretation of these data is difficult, as isoform 
expression equivalent to physiological levels has not been attained in many studies, 
meaning that the effects of isoform expression are obscured by the effects of altered 
total CD45 expression.
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1.2.4 Mechanisms for CD45 regulation
CD45 has an essential role in T and B cell signalling, so to fully understand the 
regulation of the immune response it is also necessary to understand the regulation of 
this highly conserved molecule. Several methods of regulation have been proposed 
including, ligand binding, dimerisation, localisation (both in membrane structures and 
accessibility to substrates), interactions with other protein and the action of intracellular 
inhibitors. It is likely that many if not all of these factors have some role in CD45 
regulation.
The extracellular domain of CD45 has an overall rod like structure, which projects from 
the cell, but can also bend and fold laterally. This structure allows the possibility, of 
both cis and trans, ligand interactions. The first possible ligand to be suggested for 
CD45 was the B cell activation and differentiation marker CD22 (Stamenkovic et al, 
1991). It has subsequently been demonstrated that the lectin CD22, interacts with a 
variety of glycoproteins with N-linked sialic acids, and is therefore not CD45 specific 
(Sgroi et al., 1993).
Two low molecular weight isoforms of CD45 have been shown to interact in a 
carbohydrate-dependant manner with the cysteine rich domain of the mannose receptor 
(Martinez-Pomares et al., 1999). It has further been proposed that the soluble form of 
the mannose receptor can interact with CD45 and other ligands present in the secondary 
lymphoid organs. This may suggest a role for CD45 in mediating the delivery of antigen 
to follicular areas (Martinez-Pomares and Gordon, 1999a). The serum mannose binding 
protein (S-MBP) has been found to bind to CD45R0 on immature thymocytes with the 
CD4+CD8+CD3low phenotype. Ligands for S-MBP decrease on thymocyte maturation, 
suggesting that the oligosaccharide portion of CD45 on immature thymocytes may be 
associated with maturation, development or selection events (Uemura et al., 1996).
Another lectin that has been proposed to bind with CD45 is galectin-1 (Perillo et al., 
1995; Walzel et al., 1999; Symons et al., 2000). Galectin-1, expressed by stromal cells 
in the thymus and lymph nodes, is specific for p-galactosides, and may be involved in 
the regulation of apoptosis during T cell development and maturation. Galectin-1 and
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galectin-3 can associate with the T-cell antigen receptor complex and co-receptor 
molecules, modulating TCR mediated signalling. As galectin is involvedin the 
organisation of cell surface glycoproteins, it has been speculated that the function of 
CD45 may be regulated by the interaction of CD45 isoforms with a galectin lattice on 
the cell surface (Demetriou et al., 2001).
Most of the ligands investigated so far have been shown to bind non-specifically to T 
cell glycoproteins, and there is little evidence that they can actually modulate CD45 
phosphatase activity. The extracellular domain of CD45 may participate in cis 
interactions with molecules on the surface of the same cell. Various CD45 isoforms 
have been shown to interact with different molecules, including Thyl, CD2, LFA1, 
CD4 and the TCR complex (Novak et al., 1994). Such interactions may alter access to 
substrate or phosphatase activity. As CD45 is one of the most abundant cell surface 
proteins it is possible that these molecules are associated by random cross-linking, and 
expression of multiple isoforms on single cell types makes any associations hard to 
establish. One interaction which has been established is between CD45 and the 
lymphocyte phosphatase-associated protein (LPAP) although the exact function of this 
molecule is not clearly understood (Volarevic et al., 1993; Bruyns et al., 1995). Co­
capping and co-immunoprecipitation experiments and FRET analysis have all shown a 
preferential association between CD45R0 and CD4/CD8 and the TCR (Dianzani et al., 
1990; Leitenberg et al., 1996; Leitenberg et al., 1999; Doman et al., 2002). This may 
account for the more efficient TCR signalling observed in CD45R0+ cells.
The description of homodimeric forms of CD45 has led to the suggestion that 
homodimerisation of CD45 may lead to inhibition of its tyrosine phosphatase activity 
(Takeda et al., 1992; Majeti et al., 2000; Xu and Weiss, 2002). Thus, Xu and Weiss 
(2002) proposed a model of CD45 regulation where monomeric and dimeric isoforms 
exist in equilibrium on the cell surface. This equilibrium determines the overall CD45 
activity of the cell, which is regulated by isoform expression. CD45R0 readily forms 
homodimers as it does not have the negative charges and bulky O-linked 
glycoconjugates of the CD45RA iso form, and these homodimers can down regulate 
TCR activity. In addition to isoform switching, during cell lineage differentiation and 
lymphocyte activation, total CD45 expression can be up-regulated. This increased 
expression may alter the monomer / homodimer equilibrium, so may also have a role in
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facilitating dimerisation. However, whilst plausible, dimerisation cannot be the only 
mechanism of regulation, as it does not explain how memory cells expressing CD45R0 
can respond more rapidly than naive CD45RA cells in the primary response.
The localisation of the CD45 molecule with respect to lipid rafts and the immunological 
synapse is an area of some debate. In unstimulated Jurkat cells CD45 is absent from 
membrane lipid rafts. Engagement of the TCR promotes lipid raft aggregation, which 
subsequently promotes the localisation of raft associated proteins, the TCR complex, 
Lck and LAT, but excludes CD45 (Rodgers and Rose, 1996; Xavier and Seed, 1999). 
However other studies using human leukaemia cell lines and mouse thymocytes have 
shown some association of CD45 with parts of the lipid raft (Parolini et a l, 1996; 
Ilangumaran et al., 1999). This discrepancy may be due to differences in the techniques 
used and definition of raft structure. Irles et al., (2003) have further described a role for 
the CD45 ectodomain in the control of Lck activity through its interaction with 
glycosphingolipid-enriched membranes (GEMs). The association of CD45 to the 
immunological symapse (IS) / supramolecular activation cluster (SMAC) is also of 
some debate. The CD45 molecule is large compared to the other molecules involved in 
antigen-specific recognition, and therefore would be predicted to be excluded from the 
IS/SMAC on the basis of size. Whilst some studies support this notion, others have 
shown the presence of CD45 at the site of TCR-APC interaction or at least an ability to 
migrate back into the IS/SMAC, but to a distinct region from that of the TCR (Shaw and 
Dustin, 1997; Sperling et a l, 1998; Johnson et al., 2000; Leupin et al., 2000; Freiberg et 
al., 2002). Again this discrepancy is probably due to different techniques and cells lines 
used, but is an interesting area for further study.
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1.3.0 CD45 Polymorphisms and disease association
1.3.1 CD45 and disease
Abnormal CD45 expression has been associated with a number of diseases. A 
homozygous 6 base pair deletion in exon 11 of CD45, observed in a Kurdish infant, 
resulted in a lack of surface CD45 expression and severe combined immunodeficiency 
(SCLD) (Tchilian et al., 2001c). Lack of CD45 surface expression has been linked to 
two separate genetic abnormalities in another SCID patient (Kung et al., 2000). This 
shows that CD45 has an important immune function in humans, and that lack of CD45 
expression can be a cause of SCID. Similarly a variety of mouse models have been 
described which suggest that modulation of CD45 may affect autoimmunity, cancer and 
transplantation (Penninger et al., 2001), making it a strong potential candidate for 
immunotherapy (Basadonna et al., 1998).
Because of the correlation between isoform expression and activation state of T cells, a 
number of studies have investigated alterations in isoform expression during disease. 
Associations have been reported in a number of diseases, including SLE (systemic lupus 
erythematosus), rheumatoid arthritis and HIV (Penninger et al., 2001). Alterations in 
CD45 function have also been implicated in hematologic malignancies and Alzheimer’s 
disease. In a transgenic mouse model of Alzheimer’s disease, modulation of CD45 
isoforms can activate microglia. Additionally in Alzheimer’s patients, CD45 expression 
was found to be up-regulated on microglial cells and cross-linking CD45 suppressed 
CD40 ligand-induced and p-amyloid peptide-induced microglia activation. However, 
whether this increased CD45 expression represents a cause or effect of the disease 
remains unclear (Basadonna et al., 1998; Tan et al., 2000a; Tan et al., 2000b; Penninger 
et al., 2001). Some studies of SLE patients have shown decreased CD45 expression and 
/ or phosphatase activity, suggesting that alteration of CD45 activity may have a role in 
autoimmune disease. It is plausible that altering the balance between positive and 
negative regulation of tyrosine phosphorylation could contribute to the development of 
autoimmune disease. However, it is also possible that the observed CD45 down- 
regulation is an effect of the disease or of the immune system’s attempt to control it 
(Takeuchi et al., 1997; Blasini et al., 1998a; Blasini et al., 1998b).
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The exact function of each of the CD45 isoforms remains elusive, but expression of the 
different isoforms is known to alter TCR-mediated signal transduction (Leitenberg et 
al., 1999). Previously in studies with transgenic mice the expression of only the high 
molecular weight isoform has been shown to compromise immune function 
(Kozieradzki et al., 1997). These mice could not generate cytotoxic T cell responses or 
neutralising antibodies after a viral infection. However, the transgene in these mice was 
under the control of an Lck promoter, which confers thymic specific expression. This 
resulted in a 10 fold difference in the expression of both the CD45RABC and CD45R0 
isoforms in the periphery, so no conclusions could be made regarding cells in the 
peripheral lymph nodes. However more recent studies with transgenic mice expressing 
single CD45 isoforms (discussed further in Chapter 7), have shown that expression of 
either high or low molecular weight isoforms can restore immune function, but it is the 
level of expression which is important (Ogilvy et al., 2003; Tchilian et al., 2004). The 
role of CD45 in the dephosphorylation of the Janus Kinases also indicates a function for 
CD45 in the control of cell proliferation, differentiation and cytokine mediated anti-viral 
activities. The regulation of cytokine signalling in particular may be an important factor 
in disease.
1.3.2 The C77G polymorphism
Abnormalities in the splicing of CD45 have been recognised in humans. In 1990 
Schwinzer and Wonigeit described a group of healthy individuals with variant CD45 
expression. T cells from these individuals constitutively express CD45RA, failing to 
switch to single CD45R0 expression even after mitogenic stimulation. This splice defect 
was later identified as being caused by a single point mutation in exon 4 (also known as 
exon A) of the PTPRC gene. This Cytosine to Guanine transversion mutation at 
nucleotide position 77 of exon 4 (C77G) has been shown to prevent N-terminal splicing 
of the gene (Thude et al., 1995; Tchilian et al., 2001b). The C77G mutation does not 
change the amino acid sequence, but disrupts a strong exonic silencer, preventing 
splicing (Thude et al., 1995; Zilch et al., 1998; Lynch and Weiss, 2001). In C77G 
heterozygous individuals, activated or memory lymphocytes express both the high and
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low molecular weight isoforms, rather than only low molecular weight isoforms, which 
are normally observed.
The frequency of the C77G polymorphism amongst the healthy population is variable 
but usually low (Table 1.1). In the UK, the frequency of the allele was found to be
0.85%, as opposed to 0.16% in Germany and Italy, whilst in North America and 
Sweden the frequencies were found to be 1.4 and 1.8% respectively. The polymorphism 
was found to be absent in African populations, whilst in central Asians, it was similar to 
that in Northern Europeans (Table 1.1). The highest frequency of the C77G 
polymorphism (6.7%) was found in the Pamiris, a highly endogamous population, who 
live in the remote mountain valleys of Gomo Badakshan (Tajikistan) (Tchilian and 
Beverley, 2002) The C77G polymorphism was found to be extremely rare or absent 
from the Japanese population (Stanton et a l , 2003). The reason for this frequency 
variation between different populations is unclear, but further analysis may reveal more 
about the role of the mutation, giving an indication of the selective pressures that may 
be involved in its distribution. Alternatively the variant may have originated in Europe 
and spread by subsequent migration to Asia (Wells et a l, 2001).
1.3.3 C77G and disease association
Three different case control studies in Germany (Jacobsen et a l, 2000) and one in Italy 
(Ballerini et al, 2002) have suggested an association of the C77G with multiple 
sclerosis. However, similar studies in the US, Sweden,(Vorechovsky et a l, 2001) Italy 
and another in Germany (Miterski et al, 2002) failed to show any association. An 
increased frequency of the variant C77G allele has been reported in HIV-1 positive 
individuals in the UK (Tchilian et a l, 2001a). Two patients with abnormal CD45 
splicing and displaying the variant C77G allele, have been described with 
haemophagocytic lymphohistiocytsis and erythrocytic hemophagocytosis (HLH 
syndrome) (McCormick et al, 2001). Three C77G variant individuals have been 
described with LCH (Langerhans cell histiocytosis), a rare disease which can be 
invoked by environmental triggers, such as viral infections (Willman et a l, 1994; 
Boxall et a l, 2004). A patient with common variable immunodeficiency (CVID) and a 
history of prolonged excretion of poliovirus has also been found to have the variant
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Polymorphism Population Allele
Frequency
%
Reference
Exon 4 C77G UK (236,181) 0.85-1.1 (Tchilian et al. 2002; Stanton et al. 2003)
Orkney(72) 3.5 (Stanton et al. 2003)
Sweden (1044) 1.4 (Vorechovsky et al. 2001)
Germany (303, 377) 0-1.4 (Jacobsen et al.2000; Miterski et al.2002)
Italy (222, 529) 0-0.9 (Ballerini et al. 2002; Gomez-Lira et al.2003)
Central Asia (279, 139) 1.6-2.1 (Tchilian et al.2002; Stanton et al. 2003)
Pamiris (75) 6.7 (Tchilian et al. 2002)
South East Asia (143) 0.0 (Tchilian et al. 2002)
Japan (175) 0.0 (Stanton et al. 2003)
Korea (48) 0.0 (Stanton et al. 2003)
USA (244) 1.8 (Barcellos et al. 2001)
Uganda (93,209) 0.0 (Tchilian et al.2002; Stanton et al. 2003)
Exon 4 A54G Uganda (109) 0.45 (Stanton et al. 2004)
UK & Orkney (181,72) 0.0 (Stanton et al. 2004)
Japan (175) 0.0 (Stanton et al. 2004)
Korea (48) 0.0 (Stanton et al. 2004)
Malawi (40) 0.0 (Stanton et al. 2004)
Exon 4 C59A Germany (206) 0.0 (Jacobsen et al. 2002)
Exon 4 C77T Italy (204) 0.0 (Gomez-Lira et al. 2003)
Exon 5 G69C Italy (204) 0.5 (Gomez-Lira et al. 2003)
Exon 6 T127A Italy (204) 0.3 (Gomez-Lira et al. 2003)
Exon 6 A138G UK (181) 0.3 (Stanton et al. 2003)
Orkney (72) 0.7 (Stanton et al. 2003)
Italy (204) 1.0 (Gomez-Lira et al. 2003)
Tatar (65) 4.6 (Stanton et al. 2003)
Japan (175) 23.7 (Stanton et al. 2003)
Korea (48) 7.3 (Stanton et al. 2003)
Uganda (209) 0.0 (Stanton et al. 2003)
Table 1.1 Frequency of CD45 variant alleles in healthy controls from different populations in 
published studies. Number of individuals is indicated in brackets.
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C77G polymorphism and abnormal CD45 splicing (E.Tchilian, personal 
communication). Therefore it may be speculated that abnormal CD45 splicing may be 
associated with impairment in anti-viral responses or clearance of the virus. Further 
studies have suggested an association between the C77G polymorphism and 
autoimmune diseases such as systemic sclerosis, SSc (Schwinzer et a l , 2003) and 
Autoimmune hepatitis, AIH (Vogel et a l , 2003).
We have also analysed the frequency of the C77G allele in a cohort of patients with 
hepatitis C, from the UK (E. Tchilian, Personal communication). Of 388 hepatitis C 
patients, fifteen were found to be heterozygous for the C77G polymorphism, an allele 
frequency of 1.9%. This is twice the frequency observed in the uninfected control 
population (0.95%) where only 8 out of 417 individuals carried the C77G 
polymorphism. This could suggest that the C77G polymorphism is associated with poor 
prognosis on viral infection, at least to the hepatitis C virus (HCV). To determine if 
there is an association of the variant C77G allele and disease outcome, the frequency of 
the polymorphism between hepatitis C chronic patients, who are unable to clear the 
virus (HCV RNA positive) and individuals who resolved HCV infection and became 
HCV RNA negative was investigated. Remarkably, of the 256 chronic carriers (HCV 
RNA positive), 14 were heterozygous for the C77G polymorphism (allele frequency of 
2.7%) whilst only one C77G heterozygous individual was identified in 132 HCV RNA 
negative individuals (allele frequency 0.3%). This is statistically significant (p=0.02) 
and suggests a link between the presence of the C77G polymorphism and the outcome 
of the hepatitis C infection, with an inability to clear the vims.
1.3.4 The A138G polymorphism
We have recently described a novel polymorphism, A138G (Thr47Ala) in Exon 6  
(Gomez-Lira et al, 2003; Stanton et al, 2003). This polymorphism has been found to 
be prevalent in Japanese (23.7%) and Korean (7.3%) populations, with 5.1% of the 
Japanese population homozygous for the 138G variant allele. In the proceeding chapters 
we will show that 138G carriers have altered CD45 isoform expression, with an 
increased proportion of CD45R0+ T cells in the periphery. We have further shown that 
this polymorphism is a cause of altered isoform expression, promoting splicing towards
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the low molecular weight CD45 isoforms. The high frequency of the variant allele in the 
Japanese population suggests that it confers some selective advantage for survival and 
may modulate immune responses.
1.3.5 A138G and disease association
We have investigated whether the 138G variant allele is associated with thyroid 
autoimmune disorders (Hashimoto’s thyroiditis and Graves disease) and viral infections 
(Hepatitis B and Hepatitis C) in cohorts of Japanese patients (Boxall et a l, 2004). In 
Hashimoto’s thyroiditis, humoral and cellular responses to thyroid antigens lead to the 
destruction of the organ and hypothyroidism. Graves disease is characterised by 
hyperthyroidism caused by stimulatory anti-thyrotropin receptor antibodies. Of the 126 
Hashimoto’s patients tested the number of A138G heterozygous individuals was found 
to be comparable to that in the control population. However, no G138G homozygous 
individuals were found despite an expected frequency of 5 G138G individuals 
according to the Hardy-Weinberg Law. Of the 175 patients tested who had Graves 
disease, the frequency of A138G heterozygote individuals was significantly reduced, 
and no G138G homozygous individuals were found (Table 1.2). This suggests that there 
may be a dominant protective effect of the 138G allele in Graves disease. This possible 
protective effect was also observed in the 113 hepatitis B carriers tested, with a reduced 
number of A138G heterozygous individuals (allele frequency of 11.9% compared to 
23.7% in the control population) and only 2  G138G homozygous individuals found. 
There was no significant difference in the 138G allele frequency between the hepatitis C 
and control populations. Whilst these studies are relatively small and more data is 
required to frilly understand the disease associations of the 138G variant allele, it does 
suggest that this polymorphism can have a protective effect in some diseases.
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Disease Group Total number A138A A138G  
(allele frequency %)
G138G
Control 176 111 65 (23.7%) 9
Hashimoto 126 76 50(19.8%) 0*
Graves 175 144 31 (9%)** 0
Hepatitis B 113 88 23(11.9% )*** 2
Hepatitis C 173 117 48 (19.4%) 8
Table 1.2 Frequency o f CD45 exon 6 A138G alleles in control and disease groups. Statistically 
significant differences from controls are indicated by the symbols as follows. *p =0.02 (departure from 
the Hardy-Weinberg equation with a Chi-Square for 2df o f 7.81), **p<0.001 (with a Chi-Square o f  
15.4 for ldf, which corresponds to a relative risk for the heterozygotes o f  0.44) and ***p<0.005 (with 
Chi-Square o f  9.3 for ldf, which corresponds to a relative risk o f  0.55).
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1.3.6 Other CD45 Polymorphisms
Jacobsen et al., (2002) have described another point mutation in exon 4 of CD45, which 
presents a similar T-cell phenotype to that observed in individuals with the C77G 
polymorphism. This is a C to A transversion at position 59, which alters the amino acid 
sequence (histidine to glutamine), interfering with alternative splicing and resulting in 
expression of a structurally altered CD45 molecule. Whilst this was the first mutation 
to be described in the PTPRC gene which actually alters CD45 structure, it has so far 
only been described in five out of nine members of the same family. This variant was 
identified as part of an MS study, and found in one of 311 MS patients and in none of 
the 206 healthy donors.
Several other polymorphisms have recently been described in the PTPRC gene; C77T 
(Pro59Pro) in exon 4, G69C (Aspl21His) in exon 5, and T127A (Ilel87Asn) in exon 6  
(Gomez-Lira et al., 2003). These new polymorphisms were found in Northern Italy at 
frequencies of around 0-1% and nothing is currently known about their effects on CD45 
alternative splicing (Gomez-Lira et a l, 2003). Two novel polymorphisms have lately 
been described in exon 4; A54G (Stanton et al., 2004) and A32G (D.Pretorius, personal 
communication), which will be discussed further in Chapter 6 .
1.3.7 Therapeutic applications
The essential role of CD45 in lymphocyte function and its association with various 
diseases makes CD45 an attractive target for immunointervention. Modulation of CD45 
may affect autoimmunity, immunodeficiency, cancer and transplantation. The two main 
approaches to the modulation of CD45 function are the use of selective inhibitors, or 
specific anti-CD45 antibodies. Inhibitors of CD45 include non-selective protein tyrosine 
phosphatase inhibitors, such as Sulfotyrosyl peptides, Preoxtnitrite and 
Nitroarylhydroxymethylphosphonic acids (Beers et al., 1997; Desmarais et a l, 1998; 
Takakura et al., 1999). Specific CD45 inhibitors include TU752, which may be useful 
in the treatment of allergic disease as it inhibits IgE-mediated anaphylaxis and murine 
contact hypersensitivity in vivo (Hamaguchi et al., 2001)
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Monoclonal antibodies could be used to deliver targeted therapy in the form of antibody 
mediated cellular toxicity, cytotoxic reagents or radiation. Anti-CD45 antibodies have 
been shown to have an anitleukemic effect when used unconjugated or attached to 
radioactive iodine (Nemecek and Matthews, 2002). The anti-CD45 monoclonal 
antibody MG23G2 and radioactive anti-CD45 antibodies have been used to prevent 
allograft rejection and induce donor specific tolerance in murine models and humans 
(Lazarovits et al., 1996; Auersvald et al., 1997) MG23G2 has also been shown to have 
immunosuppressive ability, being used in the treatment of preclinical models of 
autoimmunity (Zhong and Lazarovits, 1998) Whilst its precise mechanism of action 
remains unclear, with suggestions including up-regulation of CTLA-4 (Fecteau et al., 
2001), the MG23G2 antibody is a clear candidate for further study.
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1.4.0 Objectives of study
Although CD45 alternative splicing is tightly regulated and highly conserved in fish, 
birds and mammals, the exact function of the different isoforms remains obscure. 
Despite possible associations with a number of lectin like molecules, no specific ligand 
for CD45 has been identified (Perillo et al., 1995; Uemura et al., 1996; Symons et al., 
2000). In transfected cell lines it has been shown that a large extracellular domain is 
required for TCR signalling (Irles et al., 2003). Formation of homo- and heterodimers 
has been proposed as a mechanism for regulating CD45 phosphatase activity (Xu and 
Weiss, 2002) but, the precise link between expression of different isoforms to T cell 
function and regulation of CD45 phosphatase activity remains unclear.
The aim of this project is to understand how the expression of alternatively spliced 
CD45 isoforms affects the function of leukocytes. We have utilised the existence of 
human CD45 polymorphisms to study the effect of altered CD45 isoform expression on 
T cell function and investigate the mechanisms responsible for altered immune function. 
Therefore our specific objectives were to:
1. Characterise CD45 isoform expression and phenotypic changes in leukocytes from 
individuals with variant CD45 alleles
2. Identify functional changes in T lymphocytes from individuals with variant CD45 
alleles
3. Determine the molecular mechanisms responsible for altered isoform expression in 
138G variant individuals
4. Characterise the CD45 isoform expression in individuals with ‘novel’ CD45 
polymorphisms
5. Define and analyse the leukocyte phenotype and function in a transgenic mouse 
model which approximates abnormal CD45 splicing observed in humans
Understanding how expression of different CD45 isoforms affects immune function is 
important as it may lead to the development of therapeutic agents targeting CD45 and 
the signalling pathways that it modulates. It may also provide further insights into the 
function of naive and memory cells, which express different CD45 isoforms, and lead to 
new strategies for vaccination or immunomodulation.
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Materials and Methods
2.1.0 Materials
2.1.1 List of reagents and kits
Reagent
100 bp DNA ladder 
lkb DNA ladder 
Agarose
Ammonium Acetate 
Ampicillin
Bovine serum albumin (BSA)
Bromophenol blue 
Chloroform
Concanavalin A (ConA)
Chromogenic Alkaline Phospatase substrate 
Cytokine Bead Array Kit (Thl/Th2)
Diethyl pyrocarbonate (DEPC)
Dimethyl sulphoxide 
Duoset ELISA development system 
Dulbecco’s Modified Eagle Medium (DMEM) 
Ultrapure dNTP
Ethylenediamiinetetraacetic acid (EDTA) 
Ethanol
Ethidium bromide
Ficoll Paque PLUS
First strand cDNA synthesis Kit
Foetal calf serum
Formaldehyde
Geneticin (G-418 Sulphate)
Company
Invitrogen Life Technologies
Invitrogen Life Technologies
Invitrogen Life Technologies
Sigma
Sigma
Sigma
Biorad
Sigma
Sigma
BioRad
BD Pharmingen
Sigma
Sigma
R&D system s 
Gibco
Amersham Biosciences
Sigma
BDH
Sigma
Amersham Biosciences
Amersham Biosciences
Gibco
BDH
Gibco
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HEPES
(N - [2-Hydroxyethyl]piperazine-N ’ -[2 -ethane sulfonic 
Heparin (Pump-hep with sodium)
Human serum (male AB)
Iscove ’ s Modified Dulbecco ’ s Medium (IMDM)
Ionomycin
Isopropanol
Mercaptoethanol
MinElute Gel Extraction Kit
Normal mouse serum
Orthopermeafix
Phosphate Buffered Saline (PBS) lOx
Penicillin/streptomycin
Pfu polymerase
Phytohaemagglutinin-P (PHA-P)
Phenol (Buffer Saturated)
Plasmid maxi kit
Phorbol 12-Myristate 13-Acetate (PMA)
Proteinase K
QIAprep Spin miniprep kit 
RiboGreen® RNA Quantification Kit 
RNaseOUT™
RPMI-1640 (with glutamax and HEPES)
Sodium Acetate 
Sodium Citrate
Taq polymerase (& buffer, MgCl2)
3H-thymidine 
10 x TAE Buffer 
TRI-REAGENT™
Trypsin 
Trypan blue 
Tween20
Versene (0.02% EDTA in PBS)
Visigel Separation Matrix 
Xylene cyanol FF
Sigma
acid])
Leo Laboratories Ltd
Sigma
Gibco
Sigma
BDH
Gibco
Qiagen
Sigma
Ortho Diagnostic Systems
Gibco
Sigma
Stratagene
Sigma
Invitrogen
Qiagen
Sigma
Sigma
Qiagen
Molecular Probes
Invitrogen Life Technologies
Invitrogen Life Technologies
BDH
BDH
Promega
Amersham
Invitrogen Life Technologies 
Sigma
IAH, Compton.
Sigma
BDH
IAH, Compton.
Stratagene
Biorad
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2.1.2 Monoclonal Antibodies
Table 2.1 Monoclonal antibodies to human cell surface markers
Antibody Conjugate Species Clone Isotype Supplier
CD3 APC Mouse HIT3a IgG2ak Pharmingen
CD3 FITC Mouse HIT3a IgG2ak Pharmingen
CD4 Biotin Mouse RPA-T4 IgG lk Pharmingen
CD4 APC Mouse S3.5 IgG2ak Pharmingen
CD8 Bio tin Mouse 3B5 IgG2a Caltag
CD8 APC Mouse RPA-T8 IgG lk Pharmingen
C D lla FITC Mouse G43-25B IgG2a Pharmingen
CD 14 APC Mouse M5E2 IgG2ak Pharmingen
CD16 Cy-Chrome Mouse 3G8 IgG lk Pharmingen
CD 19 APC Mouse HIB19 IgG lk Pharmingen
CD25 FITC Mouse ACT-1 IgG lk DAKO
CD27 FITC Mouse LT27 IgG2a Serotec
CD28 FITC Mouse CD28.2 IgG lk Pharmingen
CD44 FITC Mouse G44-26 IgG2bk Pharmingen
CD45RA FITC Mouse HI 100 IgG2bk Pharmingen
CD45RA R-PE Mouse 4KB5 IgGl DAKO
CD45RA APC Mouse HI30 IgG l Caltag
CD45RA APC Mouse HI 100 IgG2bk Pharmingen
CD45RB FITC Mouse PD7/26 IgG lk DAKO
CD45RB R-PE Mouse MT4 (6B6) IgG lk Pharmingen
CD45RC Purified Rat YTH80.103 IgG2b Biosource Int.
CD45RO R-PE Mouse UCHL1 IgG2ak Pharmingen
CD45RO FITC Mouse UCHL1 IgG2ak Pharmingen
CD45RO APC Mouse UCHL1 IgG2ak Pharmingen
Pan45 R-PE Mouse HI30 IgG lk Pharmingen
Pan45 FITC Mouse HI30 IgG lk Pharmingen
CD56 APC Mouse B159 IgG lk Pharmingen
CD56 PE Mouse B159 IgG lk Pharmingen
CD62L FITC Mouse Dreg56 IgG lk Pharmingen
CD62L FITC Mouse LAM 1-116 IgG2ak Ancell
CD69 FITC Mouse FN50 IgG lk Pharmingen
CD95 FITC Mouse DX2 IgG lk Pharmingen
HLA-DR RPE Mouse HK14 IgG2a Sigma
CCR7 Purified Mouse 2H4 IgM Pharmingen
Table 2.2 Monoclonal antibodies to human intracellular molecules
Antibody Conjugate Species Clone Isotype Supplier
Perforin FITC Mouse 5G9 IgG2b Pharmingen
Granzyme A FITC Mouse CB9 IgGl Pharmingen
IFNy FITC Mouse 25723.11 IgG2b Pharmingen
IL4 PE Mouse 3010.211 IgGl Pharmingen
IL10 PE Rat JES3-9D7 IgGl Pharmingen
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Table 2.3 Monoclonal antibodies to murine cell surface markers
Antibody Conjugate Species Clone Isotype Supplier
CD3 FITC Armenian Hampster 145-2C11 IgG lk Pharmingen
CD4 FITC Rat (Lewis) GK1.5 IgG2bk Pharmingen
CD 8 PE Rat (LOU/W sl/M) 53-6.7 IgG2ak Pharmingen
CD 8 PcP Rat (LOU/W sl/M) 53-6.7 IgG2ak Pharmingen
CD19 FITC Rat (Lewis) 1D3 IgG2ak Pharmingen
CD44 PE Rat IM7 IgG2bk Pharmingen
CD45 Cyc Rat (LOU/W sl/M) 30-F11 IgG2bk Pharmingen
CD 62 PE Rat M EL-14 IgG2a Caltag
IgM PE Rat LO-MM IgG2a Pharmingen
IgD FITC Mouse 217-170 IgG lk Pharmingen
Table 2.4 Secondary reagents
Antibody Conjugate Species Supplier
Streptavidin PCP Pharmingen
Streptavidin APC Pharmingen
Streptavidin PE Pharmingen
Streptavidin FITC Pharmingen
Anti-mouse IgM FITC Goat Pharmingen
Anti-mouse IgM PE Goat Pharmingen
Anti-Rat IgG FITC Goat Pharmingen
Table 2.5 Isotype controls
Antibody Conjugate Species Clone Isotype
IgG2a PE Mouse G155-178 Pharmingen
IgGl PE Mouse MOPC-21 Pharmingen
IgGl FITC Mouse MOPC-21 Pharmingen
IgG2a APC Mouse G155-178 Pharmingen
IgG2b FITC Mouse 27-35 Pharmingen
IgG2a FITC Mouse G155-178 Pharmingen
IgM Purified Mouse G155-228 Pharmingen
IgG2b Purified Rat R35-38 Pharmingen
IgG IK FITC Hamster A 19-3 Pharmingen
IgG2ak FITC Rat R35-95 Pharmingen
IgG2ak PE Rat R35-95 Pharmingen
IgG2ak PcP Rat R35-95 Pharmingen
IgG2bk FITC Rat A95-1 Pharmingen
IgG2bk PE Rat A95-1 Pharmingen
IgG2bk Cyc Rat A95-1 Pharmingen
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2.1.3 Media
RPMI1640 10% Human serum
RPM I1640 medium with L-alanyl-L-glutamine and 25mM HEPES 
1 0 % human serum
RPMI 1640 10% Foetal calf serum
RPMI 1640 medium with L-alanyl-L-glutamine and 25mM HEPES 
1 0 % foetal calf serum
DMEM 10% Foetal calf serum
Dulbecco’s Modified Eagle Medium 
1 0 % foetal calf serum
Complete media
IMDM (Iscove’s Modified Dulbecco’s Medium)
10% FCS (heat inactivated)
50pM 2-Mercaptoethanol 
lOOu/ml Penicillin 
lOOpg/ml Streptomycin sulfate 
2-7mM HEPES
2.1.4 Buffers and solutions
TAE (10X)
400mM Tris acetate 
lOmM EDTA
PBS (per litre)
8 g NaCl 
0.2g KC1 
1.44g Na2P04 
0.24g KH20 4
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FACS buffer
PBS, 0.2% BSA
FACS Fixative
PBS, 0.2% BSA, 1% formaldehyde
Lysis Buffer
25mM EDTA 
lOmM NaCl 
lOmM Tris 
0.5% SDS
TE (pH8.0)
lOmM Tris.Cl (pH8.0)
ImMEDTA
Orange G loading buffer
0.5% Orange G
20% Ficoll
0.5mM EDTA
Water to appropriate volume
Blue loading buffer
0.25% bromophenol blue 
0.25% Xylene cyanol FF 
30% Glycerol
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2.1.5 Oligonucleotides
All Primers were obtained from MWG-Biotech (Germany) and were synthesised to 
0.5nmol and purified by high performance liquid chromatography.
Table 2.6 Oligonucleotides
Primer Sequence (5* >3*)
Exon 4 (Mut) Forward GACTACAGCAAAGATGCCCAGTG
Exon 4 (Mut) Reverse GCATTATCCAAAGAGTCCGGGG
Exon 2 Forward CGAAGCTTGCTGTTTCTTAGGGACACG
Exon 7 Reverse GTGAATTCCAGAAGGGCTCAGAGTGGT
Exon 7 Forward ATGCCTACCTTAATGCCTCTG
Exon 10 Reverse CATATTACCACACTGAAATC
(3-actin Forward TCGTGCGTGACATCAAAGAG
P-actin Reverse TGGACAGTGAGGCCAAGATG
Exon 4 Forward GGAGGAGCATACATTTAGGGT
Exon 4 Reverse GTCTTTAACGTCCTTTAATCATAGAC
Exon 4 (Intron) Forward CTCCTTCTCCCATTTTCCAT
Exon 4 (Intron) Reverse CCCTGATATTTAAGTTAACA
Exon 2 Forward TAGGGACACGGCTGGCTTCCAG
Exon 2 A Forward GTGGCTTAAACTCTTGGCAT
Exon 8 Reverse CATGTTGGCTTAGATGGAGTAG
Intron 5 Forward GTTGGCTATCTGGCTATTGCCC
Intron 6 Reverse CT G A AG AC ACT ACT AG AGC AGC
Exon 6 (Mutagenesis) Forward CATCACAGCGAACGCCTCAGGTCTGAC
Exon 6 (Mutagenesis) Reverse GTCAGACCTGAGGCGTTCGCTGTGATG
M l3 Forward GTAAAACGACGGCCAGT
M13 Reverse CAGGAAACAGCTATGAC
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2.1.6 Plasticware
Plasticware used in laboratory work.
Description Company
30ml Universal tubes Sterilin
7ml Bijou Sterilin
50ml polypropylene tubes Falcon
15ml polypropylene tubes Falcon
5ml polypropylene tubes Falcon
Cryovial Nalgene, Nunc International
Microamp PCR tubes Applied Biosystems
Thermo-Fast 96 well PCR plates AB gene
Microamp PCR caps Applied Biosystems
Eppendorf tubes (1 .5ml) Anachem
Eppendorf tubes (0.5ml) Anachem
96-well U bottom plates (Sterile) Nunc international
96-well flat bottom plates (Sterile) Coming, Costar
MutiScreen 96-we 11 Filtration Plate (Sterile) Millipore UK Ltd
96-well maxisorb immunoplates Nunc, International
PVC microtitre 96well U bottom plates Dynex, USA
25 cm2 Tissue Culture treated Flasks (vented) TPP, Helena Biosciences
75 cm2 Tissue Culutre Treated Flasks (vented) TPP, Helena Biosciences
Cell Culture Dish (Sterile) 60mmxl5mm Coming Inc.
Petri Dish (Sterile) 90mmxl5mm Sterilin Ltd.
Gene Pulser cuvette (4mm) BioRad
2.1.7 Glassware
All glassware was provided by the Institute of Animal Health, Compton, and was 
autoclaved before use.
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2.1.8 Sample Information
All assays were performed on cryopreserved PBMC. For C77G heterozygous and C77G 
common variant individuals, PBMC were isolated from Buffy Coat bags obtained from 
the National blood donor service (Colindale, North London). PBMC from all other 
individuals were isolated in the respective country and were cryopreseved before 
shipping at -20°C.
Table 2.7 Sample Information
Genotype N o.of individuals Age range 
(Years)
Health Status Origin
C77C 10 32-48 Healthy North London, England.
C77G 10 36-57 Healthy North London, England.
A138A 9 27-41 Healthy Osaka, Japan.
A138G 6 23-30 Healthy Osaka, Japan.
G138G 6 30-58 Healthy Osaka, Japan.
A54A 2 HIV1+ Uganda
A54G 1 HIV1+ Uganda
A3 2 A 1 HIV1+ South Africa
A32G 2 HIV1+ South Africa
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2.2.0 Methods 
Cellular techniques
2.2.1 Isolation of peripheral blood mononuclear cells (PBMCs)
Buffy Coat bags (50ml) were obtained from the National blood donor service 
(Colindale, North London). When fresh blood was required, venous blood was collected 
in heparinised syringes with 19G x 1 inch needles (Terumo Europe, Belgium). The 
buffy coat/ blood samples were diluted in an equal volume of phosphate buffered saline 
(PBS) and slowly layered onto Ficoll Paque in 50ml Falcon tubes. The tubes were 
centrifuged at 500 x g, for 30 minutes at room temperature with the brake switched off. 
Cells were removed from the interface and washed twice with sterile PBS or appropriate 
media at 400 x g (10 minutes, brake on). The cells were resuspended at the required 
concentration in appropriate media.
2.2.2 Preparation of murine cells
Spleen and lymph nodes were removed from the mice and made into a single cell 
suspension in PBS or Complete medium by mashing and forcing through a 40pm falcon 
cell strainer (Becton Dickinson).
2.2.3 Cell viability testing
Viable cells were counted using the Trypan blue exclusion method. A small aliquot was 
taken from the cell suspension and diluted in an equal volume of Trypan blue solution. 
The live cells, as determined by the exclusion of trypan blue, were counted on a 
haemocytometer (improved Neubauer chamber) viewed under a light microscope 
(Leica). The number of cells in the suspension was calculated using the formula below.
Number of viable cells in 25 squares x Dilution factor x 104 = Number of cells / ml
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2.2.4 Cryopreservation of cells
Cells for cryopreservation were spun down and resuspended, at approximately 20x106 
cells/ml, in 90% foetal calf serum (FCS) and 10% dimethyl sulphoxide (DMSO). The 
cell suspension was transferred into cryovials in 1ml aliquots, and placed in a 
polystyrene box at -80°C overnight. The cells were then transferred to liquid nitrogen 
for long term storage.
2.2.5 Cell surface staining of human PBMCs
The cells (l-2xl05/well) were incubated in flexible microtitre plates with 50pi of 
antibody, in PBS, 0.2% BSA (FACS buffer) for 20 minutes at 4°C. Antibodies were all 
used at pre-determined optimum concentrations. The cells were washed three times in 
FACS buffer at 400 x g and resuspended in an appropriate volume. If samples were to 
be left overnight, they were resuspended in lOOpl FACS fixative buffer (PBS, 0.2% 
BSA, 1 % formaldehyde) and stored at 4°C in the dark.
2.2.6 Cell surface staining of murine cells
The spleen and lymph node cell suspensions were made as described previously 
(Section 2.2.2). In order to lyse erythrocytes, the spleen cells were spun down and the 
pellet resuspended in 8 ml of 0.83% Ammonium Chloride. The cells were incubated on 
ice for 4 minutes, before adding 20ml of PBS and passing the cells through a 0.2pm cell 
strainer (Falcon). The cells were spun down and resuspended in 4ml of FACS buffer.
Non-specific binding in cells isolated from spleen and lymph nodes (2xl05cells/well) 
was blocked with either normal mouse serum or FC Block (purified anti-mouse 
CD16/CD32, Pharmingen) for 30 minutes at 4°C. The cells were washed in FACS 
buffer before incubating with a range of antibodies and appropriate isotype controls, at 
predetermined concentrations in a 20pl volume. The cells were incubated for 20 
minutes, on ice, in the dark before washing three times at 400 x g and resuspending in 
an appropriate volume of FACS buffer. If samples were to be left overnight, they were 
resuspended in lOOpl of FACS fixative buffer and stored at 4°C in the dark.
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2.2.7 Intracellular staining
Cells were stained for cell surface markers as described previously (section 2.2.5-6 ) and 
then resuspended in 40pl of Permeafix (Ortho Diagnostics, UK) diluted 1:2 in distilled 
water. Following incubation for 40 minutes at room temperature in the dark, cells were 
washed thoroughly in FACS buffer at 400 x g. The cells were incubated with a 
predetermined optimum concentration of intracellular antibody, for 2 0  minutes, at room 
temperature in the dark. The cells were washed three times at 400 x g and resuspended 
in an appropriate volume of FACS buffer.
2.2.8 Intracellular cytokine staining
One hundred microlitres of cell suspension was plated out in 96-well U-bottomed 
plates. To each well was added 99 j l i 1 of either medium alone, or medium containing 
PM A and Ionomycin (to give final concentrations of 50ng and 500ng/ml respectively). 
The Cells were incubated at 37°C, 5% CO2 for 2 hours, before adding lpl per well of 
GolgiPlug (BD Pharmingen) diluted 1:10 in PBS. The cells were incubated at 37°C, 5% 
CO2 for a further 1 2  hours.
The cells were washed in FACS buffer, before staining for surface markers for 20 
minutes on ice with the appropriate dilution of antibody. The cells were washed in 
FACS buffer and resuspended in 40jul Permeafix (diluted 1 in 2 in distilled water). The 
cells were incubated for 40 minutes (at room temperature, in the dark) and washed twice 
in FACS buffer. The cells were incubated with a predetermined optimum concentration 
of intracellular cytokine antibody for 30 minutes at room temperature, in the dark. The 
cells washed three times at 400 x g and resuspended in the appropriate volume of FACS 
buffer.
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2.2.9 Flow Cytometery
Either freshly stained or fixed samples (with 1% formaldehyde stored in the dark at 4°C) 
were run on a FACSCalibur (Becton Dickinson, UK). Ten to twenty thousand events 
were collected and analysed using WinMDI software. Settings and compensation were 
established on single stained controls.
2.2.10 Proliferative responses of human PBMCs
A single cell suspension was plated out into 96 well flat bottom plates at 
2xl05cells/well. Cells were stimulated with a variety of stimuli: PHA-P was used as 
positive control at lOpg/ml. UCHTl-2a (anti-CD3 antibody) was titrated out, and then 
used optimally at 1.25pg/ml. CD28 was used for co-stimulation with UCHTl-2a at 
2.5pg/ml after titrating out. Tetanus Toxoid (TT) and purified protein derivative (PPD) 
from M. Tuberculosis (Statens serum institute, Denmark) were used at 5 and 10pg/ml.
Cells were incubated at 37°C, 5% CO2 and tritiated thymidine (3H) incorporation assays 
were performed on days 2-5 inclusive, for UCHTl-2a, CD28 and PHA, and on days 4-7 
inclusive for Tetanus Toxoid and PPD. Cells were pulsed with 1 pCi/well of H- 
thymidine in RPMI and plates were harvested 16 hours later. Measurement of thymidine 
incorporation was carried out using a Microbeta Scintillation Counter (Wallac).
2.2.11 Proliferative response of murine cells
96 well round bottom plates were pre-coated with CD3 (anti-mouse CD3s chain, clone 
145-2C11, no azide/low endotoxin, Pharmingen) and CD28 mAh (anti-mouse CD28, 
clone 37.51, no azide/low endotoxin, Pharmingen) overnight. CD3 was coated at 0, 0.1, 
0.25, 0.5, 1, 5 and 10pg/ml in the presence or absence of CD28 at 2.5pg/ml. The plates 
were washed three times in PBS and once in medium. The cells were resuspended at 
lx l0 6 cells/ml in complete medium and 200pl (2xl05 cells) was added to each well. A 
thymidine (3H) incorporation assay was performed as previously described.
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2.2.12 Elispots
96 well filtration plates were pre-coated in anti-IFN-y mAh (clone D1-D1K, Mabtech), 
anti-ILlO mAb (clone 9D7, MabTech) or anti-IL4 mAb (clone 82.4, MabTech) at 
lOmg/ml in sodium bicarbonate buffer, overnight. Plates are washed 4 times with sterile 
PBS, before adding 50pl of blocking solution (RPMI, 10% Human Serum) and 
incubating at 37°C, 5% CO2 for 1 hour.
Cells were prepared by washing 3 times in RPMI, 15% FCS and resuspending in RPMI, 
10% Human serum. lOOpl of cell suspension (l-2xl05cells) was added to the plates 
(without removing the blocking solution). PHA or UCHTl-2a was then added to a final 
concentration of 10 or 5pg/ml respectively. After incubating for 1 hour at 37°C, 5% 
CO2, 30pl of filtered FCS was added to each well. The plates were then incubated at 
37°C, 5% C 02, for 48 hours.
The contents were removed and the plates washed four times in PBS, 0.05% Tween 20 
solution. Biotin-conjugated anti-IFN-y mAb (clone 7-B6-1 -biotin, MabTech, at ljag/ml), 
Biotin-conjugated anti-ILlO mAb (clone 12G8, MabTech, at 2jug/ml) or Biotin- 
conjugated anti-IL4 mAb (clone IL4-II (12.1), MabTech, at 2pg/ml) was added to each 
well as appropriate and incubated for 2  hours in a damp box at 37°C, 5% CO2. The 
secondary antibody was removed and the plates were washed four times in PBS, 0.05% 
Tween 20 solution.
To each well was added lOOpl of anti-biotin-ALP (Vector Laboratories) diluted 1:1000 
in filtered PSB, 0.05% Tween 20, before incubating for 1-2 hours at room temperature. 
Plates were washed four times with PBS, 0.1% Tween 20, including the back of the 
filters to reduce background. lOOpl of chromogenic alkaline phosphatase substrate 
(BioRad) was added to each well and incubated at room temperature for 30 minutes. 
The plates were then washed three times in water and dried before counting on an 
Elispot plate reader (AID).
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2.2.13 IFNy ELISA
The Duoset human IFNy ELISA development system (R&D systems) was used 
according to the manufacturers protocol.
Briefly, 96-well plates (Maxi-sorp immunoplate, Nunc) were pre-coated with lOOpl of 
mouse anti-human IFNy capture antibody (diluted 4pg/ml in PBS). The plate was 
covered and incubated overnight at room temperature. The capture antibody was 
removed and the plates washed 3 times in 400|l l 1 of wash buffer (0.05% Tween 20 in 
PBS, pH7.2-7.4). To each well was added 300pl of Block buffer (1% BSA, 5% Sucrose 
in PBS with 0.05% NaN3), and the plate incubated for 1 hour at room temperature 
before repeating the wash step as previously.
Sample and standards were diluted as appropriate in reagent diluent (0.1% BSA, 0.05% 
Tween 20 in Tris-buffered Saline) and 100 pi added to each well before incubating at 
room temperature for 2 hours. The samples were removed and the wash step repeated. 
lOOpl of biotinylated goat anti-human IFNy detection antibody, diluted to lOOng/ml in 
reagent diluent, was added to each well and incubated at room temperature for 2  hours.
The detection antibody was removed and the plate washed 3 times as previously. lOOpl 
of Streptavidin-HRP (diluted 1/200) was added to each well and the plates incubated in 
the dark for 20 minutes at room temperature. The plates were washed as previously and 
lOOpl of substrate solution (1:1 mix of H2O2 and Tetramethylbenzidine) was added to 
each well. The plates were incubated at room temperature for 20 minutes in the dark 
before adding 50 pi of stop solution (2N H2SO4) to each well. The plate was tapped 
gently to ensure thorough mixing before immediately determining the optical density at 
450nm.
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BD Biosciences Cytometric Bead Array (CBA) kits (Human Thl/Th2 and Mouse 
Thl/Th2 Cytokine CBA kits) were used following the manufacturer’s protocol.
The Thl/Th2 cytokine standards were reconstituted (15 minutes at room temperature in 
0.2ml of assay dilutent), and serial dilutions made (undiluted-1:256). For each test 
sample, lOpl of each cytokine capture bead suspension was mixed and 50pl of the 
mixed beads were transferred to each assay tube. To each assay tube was added 50jnl of 
PE detection reagent and 50pl of diluted standard or test sample. The samples were 
incubated for 3 hours (human) or 2 hours (mouse) at room temperature, in the dark.
The samples were washed with 1ml of wash buffer (centrifuged at 200 x g for 5 
minutes) and resuspended in 300pl of wash buffer. The standards and test samples were 
then run and analysed on a FACSCalibur (Becton Dickinson, UK), using CellQuest and 
BD CBA software, in accordance with the manufacturer’s instructions.
Molecular Techniques
2.2.15 DNA Isolation
Human PBMCs were isolated from suspension by centrifugation. The cell pellet (~2- 
5xl06 cells) was re-suspended in lysis solution (500j l x 1 Lysis buffer, lOpl Proteinase K 
(5mg/ml) and 1 jlxI RNase (40u/pl)). For DNA extraction from whole blood and blood 
clot samples, the samples were diluted with an equal volume of lysis solution. The 
samples were incubated at 56°C overnight. Samples not used immediately were stored 
at -20°C.
To each sample was added an equal volume of buffer saturated phenol. The samples 
were mixed and then centrifuged (12,000 x g) for one minute. The top layer was 
removed to a clean microcentrifuge tube and re-extracted with phenol. The top layer 
was removed to a clean tube and 0.2 volumes of 10M Ammonium Acetate and 2
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volumes of absolute ethanol were added. The samples were centrifuged for 30 minutes 
(12,000 x g), before washing the DNA pellet in 70 % ethanol (7,500 x g, 5 minutes). 
The DNA pellet was air-dried (5 minutes) before re-suspending in 15 pi of TE buffer. If 
not used immediately, the DNA samples were stored at -20°C.
DNA isolation from samples in TRI-REAGENT™
Samples were prepared as described in the RNA isolation procedure (Section 2.2.16). 
After removal of the aqueous phase for RNA isolation, DNA was precipitated from the 
interphase and organic phase by adding 0.3ml of ethanol per 1ml TRI-REAGENT™ 
used in sample preparation. The samples were mixed by inversion and allowed to stand 
at room temperature for 2-3 minutes before centrifuging (2,000 x g, 5 minutes, 4°C).
The supernatant was removed and the DNA pellet washed twice (30 minutes per wash, 
with occasional mixing) in 1ml 0.1M Sodium Citrate, 10% ethanol solution. After 
centrifugation (2,000 x g, 5 minutes, 4°C), the DNA pellet was re-suspended in 75% 
ethanol and stored at room temperature for 20 minutes. After centrifugation (2,000 x g, 
5 minutes, 4°C), the DNA pellet was air-dried and re-suspended in an appropriate 
volume of TE buffer. If not used immediately, the DNA samples were stored at -20°C.
2.2.16 RNA Isolation
Cells were isolated from suspension by centrifugation, and washed once in PBS. The 
cell pellet was lysed with TRI-REAGENT™ by repeated pipetting. Lysed samples can 
be stored at -70°C for up to a month. One millilitre of TRI-REAGENT™ is sufficient to 
lyse 5-10xl06 cells.
The lysed samples were centrifuged (12,000 x g, 10 minutes, 4°C) to remove the 
insoluble material, and transferred to a clean tube. The samples were allowed to stand at 
room temperature for 5 minutes before adding 0.2ml of chloroform per 1ml of TRI­
REAGENT™. The samples were mixed vigorously by shaking for 15 seconds and 
allowed to stand for 1 0  minutes at room temperature before centrifuging (1 2 , 0 0 0  x g,
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4°C, 15 minutes). Centrifugation separates the mixture into 3 phases, a colourless 
upper phase (containing RNA), an interphase (containing DNA) and a red organic phase 
(containing protein).
The upper aqueous phase was transferred to a clean tube and mixed with 1/10 volume of 
isopropanol. The samples were stored at room temperature for 5 minutes then 
centrifuged (12,000 x g, 10 minutes, 4°C). The supernatant was transferred to a clean 
tube, and the RNA was precipitated by adding 0.5ml of isopropanol per 1ml TRI­
REAGENT™ used in sample preparation. The samples were stored at room temperature 
for 5-10 minutes, before centrifuging (12,000 x g, 1 0  minutes, 4°C).
The supernatant was removed and the RNA pellet was washed with 1ml of 75% ethanol 
in DEPC-treated water (0.1% Diethyl Pyrocarbonate) per 1ml TRI-REAGENT™ used 
in sample preparation. The samples were mixed before being centrifuged (7,500 x g, 5 
minutes, 4°C). The RNA pellet was air-dried (5-10 minutes) before re-suspending in an 
appropriate volume of DEPC-treated water. RNA not immediately used was stored at - 
80°C.
2.2.17 cDNA Synthesis
Using the First strand cDNA synthesis kit (Amersham Biosciences) as per the 
manufacturers instructions.
One to five micrograms of total RNA was placed into a microcentrifuge tube and 
DEPC-treated water added to bring the volume to 8 pl. The RNA solution was heated to 
65°C for 10 minutes, before cooling on ice. The Bulk-First Strand cDNA reaction mix 
(containing: murine reverse transcriptase, RNAguard™ (porcine), RNase/DNase-ffee 
BSA, dATP, dCTP, dGTP and dTTP in aqueous buffer) was mixed by gentle pipetting 
to obtain a uniform suspension. Into a sterile microcentrifuge tube was placed 5 pi of the 
reaction mix, lpl of DTT solution (200mM), lpl of pd(N) 6  primer (0.2pg/ul random 
hexadeoxynucleotides) and the heat denatured RNA. The solution was mixed by 
pipetting before incubating at 37°C for 1 hour.
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2.2.18 Estimation of nucleic acid concentration 
Quantitating RNA using RiboGreen®
RNA was quantified using the RiboGreen RNA quantification Kit (Molecular probes) 
according to the manufacturers protocol.
The appropriate quantity of RiboGreen dye was diluted in lxTE buffer. The Ribosomal 
RNA standard was made up in duplicate, in a 200pl volume (final concentration of 1, 
0.5, 0.1, 0.02 and 0 pg/ml) and plated into a 96-well maxi-sorb immunoplate. Samples 
were plated in duplicate. To each well was added, lOOpl of TE buffer, 0.5pl of RNA, 
and lOOpl of pre-diluted ribogreen dye. The plate was read under blue fluorescence, 
using the Storm 860 imager (Molecular dynamics) and the RNA quantified using 
Quantity-One software (Bio-Rad).
Quantification of DNA by Spectrophotometry
DNA concentration was determined by measuring optical density (OD) at the 260nm 
and 280nm wavelengths. Background absorbance was set 320nm. The DNA was 
measured neat, or diluted as necessary in TE buffer, in a capillary tube. The DNA 
concentration (pg/ml) was calculated by multiplying the absorbance reading by 50 and 
taking into account any dilution factor. The purity of the DNA was determined using the 
260/280 OD ratio, which was routinely greater than 1.8, indicating low protein 
contamination and sufficient purity.
2.2.19 Polymerase Chain Reaction
cDNA was amplified with Taq polymerase (in storage Buffer A; 50mM Tris-HCl pH8, 
lOOmM NaCl, 0.1 mM EDTA, ImM DTT, 50% glycerol, 1% TritonX-100; Promega, 
UK). 500ng -  lpg of DNA was amplified with lpl (lOpM) specific primers. For each 
reaction was used 5pi lOx taq buffer (lOmM Tris-HCL, 50mM KCL, 0.1%Triton® X-
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100), 3pl 25mM MgCl2, lpl lOmM dNTP’s (2.5mM each), 0.5pl Taq polymerase and 
dH20 to a final volume of 50pl.
When necessary for sequencing, PCR reactions were carried out using Pfu Turbo® 
DNA polymerase (in 50mM Tris-HCL (pH 8.2), ImM DTT, O.lmM EDTA, 0.1% 
Tween20 and 50% (v/v) glycerol; Stratagene). 500ng -  lpg of DNA was amplified with 
lpl (10pM) specific primers. For each reaction was used 5pi lOx Reaction buffer 
(200mM Tris-HCL (pH8.8), lOOmM KCL, lOOmM (NH4)2S04, 20mM MgS04, 1% 
Triton® X-100, lmg/ml nuclease-free BSA), lpl lOmM dNTP’s, 0.5pl Pfu Turbo® 
polymerase and dH20  to a final volume of 50pl.
The PCR was performed in thin-walled PCR tubes using the Perkin Elmer thermal 
cycler. The standard PCR conditions were as follows:
1 Cycle: Denaturing 92°C for 4 minutes
30 Cycles: Denaturing 92°C for 1 minute
Annealing 55°C for 1 minute 
Extension 72°C for 4 minutes 
1 Cycle: Extension 72°C for 16 minutes
Hold at 4°C
The PCR conditions were altered slightly for the minigene experiments (see chapter 5). 
The new PCR conditions were as follows:
1 Cycle: Denaturing 94°C for 3 minutes
30 Cycles: Denaturing 94°C for 1 minute
Annealing 55°C for 1 minute 
Extension 72°C for 1 minute 
1 Cycle: Extension 72°C for 10 minutes
Hold at 4°C
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2.2.20 Gel Electrophoresis 
Agarose gel electrophoresis
DNA fragment size was determined by agarose gel electrophoresis. Gels were prepared 
with 0.5-3% agarose (according to size) in lxTAE buffer and ethidium bromide 
(0.5pg/ml) added. The samples were mixed with loading buffer at a ratio of 1:6 and 
loaded against 1Kb or lOObp ladders as appropriate. Electrophoresis was carried out at 
50-80v for the appropriate length of time, and the DNA bands were then visualised 
under UV light.
VisiGel™ Separation Matrix
The VisiGel™ separation matrix was used to determine the fragment size of PCR 
products 100-1200bp in length. Gels were prepared with 3ml of VisiGel™ separation 
matrix concentrate per 50ml of lxTAE buffer, and ethidium bromide (0.5pg/ml) added. 
The samples were mixed with loading buffer at a ratio of 1:6 and loaded against a lOObp 
ladder. Electrophoresis was carried out at 50-80v for the appropriate length of time, and 
the DNA bands were then visualised under UV light.
2.2.21 Purification of fragments from Agarose gels
DNA bands were extracted from 2-3% Agarose gels for subsequent cloning and / or 
sequencing. The DNA was visualised under UV light and excised from the gel with a 
clean scalpel. The DNA was extracted from the gel fragment using the Qiagen MinElute 
Gel Extraction Kit, following the manufacturer’s protocol.
In brief, the gel fragments were dissolved in 3x the gel volume of buffer QG at 50°C for 
10 minutes (with regular vortexing). Isopropanol (lx gel volume) was added and the 
sample mixed by inversion. The samples was applied to the MinElute column and 
centrifuged (10,000 x g) for 1 minute. The flow-through was discarded and 500pi of 
buffer GC added, before centrifuging (10,000 x g) for 1 minute. The flow-through was 
discarded and the column washed with 750pl of buffer PE (centrifuging for 1 minute,
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10,000 x g). The flow-thorough was discarded and the column centrifuged for an 
additional minute (10,000 x g). The column was placed into a clean 1.5ml 
microcentrifuge tube and the DNA eluted by adding 10pl of Buffer EB to the centre of 
the column and allowed to stand for 1 minute before centrifuging (1 minute, 10,000 x 
g)-
2.2.22 Preparation of Plasmid DNA 
Small scale preparation (miniprep)
Small scale preparation of plasmid DNA was carried out using QIA Spin Miniprep kit 
(Qiagen, UK) following the manufacturers recommended protocol.
Bacterial cultures (3ml), picked from a single colony, were incubated overnight at 37°C. 
One millilitre of the bacterial culture was transferred to a sterile microcentrifuge tube. 
The cells were collected by centrifugation at 14,000 x g for 5 minutes before re- 
suspending in 250pl of buffer PI (50mM Tris-Cl (pH8.0), lOmM EDTA, lOOpg/ml 
RNaseA). Two hundred and fifty microlitres of lysis buffer P2 (200mM NaOH, 1% 
SDS) was added and the samples mixed by inversion before adding, 350pl 
neutralisation buffer N3. The mixed samples were centrifuged at 14,000 x g, for 10 
minutes and the supernatant transferred onto a QIAprep spin column (in a 2ml 
collection tube). This was centrifuged at 14,000 x g for 30-60 seconds and the flow­
through discarded. The column was washed in 0.5ml Buffer PB and 0.75ml Buffer PE, 
centrifuging as previously after each wash, with an additional spin following the buffer 
PE wash. DNA was eluted into a sterile microcentrifuge tube in 50pl Buffer EB (lOmM 
Tris-Cl (pH8.5)).
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Large scale preparation (maxiprep)
Large scale preparation of plasmid DNA was carried out using QIAfilter Plasmid Maxi 
Kit (Qiagen, UK) following the manufacturers recommended protocol.
Bacterial culture (3ml) prepared from a single colony was further grown in 400ml LB- 
medium with lOOjug/ml ampicillin overnight at 37°C in a horizontal shaker at 225rpm. 
The cells were collected by centrifugation at 6,000 x g for 15 minutes (at 4°C). The 
pellet was resuspended in 10ml of buffer PI (50mM Tris-Cl (pH8.0), lOmM EDTA, 
lOOpg/ml RNaseA) before adding lysis buffer P2 (10ml, 200mM NaOH, 1% SDS). 
Samples were mixed and incubated for 5 minutes at room temperature before adding 
10ml chilled neutralisation buffer P3 (3.0M potassium acetate, pH5.5), and inverting to 
mix. The lysate was transferred into the barrel of the QIAfilter maxi cartridge and 
incubated for 10 minutes at room temperature. The lysate was filtered through the maxi 
cartridge before applying to a pre-equilibrated (with 10ml equilibration buffer QBT 
(750mM NaCl, 50mM MOPS, pH7.0, 15% isopropanol; 0.15% triton)) QIAGEN-tip 
500 column and allowing it to enter the resin by gravity flow.
The column was washed twice with 30ml wash buffer QC (1.0M NaCl, 50mM MOPS, 
(pH7.0) 15% isopropanol) and the DNA was eluted into a sterile tube in 5ml elution 
buffer QF (1.25M NaCl, 50mM Tris-Cl (pH8.5), 15% isopropanol). To precipitate the 
DNA, 0.7 volumes of isopropanol was added and the samples centrifuged at 15,000 x g 
for 30 minutes, before washing in 70% ethanol, air drying the pellet and re-suspending 
it in an appropriate volume of TE buffer.
2.2.23 Restriction Endonuclease Digests
Specific restriction enzymes were used to digest double stranded DNA. Enzymes were 
used at a concentration to give 1 to 5 units per jug of DNA. The appropriate buffers 
(supplied with the enzymes) were used at 1:10 dilution according to manufacturer’s 
instructions. Reactions were incubated at 37°C for 1 to 2 hours unless otherwise 
recommend.
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Table 2.8 Restriction Enzymes
Enzyme Sequence recognised
EcoRl 5 ’-G/AATTC-3’
Dpnl 5 ’-GmA/TC-3’
Mspl 5 ’-C/CGG-3’
Pvul 5 ’-CGAT/CG-3’
Buffers
lOx OPA+ 
lOx React 4 
lOx T buffer 
0.1% BSA 
1 Ox K buffer 
0.1% BSA
Manufacturer
Amersham Biotech 
Invitrogen
Amersham Biotech
Amersham Biotech
2.2.24 Site directed mutagenesis
Maxiprep DNA of the plasmid containing exons 2, 6 and 8, was linearised using the 
restriction enzyme Pvu 1, and then purified by adding 0.1 volumes of 3M Sodium 
Acetate (pH5.2) and 2.5 volumes of 100% Ethanol. The samples were centrifuged at
12,000 x g for 15 minutes at 4°C, before washing in 70% ethanol, air-drying the DNA 
pellet and resuspending in 20pl of TE buffer.
The mutagenesis PCR reactions were carried out using Pfu Turbo® DNA polymerase 
(Stratagene). 500ng of DNA was amplified with lpl (125ng) of Exon 6 mutagenesis 
forward and reverse primers. For each reaction was used 5pi of lOx Reaction buffer, lpl 
of dNTP mix (2.5mM each), 1 j l i I  of Pfu Turbo® polymerase (2.5u/pl) were used and 
dfhO was added to a final volume of 50pl.
The PCR was performed in thin-walled PCR tubes using the Perkin Elmer thermal 
cycler. The mutagenesis PCR conditions were as follows:
1 Cycle: Denaturing 95°C for 30 Seconds
12 Cycles: Denaturing 95°C for 30 Seconds
Annealing 55°C for 1 minute
Extension 68°C for 12 minutes (2min/kb plasmid length)
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The mutagenesis PCR products were then digested with Dpnl, and a small sample run 
out on an agarose gel to check the reaction, before transforming into XL 1-blue 
supercompetent cells.
2.2.25 Transformation of E. Coli Strains 
XL 1-Blue MR
Plasmid was transformed in XL 1-Blue MR supercompetent cells (Stratagene) using the 
manufacturers standard protocol.
The competent cells were thawed on ice, and mixed gently before adding lOOjal of cell 
suspension into each pre-chilled 15ml Falcon tube. To each tube was added 1 .7 jli1 of p -  
mercaptoethanol (to 25mM final concentration), before incubating them on ice for 10 
minutes, mixing the contents gently every two minutes. Plasmid DNA (0.1-50ng) was 
added and the cells incubated on ice for 30 minutes. The cells were heat pulsed at 42°C 
for 45 seconds, before incubating on ice for 2 minutes. To the cells was added 0.9ml of 
preheated (42°C) SOC medium, before incubating at 37°C, 225rpm for 1 hour. 
Appropriate volumes of the transformation mixture were plated onto LB plates 
containing 1 OOpg/ml ampicillin and incubated for a minimum of 17 hours at 37°C. 
Single colonies were picked and grown up in 3ml overnight cultures ready for DNA 
extraction by miniprep.
One Shot® TOPIO cells
Cloned PCR products were transformed into One Shot® TOPIO cells (Invitrogen Life 
Technologies) using the manufactures standard protocol.
Two microlitres of the TOPO cloning reaction was added to a vial of One Shot® 
Chemically Competent E.Coli (TOPIO) and incubated on ice for 5-30 minutes. The cells 
were heat shocked for 30 seconds at 42°C without shaking, and immediately transferred 
onto ice. Two-hundred and fifty microlitres of room temperature SOC medium was
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added and the cells incubated at 37°C, 200rpm, for 1 hour. Appropriate volumes (10- 
50pl) of each transformation reaction were plated onto pre-warmed selective plates (LB 
plates containing lOOpg/ml Ampicillin and pre-coated with lOOpl of 2% X-gal). The 
plates were incubated for a minimum of 17 hours at 37°C and single white or very light 
blue (not dark blue) colonies were picked and grown up in 3ml overnight cultures, 
before extracting the DNA by miniprep.
2.2.26 Transfection of COS-7 cells
COS-7 cells were grown in DMEM +10% FCS until 80% confluent. The cells were 
harvested with 0.25% Trypsin diluted 1:8 with Versene. The cells (~5xl06cells/ml) 
were washed once in cold PBS (centrifuging at 400 x g), and once in cold PBS + lOmM 
HEPES. One-hundred micro-litres of cell suspension were placed into a sterile 
electroporation cuvette and lpg of linearised {Pvul digested) plasmid was added to the 
cells. For stable transfections lpg of linearised (EcoRl digested) pcDNA3 was added to 
the cells with 2pg of linearised (Pvul digested) plasmid. The cells were electroporated 
using the BioRad Gene Pulser II (280v, 25 pF, 200Q).
To the cells was added 1ml of medium (DMEM+10%FCS+lmM Hepes). The cell 
suspension was transferred to a 60mm sterile tissue culture dish and a further 4ml of 
media was added. The cells were incubated at 37°C, 5% CO2. For transient transfections 
the cells were harvested with Trypsin solution (0.25% Trypsin diluted 1:8 with Versene) 
after 48 hours. For stable transfections, geneticin (G418 sulphate) was added to the cells 
(5-10mg/ml) after 48 hours. The cells were maintained in this selective medium for a 
further two weeks until stable clones had been established. The stably transfected cells 
were harvested and washed once in PBS before being resuspended in TRI­
REAGENT™ for RNA extraction.
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2.2.27 Cloning PCR products
Using the TOPO TA cloning® kit (Invitrogen life technologies), according to the 
manufacturers protocol.
The cloning reaction was set up with 0.5-4pl of fresh PCR product, lpl of salt solution, 
lpl of TOPO® Vector and sterile water to a total volume of 5 pi. The reaction was 
incubated at room temperature (22-23°C) for 5 minutes before placing on ice. The 
cloning reaction was then transformed into chemically competent TOPIO cells (See 
transformation of E.Coli strains).
2.2.28 Sequencing
DNA samples were sent for sequencing with the appropriate custom primers. All 
sequencing reactions were carried out by Lark Technologies Inc, Essex, UK.
2.2.29 Statistical Analysis
Chi-square test, using Yates continuity correction to allow for small numbers, was used 
to analyse the disease association of the 138G variant allele. For comparison of the 
phenotypic analysis between cell subsets in CD45 variant and control individuals, the 
Mann-Whitney test was used. Analysis of variance (ANOVA) was carried out to 
determine the significance of the observed difference between the proliferative 
responses of PBMC from CD45 variant and control individuals. All statistical analysis 
was carried out using MINTAB statistical software, version 13.1, MINITAB Ltd., USA.
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Effect of variant CD45 expression on cell phenotype
3.1 Introduction
An essential aspect of immune function is the differentiation of lymphoid cells in the 
periphery. Alterations in the expression of various surface markers, including molecules 
involved in adhesion, co-stimulation and migration are critical in the homing of 
lymphocytes and the activation of the immune response. Changes in expression are 
related to the different properties of naive, effector and memory cells (as discussed in 
Chapter 1) and have commonly been used to define these different populations.
The expression of different CD45 isoforms is cell type specific and dependant upon the 
activation and differentiation state of the cells (Akbar et al., 1988; Powrie, 1990). 
Following activation human T cells are found to lose expression of the high molecular 
weight isoforms containing the A exon and gain expression of the low molecular weight 
CD45R0 isoform. For this reason CD45 isoform expression is often used to distinguish 
naive (CD45RA+) and memory (CD45R0+) T cells. Despite this, little is known about 
the exact function of the different CD45 isoforms. It has been shown that CD45 
knockout mice and humans lacking CD45 expression are severely immunodeficient 
with few peripheral T lymphocytes (Kishihara et al., 1993; Byth et al., 1996; Kung et 
al., 2000; Tchilian et al., 2001). Therefore it is important to establish whether variant 
CD45 isoform expression has an effect on the proportions of different cell types or on T 
cell phenotype.
Schwinzer and Wongeit (1990) first observed a group of individuals with constitutive 
CD45RA expression on their T cells even after mitogen stimulation. This variant CD45 
expression was later associated with the exon 4 C77G polymorphism, which disrupts a 
strong exonic splice silencer, ESS1, that usually represses the inclusion of exon 4 
(Thude et a l 1995; Zilch et al., 1998; Lynch and Weiss, 2001). Recently a more
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prevalent polymorphism has been described in exon 6, with the A138G variant being 
present at an allele frequency of 23.7% in the Japanese population. One of the aims of 
this chapter is to determine the effects of the 138G variant allele on CD45 isoform 
expression. Using some of the important cell surface markers for characterising naive 
and memory cells we will also investigate the altered CD45 isoform expression on other 
aspects of lymphocyte phenotype.
T cell activation results in changes in the expression of cell surface markers including 
molecules involved in activation (CD25, CD69, HLA-DR), co-stimulation (CD27, 
CD28) and adhesion (CD 11 a, CD62L, CD44) as well as cytokine receptors such as 
CD25 and CCR7. CD69 is one of the earliest antigens to emerge upon activation of 
lymphocytes, appearing within two hours of stimulation. Although not expressed on 
resting lymphocytes, it is rapidly induced upon activation of T cells, B cells and NK 
cells. There are a number of markers for activation including MHC Class II molecules, 
which are expressed on various cells including dendritic cells, B cells, monocytes, and 
macrophages. HLA-DR (MHC Class II) is expressed on activated T cells. Expression is 
regulated by cytokines, including Interferon gamma. A marker of activation and a 
cytokine receptor, CD25 is the a-chain subunit of the IL-2 receptor, which is expressed 
on activated T cells, B cells and mononcytes. IL-2 is an important cytokine in the 
activation and proliferation of T cells, thymocytes, NK cells, B cells and macrophages.
CD27 is a member of the tumour necrosis factor receptor family, and is known to be a 
co-stimulatory molecule on T cells. It is expressed on naive cells, but down regulated 
on chronically activated cells, decreasing with cell division after activation. Work on 
CD27-/- mice suggest that it is important in memory responses, particularly in the 
responses of primed CD8+ cells to influenza virus (Hendriks et al, 2000). CD28 is 
another co-stimulatory molecule which is constitutively expressed on most T lineage 
cells and plasma cells. Generally, activation of T cells leads to enhanced CD28 
expression, while ligation of CD28 leads to its transient down-regulation. However, loss 
of CD28 is also associated with increasing differentiation, particularly among CD8 
cells.
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CD1 la, or the Leukocyte function antigen -  1 (LFA-1), is an adhesion molecules that is 
expressed on lymphocytes, granulocytes, monocytes and macrophages, with higher 
expression levels on memory T cells. CD lla is an integrin achain, which is expressed 
as a heterodimer non-covalently associated with CD 18 (integrin 02). It mediates cell­
cell and cell-matrix adhesion, so is important in many leukocyte functions, including 
proliferation and the interaction of leukocytes with tissues, such as the endothelium. 
Expression of the adhesion molecule CD44 is increased on memory T cells. It is the 
principal cell surface receptor for hyaluronate, and this interaction mediates binding of 
lymphocytes to high endothelial venules (HEV’s). Another cellular adhesion molecule 
important for the recirculation of lymphocytes through lymphoid tissue is CD62L or L- 
Selectin. It is involved in the initiation of rolling and the adhesion of lymphocytes to 
specialised HEV’s in lymph nodes and Peyer's patches. Whilst found on most resting 
lymphocytes, it is rapidly shed upon T cell activation (Chao et al., 1997). However, it 
can then be re-expressed and increased expression levels are seen after culturing in 
medium (Wallace and Beverley, 1993).
The chemokine receptor CCR7 is also involved in the control of lymphocyte homing to 
secondary lymphoid tissues. CCR7 has been used to divide human memory T cells into 
two functionally distinct subsets. These are CCR7+ central memory cells, which 
express lymph node homing receptors and lack immediate effector function and CCR7- 
effector memory cells which express receptors for migration to inflamed tissues and 
have immediate effector function (Sallusto et al, 1999). Expression of CCR7 is often 
correlated with that of other adhesion molecules such as CD62L and the combined loss 
of CCR7 and CD62L is predicted to be responsible for the loss of homing to lymphoid 
tissues of effector memory T cells.
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Objectives
The first objective of this chapter is to characterise the specific isoforms and level of 
CD45 expression, on different subsets of cells from individuals with the exon 4 C77G 
and exon 6 138G variant alleles. The second objective of this chapter is to investigate 
the phenotype of T cells from individuals with variant CD45 expression.
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3.3 Results
3.3.1 The C77G Polymorphism
3.3.1.1 Variant CD45 splicing
PBMC were isolated from Buffy Coat bags obtained from the National blood donor 
service (Colindale, North London). All of the samples were screened for the presence of 
the exon 4 C77G polymorphism by flow cytometry and confirmed by PCR 
amplification of genomic DNA and MspI digestion or direct sequencing. All of the 
assays were performed on cryopreserved PBMC.
In accordance with the previously published data (Schwinzer and Wonigeit, 1990) flow 
cytometric analysis of CD45RA and CD45R0 expression on T cells from C77G 
heterozygous individuals shows a distinct expression pattern (Figure 3.1a), with the 
absence of single positive CD45R0 cells. Whilst normal CD45 expression is 
characterised by the loss of CD45RA and the gain of CD45R0 expression upon 
activation, the lymphocytes from C77G heterozygous individuals are characterised by a 
lack of single CD45R0+ cells, even after stimulation (Figure 3.1b).
The C77G transversion introduces a new restriction site for the MspI endonuclease 
(C/CGG). Therefore the presence of the polymorphism can also be detected by the PCR 
amplification of genomic DNA (using Exon 4 (Mut) forward and reverse primers, see 
Chapter 2) and digestion of the PCR product with MSPI. Digestion with MSPI cleaves 
that mutant PCR product into two fragments of 72 and 83 base pairs (bp) as can be seen 
in Figure 3.2. All of the individuals identified so far have been heterozygous for the 
C77G polymorphism, so the presence of the 77C wild-type allele is shown by the un­
cleaved 155bp PCR product.
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Figure 3.1 Flow cytometric analysis of exon 4 C77G and control individuals. PMBCs were stained 
with CD45R0-PE, CD45RA-FITC and either CD4 or CD8-APC antibodies pre and post-stimulation 
with 10|ig/ml PHA for 10 days. Analysis was performed on CD4 and CD8 gated T cells. Normal 
expression is characterised by the loss o f CD45RA and gain o f CD45R0 expression upon activation. 
Variant CD45 expression is characterised by the absence o f the single CD45R0+ population even after 
stimulation.
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Figure 3.2 The detection of the exon A C77G 
polym orphism  was perform ed on genomic DNA by PCR 
and restriction enzyme digestion with MspI. The
polymorphism introduces a new MspI restriction site, and 
the mutant PCR product is cleaved into two fragments o f 72 
and 83bp.
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Figure 33 Percentage of different populations of cells in PBMC from common varian t C77C 
and heterozygous C77G individuals. Mean and standard deviation of ten individuals per group.
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3.3.1.2 Cell populations
PBMC from healthy C77C common variant and C77G heterozygous individuals were 
stained with anti- CD3, CD4, CD8, CD14, CD16, CD19 and CD56 antibodies. Figure
3.3 shows the proportion of the different cell types (mean of ten individuals per group). 
Although there is some individual variation, no significant differences were observed in 
the proportions of either CD4+ or CD8+ T cells between the C77C and C77G variant 
individuals (p>0.1 for all markers). This is also true for the proportions of B cells 
(CD 19+) and monocytes (CD 14+).
No differences were observed in the proportions of CD 16+ cells, which include natural 
killer (NK) cells, macrophages and mast cells. The proportions of NK cells were also 
confirmed by CD56 staining, and no significant differences were found in either the 
proportion of classical NK cells (CD56+ CD3- cells) or NK T cells (CD56+CD3+ cells) 
(data not shown). This data suggests that the variant CD45 expression caused by the 
C77G polymorphism does not have an effect on the proportions of different populations 
of cells.
3.3.1.3 CD45 isoform expression
Studies with CD45 transgenic mice have shown that CD45 expression level is important 
for the development and function of T cells (Tchilian et al., 2004). It is important to 
establish whether variant CD45 expression has an effect on the total CD45 expression 
level of different cell types. Figure 3.4a shows representative histograms of total CD45 
expression on different cell types of one C77C common variant and one C77G 
heterozygous individual. These cells were stained with PanCD45, a monoclonal 
antibody against an epitope present on all CD45 isoforms. Interestingly there does 
appear to be a slight shift in the total CD45 expression level, with the T cells, B cells 
and monocytes from C77G heterozygous individuals staining slightly brighter (Figure 
3.4b).
Despite the observable trend, large individual variation means that there is no 
significant difference in the CD45 expression level on T and NK cells from C77G
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Com m on variant C 77C  
Heterozygote C 77G
CD3+ cells CD4+ cells CD8+ cells
CD14+ cells CD16+ cells C D 19+cells
,-----
Pan45
Cell Type
CD45 Expression (Mean 
C77G
Fluorescence Intensity) 
C77C
CD3+ 942 +/- 360 620 +/- 304
CD4+ 795 +/- 293 539 +/- 159
CD8+ 1089 +/- 282 945 +/- 435
CD 14+ 1738 +/- 505* 1048 +/- 247
CD16+ 786 +/- 126 617+ /-269
CD19+ 1661 +/-413* 1176+/-258
Figure 3.4 Total CD45 expression on a range of different cell types. PBMC were stained with 
Pan45-PE (a monoclonal antibody against an epitope present on all CD45 isoforms) and a range of 
markers for different cell types. (A) Histograms showing one representative individual from each group 
o f 6 C77C common variant individuals (Black lines) and 6 C77G heterozygous individuals (Red lines). 
(B) Mean Fluorescence intensity of pan45 staining on each cell type. Mean o f 6 individuals per group, 
with standard deviation. Differences between C77G homozygous and C77C common variant 
individuals was analysed using the Mann-Whitney test: * p= 0.030.
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variant individuals (p> 0.05). However, it does appear that CD45 expression level is 
significantly increased on both B cells and monocytes from C77G variant individuals 
(p= 0.030).
Whilst the CD45R0 / CD45RA expression profiles have previously been described for T 
cells in variant individuals, relatively little is known about the expression profiles of the 
CD45 isoforms on other cell types. Figure 3.5 shows the CD45RA / CD45R0 and 
CD45RB / CD45RA expression profiles on different cell types. As unstimulated B cells 
(CD 19+) and NK cells (CD56+) are predominantly CD45RA+ CD45R0- there is no 
observable difference in the expression profiles of these isoforms between the C77G 
heterozygous and C77C common variant individuals on these cell types.
Previously, Schwinzer et al, (1992) studied CD45RA expression on monocytes and 
granulocytes from C77G variant individuals, and found that their monocytes expressed 
higher levels of CD45RA than those from C77C common variant individuals. Our data 
also show no observable difference in the CD45R0 / CD45RA expression pattern on 
monocytes (CD 14+), which are all double positive (CD45RA+ CD45R0+). However, 
in accordance with the previous study it does appear that the CD45RA expression is 
slightly brighter on monocytes from the C77G variant individuals. Schwinzer et al., also 
described the granulocytes from variant individuals as CD45RA+ when granulocytes 
from C77C common variant individuals did not express the CD45RA antigen. This 
may be an interesting area for further investigation, but due to sample constraints was 
not covered in this investigation.
The only obvious difference in the CD45R0 / CD45RA expression pattern is seen on T 
cells, with CD8+ T cells being particularly affected. When looking at the CD45RA / 
CD45RB expression pattern, it can again be seen that the cells from C77G heterozygous 
individuals are always CD45RA+, and correspondingly have less CD45RB low cells 
(Figure 3.5). This increase in the proportion of CD45RB high cells is predominantly 
observed in T cells, whilst other cell types such as B and NK cells which are generally 
found to be CD45RB high are not affected. CD45 isoform expression as determined by 
message level will be further discussed in Chapter 5.
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Figure 3.5 CD45 isoform expression on different cell types. PBMC were stained with a range o f 
cell type specific antibodies with isoform specific CD45R0, CD45RA and CD45RB antibodies. 
Profiles are shown gated on a different cell types. Examples are representative o f similar analysis on 
6 C77C common variant individuals and 6 C77G heterozygous individuals.
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3.3.1.4 T cell phenotype
To investigate the effects of C77G variant allele on other aspects of T cell phenotype, 
PBMC were stained with antibodies to a variety of cell surface markers. The markers 
investigated included molecules involved in activation (CD25, CD69, HLA-DR), co­
stimulation (CD27, CD28) and adhesion (CD 11 a, CD62L, CD44, CCR7). Other than 
the previously discussed difference in CD45RA expression, no significant differences 
are found in the phenotype of CD4 cells (Figure 3.6a).
Perhaps of more interest are the differences observed in the CD8+ T cells. Figure 3.6b 
shows a summary of the CD8 T cell phenotype. The most interesting differences are an 
increase in the percentage of C D lla high cells and a decrease in the percentage of 
CD28, CD62L and CCR7 positive cells. Although only the differences in CD28 
expression were found to be statistically significant (p= 0.04), this trend could suggest 
that the C77G heterozygous individuals have an increased proportion of antigen 
experienced or ‘primed’ CD8 T cells.
Further analysis was carried out to determine the distribution of these CD8 primed cells 
between the CD45R0+ and CD45RA+ subsets. As T cells from C77G heterozygous 
individuals are always CD45RA+, it is necessary to compare CD45R0- cells, which by 
default are single CD45RA+. This means that when comparing cells, we are comparing 
single positive CD45RA cells from C77G heterozygous individuals with the same 
subset from C77C common variant individuals. When comparing CD45R0+ cells it is 
important to remember that we are not comparing entirely equivalent populations. T 
cells from C77C common variant individuals express both double positive (CD45RA+ 
CD45R0+) cells, and single positive (CD45R0+) cells, which are both included in the 
analysis of the CD45R0+ subset. However, T cells from C77G individuals only have 
double positive (CD45RA+ CD45R0+) cells. With CD8 cells in particular this 
comparison is further complicated by the disparity in the proportions of the different 
populations (Figure 3.1a).
Figure 3.7 shows the further analysis of CD4 and CD8 cells in both the CD45R0+ and 
CD45R0- subsets. No real differences were observed in the CD4 cells other than a slight 
alteration in the proportion of CCR7+ cells. Figure 3.7b indicates that there is a slight
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Figure 3.6 Phenotype of CD4 and CD8 cells in common variant C77C and heterozygous C77G 
individuals. PBMC were stained with CD4 or CD8 and CD 11 a, CD27, CD28, CD45RA, CD62L, 
CD95 and CCR7. Proportions of (A) CD4 and (B) CD8 T cells expressing different markers. Data 
shows means and standard deviation o f  10 C77C common variant and 10 C77G heterozygous 
individuals. Differences between C77G homozygous and C77C common variant individuals were 
analysed using the Mann-Whitney test: * p= 0.0004, + p=0.04.
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Figure 3.7 Phenotype of CD4 and CD8 cell subsets in common variant C77C and heterozygous C77G individuals. Proportions of (A) CD4 and (B) CD8 T
cells that express CD45R0 and CD1 la, CD27, CD28, CD62L, CD95 or CCR7. Proportions of (C) CD4 and (D) CD8 T cells which are CD45R0 negative and 
express C D lla , CD27, CD28, CD62L, CD95 or CCR7. Data shows means and standard deviation of 10 C77C common variant and 10 C77G heterozygous 
individuals. Differences between C77G heterozygous and C77C common variant individuals were analysed using the Mann-Whitney test: * P=0.045, + P= 0.049
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decrease in the proportion of CD8 cells which are CD45R0+ CD27+, CD45R0+ 
CD28+, CD45R0+ CD62L+ and CD45R0+ CCR7+. This suggests an increased 
proportion of effector memory cells. Interestingly there is also an alteration in the 
proportion of CD8 cells which are CD45R0- CD lla high, CD45R0- CD28+ and 
CD45R0- CD62L+, which is indicative of an increased proportion of primed CD45RA 
effector cells.
This analysis has so far determined the proportion of subsets within the CD4 or CD8 
populations. This is valid, as we have shown that the proportions of CD4 and CD8 cells 
are equivalent in C77G variant and C77C common variant individuals. However, the 
differences in the proportion of CD8+ CD45R0+ effector memory cells may be partially 
caused by the altered proportions of CD45R0+ cells in variant individuals. Therefore it 
is also necessary to look at the distribution of different subsets within the CD8+ 
CD45R0+ population. The size of the CD8+ CD45R0+ population does differ slightly 
between the C77C common variant (42.5% +/- 14.2) and C77G heterozygous 
individuals (32.8% +/- 8.5). However, what we are interested in here is the distribution 
of different subsets within this population, which theoretically should not be affected. 
Figure 3.8 shows the distribution of CDlla, CD27, CD28 and CCR7 within the CD8+ 
CD45R0+ subset. The individual variations in this analysis are large, and none of the 
observed differences were found to be statistically significant. However, there are some 
consistent trends in the data, which may become more significant if larger sample 
groups can be used.
There appears to be an increased proportion of primed CD45RA cells in the C77G 
heterozygous individuals. The difference in the proportion of cells is approximately a 
10% shift in each of these four markers. Whilst there is no conclusive proof, it does 
suggest that what we are observing is actually a change in one particular subset of cells. 
Remarkably, with the exception of CCR7, analysis of the markers within the CD8+ 
CD45R0- subset shows exactly the same expression pattern. Figure 3.9 clearly shows an 
increased proportion of CDlla high cells and an increased proportion of CD28- and 
CD62L- cells, all indicating an increased proportion of ‘primed’ or ‘antigen- 
experienced’ cells. If anything this bias towards the primed population is slightly larger 
than the shift from central to effector memory observed in the CD8+ CD45R0+ subset, 
with a shift of around 15%. It is possible that this is a population of CD45RA ‘revertant’
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cells, stable populations of virus specific CD45RA+ cells which are CD lla high and 
CCR7 low and have shorter telomeres than ‘naive’ CD45RA+ cells (Warren and 
Skipsey, 1991; Faint et al., 2001; Kuijpers et al., 2003).
Although usually a good indicator, phenotype does not necessarily correlate with 
function of cells. Functional studies need to be carried out to establish whether these 
primed CD45RA+ cells are true memory cells, or indeed if they have the same 
functional abilities of equivalent subsets of cells from C77C common variant 
individuals. Further studies could include looking at responses to antigen, ability to 
produce cytokines, clonality or telomere length of T cells.
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Figure 3.8 Phenotype of CD8+ CD45R0+ subset of cells in common varian t C77C and 
heterozygous C77G individuals. PBMC were gated on CD8+ CD45R0+ cells and percentage o f cells 
that express C D lla , CD28, CD62L, and CCR7 was determined. Data shows mean o f 10 C77C 
common variant and 10 C77G heterozygous individuals.
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Phenotype of CD8+ CD45R0- subset
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Figure 3.9 Phenotype of CD8+ CD45R0- subset of cells in common varian t C77C and 
heterozygous C77G individuals. PBMC were gated on CD8+ CD45R0- cells and percentage of 
cells that express C D lla , CD28, CD62L, and CCR7 was determined. Data shows mean of 10 C77C 
common variant and 10 C77G heterozygous individuals.
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3.3.2 The exon 6 A138G polymorphism. 
3.3.2.1 Variant CD45 splicing
PBMC were isolated from healthy Japanese donors at the Osaka City University 
Medical School and cryopreseved before shipping to the UK (Courtesy of Kouzo Hirai, 
Osaka, Japan). Genomic DNA was extracted and all samples were screened for the 
presence of the 138G exon 6 polymorphism by ARMS PCR and confirmed by 
sequencing (Stanton et al., 2003).
To determine whether the novel exon 6 138G polymorphism has an effect on CD45 
splicing we investigated the expression of CD45RA and CD45R0 on T cells. Figure 
3.10a shows the CD45RA / CD45R0 expression profile of CD3+ T cells before and 
after stimulation with PHA. Unlike the previously described exon 4 C77G 
polymorphism, the 138G polymorphism does not appear to prevent splicing of any 
particular isoform, but promotes splicing towards the low molecular weight CD45R0 
isoform. This effect is particularly pronounced in the G138G homozygous individuals. 
Unsurprisingly no differences are observed in PHA stimulated T cells, which after 
activation only express the CD45R0 isoform. Analysis of CD4 and CD8 T cells shows 
that whilst the proportion of CD45R0 + cells is increased in both cell types, for G138G 
homozygous individuals it is particularly pronounced in the CD8+ cells (Figure 3.10b). 
The effects of the 138G polymorphism on CD45 splicing will be investigated further 
using minigene constructs in Chapter 5.
3.3.2.2 Cell populations
To establish whether the 138G polymorphism has any affect on the proportions of 
different cell types, PBMC from healthy A138A common variant and G138G 
homozygous individuals were stained with antibodies against CD3, CD4, CD8, CD 14, 
CD 19 and CD56. Figure 3.1 la shows the proportion of the different cell types (mean of 
four individuals per group). Although there is some individual variation, there are no 
significant differences (p>0.1) in the proportions of T cells (CD3+, CD4+ or CD8+), B 
cells (CD 19+), monocytes (CD 14+) or NK cells (CD56+).
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Figure 3.10 Flow cytometric analysis of variant CD45 splicing. A. PMBCs were stained with 
CD3-APC, CD45R0-PE and CD45RA-FITC antibodies pre and post-stimulation with lOpg/ml PHA 
for 10 days. Analysis was performed on CD3 gated T cells. Variant CD45 expression is 
characterised by the increased number o f cells expressing CD45R0 before stimulation. Normal and 
variant CD45 cells show loss of CD45RA and gain o f CD45R0 expression upon activation. B. 
PBMC were stained with CD4 or CD8 and CD45R0. Both heterozygous A138G and homozygous 
G138G individuals have increased percentages of CD45R0+ cells. Data shows mean and standard 
deviation for 4 individuals per group. * p= 0.030. Differences between A138G or G138G and 
A 138A individuals were analysed using the Mann-Whitney test.
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Figure 3.11 (A). Percentage of different populations of cells in PBMC from common variant 
A138A and homozygous G138G individuals. Mean o f four individuals per group, error bars give 
standard deviations. (B). Total CD45 expression profiles on CD4+, CD8+ and CD 19+ cells. PBMC 
were stained with Pan45-PE (a monoclonal antibody against an epitope present on all CD45 isoforms) 
and CD4, CD8 or CD 19. Histograms show one representative individual from 2 A138A common 
variant individuals (black line), 2 A138G heterozygous individuals (purple line) and 2 G138G 
homozygous individuals (red line).
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3.3.2.3 CD45 isoform expression
It is important to establish whether the 138G polymorphism has an effect on the total 
CD45 expression level. Figure 3.11b shows preliminary data of total CD45 expression 
profiles of CD4+ and CD8+ T cells and CD 19+ B cells. Although larger sample groups 
will be necessary for confirmation, the histograms suggest that there is no difference in 
the total CD45 expression level on these different cell types between the A138A, 
A138G or G138G individuals.
Further analysis of CD45RA / CD45R0 expression profiles on different cell types 
shows that whilst there is an increased proportion of CD45R0+ T cells in the G138G 
homozygous individuals, the expression profiles on the other cell types are unaltered 
(Figure 3.12). The 138G variant individuals, whether heterozygous or homozygous, 
have increased proportions of T cells expressing CD45R0 in either the presence or 
absence of CD45RA (Figure 3.10) or the absence of CD45RC (Figure 3.13). Further 
investigations into CD45 isoform expression on CD3+ T cells reveals that 138G variant 
individuals have decreased proportions of T cells expressing both the CD45RA and 
CD45RC or CD45RA and CD45RB isoforms (Figure 3.13). Correspondingly there is an 
increase in the proportion of CD45RA- CD45RC- and CD45RA- CD45RB- cells in 
138G variant individuals, further suggesting a bias towards CD45R0 expression.
3.3.2.4 T cell phenotype
Although we have shown that the 138G variant allele has a quantitative effect on CD45 
splicing, with an increase in the proportion of CD45R0+ T cells, little is known about 
the effects of this on other aspects of T cell phenotype. Whilst phenotypic 
characterisation is useful for defining populations of cells, particularly for identifying 
naive / memory cell populations, none of the markers used are completely accurate in 
representation of cell function and stage of differentiation. Establishing that there are an 
increased proportion of CD45R0+ cells does not necessarily mean that there is a 
corresponding increase in true memory cells (i.e. members of expanded clones).
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Figure 3.12 CD45 isoform expression on different cell types. PBMC were stained with a range of 
cell type specific antibodies together with isoform specific CD45R0 and CD45RA antibodies. 
Profiles are shown gated on a different cell types. Examples are representative of similar analyses on 
6 A138A common variant individuals and 4 G138G homozygous individuals.
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CD45RA
Common variant Heterozygote Homozygote
A138A A138G G138G
t
CD45RC
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CD45RA
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Cell Subset
Common Variant 
A138A
Heterozygote
A138G
Homozygote
G138G
CD45RA+ CD45RC+ 73.7 +/- 12.0 49.6+/- 1.9 41.5+ /-5 .5
CD45RA- CD45RC- 18.7+/-8.4 34.5 +/- 5.5 36.0 +/- 3.7
CD45RA+ CD45RB+ 71.3+/- 14.1 55.9 +/- 12.5 56.3 +/- 5.5
CD45RA- CD45RB- 10.1 +/- 7.8 20.7 +/- 7.6 21.8+/-2.1
CD45RC+ CD45R0+ 11.2+/-5.4 13.4 +/- 6.3 40.6 +/- 5.7
CD45RC- CD45R0+ 20.1 +/- 6.6 32.0 +/- 6.4 36.1 +/-5.0
Figure 3.13 Expression of CD45 isoforms on CD3+ T cells. (A) PBMC were stained with 
isoform specific antibodies against CD45RA, CD45RB, CD45RC and CD45R0. Analysis was 
performed on CD3+ gated cells. Examples representative of similar analysis o f four individuals per 
group. (B) CD45 isoform expression expressed as a percentage o f CD3+ T cells. Mean and 
standard deviation o f four A138A common variant, four A138G heterozygous and four G138G 
homozygous individuals.
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Initial phenotypic analysis shows that the phenotype of CD4 cells from 138G variant 
individuals is ‘primed’ or antigen experienced, with a reduction in the proportions of 
CD27+ and CD62L+ cells and an increase in CD95+ cells. No change was detected in 
CDlla, CD25, CD28, CD69 or CCR7 expression (Figure 3.14a). The difference in the 
CD8 cell phenotype is more striking, as although not always statistically significant, 
there is a consistent trend in all of the markers investigated. Figure 3.14b shows an 
increase in the percentage of CD lla high and CD95+ cells, with a corresponding 
decrease in the percentage of CD27+, CD28+ CD45RA+, CD62L+, and CCR7+ cells. 
This is suggestive of an increased proportion of antigen experienced effector cells.
Figure 3.15 shows the further analysis of CD45R0+ and CD45R0- subsets of CD4 and 
CD8 T cells. Again whilst the CD4 cells show the same trends as those observed in the 
CD8 cells, they tend to be weaker. The most striking difference is that completely 
different expression patterns are observed in the CD45R0+ and CD45R0- subsets. 
Amongst the CD8+ CD45R0- subset (Figure 3.15d) there is a decrease in the percentage 
of cells which are CD27+, CD28+, CD62L+, and CCR7+. This may be indicative of an 
increased proportion of primed CD45RA cells.
In the CD8+ CD45R0+ subset, G138G homozygous individuals appear to have 
increased proportions of CD27+, CD28+ and CCR7+ cells (Figure 3.15b). This would 
suggest the presence of increased proportions of resting or central memory cells. To 
further establish the relative proportions of antigen experienced cells within each subset, 
the phenotype of cells within the CD8+ CD45R0+ subset was determined.
Whilst not statistically significant on this limited sample set, consistent differences can 
be observed in both the CD8+ CD45R0+ and CD8+ CD45R0- subsets from G138G 
homozygous compared to A138A common variant individuals. Figure 3.16 shows that 
an increased proportion of the CD8+ CD45R0+ subset are CD1 la low, CD27+, CD28+ 
and CCR7+ in the G138G variant compared to A138A common variant individuals. 
This may be indicative of a central memory phenotype. However, caution must be taken 
when interpreting this subset, as the CD45R0+ subset also includes double positive 
CD45RA+ CD45R0+ cells. In this instance the CD8+ cells from A138G homozygous 
individuals contains an increased proportion of CD45R0+ CD45RA+ cells (22.5% +/- 
5.1) compared to the A138A common variant individuals (12.7% +/- 10.2). This double
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positive population is a transient population, with a variable phenotype, which when 
included in the analysis of the CD45R0 subset may have an effect on the observed 
phenotype.
When looking in further detail at the CD8+ CD45R0- subset it can be seen that, with 
some individual variation, the G138G variant individuals tend to have an increased 
proportion of CD lla high, CD28- and CCR7- cells compared to A138A common 
variant individuals (Figure 3.17). It is also worth noting that the difference in each of 
these markers is 10-15%, suggesting that rather than a general increase in the proportion 
of primed effector cells, there may be an increase in a particular subset of antigen 
experienced cells.
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Figure 3.14 Phenotype of CD4 and CD8 ceils in 138G variant and A138A control individuals.
PBMC were stained with CD4 or CD8 and C D lla , CD27, CD28, CD45RA, CD62L, CD95 and 
CCR7. Proportions o f (A) CD4 and (B) CD8 T cells expressing different markers. Data shows means 
and standard deviation of 6 A138A common variant and 4 A138G heterozygous and 4 G138G 
homozygous individuals. Differences between G138G or A138G individuals and A138A controls 
were analysed using the Mann-Whitney test: * p< 0.030.
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Figure 3.15 Phenotype of CD4 and CD8 cell subsets in 138G variant and A138A control individuals. Proportions of (A) CD4 and (B) CD8
T cells that express CD45R0 and C D lla , CD27, CD28, CD62L, CD95 or CCR7. Proportions of (C) CD4 and (D) CD8 T cells which are 
CD45R0 negative and express C D llahi, CD27, CD28, CD62L, CD95 or CCR7. Data shows means and standard deviation of 6 A138A 
common variant and 4 A138G heterozygous and 4 G138G homozygous individuals. Differences between G138G or A138G individuals and 
A138A controls were analysed using the Mann-Whitney test: **p=0.014, * p=0.025, + p= 0.043.
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Figure 3.16 Phenotype of the CD8+ CD45R0+ subset of cells in common variant A138A and 
G138G homozygous individuals. PBMC were gated on CD8+ CD45R0+ cells and percentage o f cells 
that express C D lla , CD28, CD62L, and CCR7 was determined. Data shows mean of 6 A 138A 
common variant and 4 G138G homozygous individuals.
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Phenotype of CD8+ CD45R0- subset
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Figure 3.17 Phenotype of CD8+ CD45R0- subset of cells in common varian t A138A and 
homozygous G138G individuals. PBMC were gated on CD8+ CD45R0- cells and percentage o f cells 
that express C D lla , CD28, CD62L, and CCR7 was determined. Data shows mean of 6 A138A 
common variant and 4 G138G homozygous individuals.
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3.4 Discussion
The purpose of the work discussed in this chapter has been to define the CD45 
expression patterns and T cell phenotype of exon 4 C77G and exon 6 138G variant 
individuals. We have established that neither the exon 4 C77G nor exon 6 A138G 
polymorphisms have any significant effect on the proportions of the different 
leukocytes. It is interesting that whilst the total CD45 expression level is slightly 
increased on T cells from C77G variant individuals, it is significantly increased on both 
monocytes and B cells. The increase in expression is small and individual variability in 
expression is large, so this analysis should be confirmed using a more precise method of 
quantification, such as real time PCR. Recent studies using transgenic mice expressing 
single CD45 isoforms have shown that whilst expression of either high or low 
molecular weight isoforms can restore immune function, it is the total level of CD45 
expression which is important (Ogilvy et al, 2003; Tchilian et al., 2004). This makes 
further clarification of CD45 expression level on variant individuals essential, as we 
could potentially be investigating two different but inter-related phenomena; the effect 
of both total expression level, and altered isoform expression.
The fact that monocytes have been observed to be CD45RA bright (Schwinzer et al., 
1992) is in agreement with the finding of increased total CD45 (Figures 3.4 and 3.5). 
Although not studied here granulocytes have been shown to be CD45RA bright in 
C77G individuals (Schwinzer et al., 1992) so it could be postulated that they may also 
be found to have increased CD45 expression in C77G variant individuals. The 
activation state of B cells and monocytes in C77G variant individuals has yet to be 
established and it is possible that variant CD45 isoform expression does have an effect 
on cell phenotype. This would not have necessarily been expected, particularly in the 
case of B cells which in unstimulated PBMC are all found to be single CD45RA+. One 
of the many areas for further investigation in CD45 variant individuals is whether there 
is any difference in the phenotype or function of their peripheral B cells.
The frequency of the C77G polymorphism is low, but its presence in the healthy 
population suggests it is unlikely to have a dramatic effect on any of the cells types. 
Certainly from our observations on T cells the effects of variant isoform expression 
appear to be relatively subtle and more involved with altering the proportions of
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subpopulations of cells. In accordance with previous studies, we have shown that 
individuals heterozygous for the C77G allele have a variant pattern of CD45RA / 
CD45R0 isoform expression on their T cells. T cells from variant individuals fail to 
express the single CD45R0 isoform, even after stimulation with PHA for 10 days.
The CD4+ T cells from variant individuals have a similar phenotype to that of C77C 
common variant individuals, both in the CD45R0+ and CD45R0- subsets. It is 
interesting that the CD8 T cells are more affected, a phenomenon which will be 
discussed further in terms of functional responses in later chapters. Despite having the 
same proportion of CD8 cells, the proportion of primed effector cells appears to be 
increased in the C77G variant individuals. This is found both in terms of the proportion 
of CD8 cells and also the proportions of the CD45R0+ and CD45R0- subsets within the 
CD8 population. However, the most pronounced effect is the increased proportion of 
primed CD8+ CD45RA+ cells in C77G variant individuals. As we have demonstrated 
that the percentage of the different cell types is equivalent in C77G variant and C77C 
control individuals, assuming that variant individuals do have the same total lymphocyte 
counts, it can be postulated that this alteration in the proportion of primed CD8+ 
CD45RA+ cells will equate to an increase in the absolute number of these cells in C77G 
variant individuals.
Previously a subset of CD8+ CD45RA+ T cells have been described with a distinct 
phenotype, which after priming ‘revert’ from expressing CD45R0 to expressing 
CD45RA. These were found to be a stable population of virus specific cells, with a 
C D lla high, CCR7 low phenotype and shorter telomeres than CD45RA+ CD lla low 
cells (Warren and Skipsey, 1991; Wills et al., 1999; Faint et al., 2001; Dunne et al., 
2002; Kuijpers et al., 2003). The existence of CD4+ CD45RA+ revertant cells is more 
controversial. Whilst memory cells have been shown to be present in the CD4+ 
CD45RA+ population (Richards et al., 1997) reversion from CD45R0 to CD45RA 
expression has not been well documented in CD4 cells. This may in part explain why in 
the C77G variant individuals, primed cells are primarily observed in the CD8+ 
CD45RA+ and not CD4+ CD45RA+ cell subsets.
The increased proportion of CD8+ CD45RA+ ‘primed’ effector type cells observed in 
the C77G variant individuals may be a ‘revertant’ population. It is plausible that the
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block in completely switching to single CD45R0 expression in some way increases their 
ability to ‘revert’ to CD45RA expression. Of course the phenotypic identification of a 
‘primed’ population CD8+ CD45RA+ cells is not conclusive proof that these are 
revertant cells. To prove this, detailed analysis of the naive and primed CD8+CD45RA+ 
cells would be required, which may include looking at telomere length to determine 
number of cell divisions or proliferative and cytokine responses. The problem with such 
experiments is that the better defined the subset of cells is, the smaller it is, requiring 
large amounts of starting material and making them unfeasible in the present study.
If this population is identified as a ‘revertant’ population it does pose an interesting 
question. In Chapter 1 we discussed the possible associations of the C77G 
polymorphism with disease. The most striking associations are with viral infection, 
particularly with susceptibility to and failure to clear Hepatitis C infection (E.Tchilian, 
Personal communication). As CD45RA ‘revertant’ cells are usually virus specific, 
often correlating with CMV seropositivity (Kuijpers et a l , 2003) the question is 
whether the abnormal T cell phenotype observed in C77G variant individuals has a role 
in the susceptibility to and inability to clear viral infections, or is merely a consequence 
of it. It should also be remembered that the proportions of CD8+ CD45RA+ effector 
cells increases with age (Hong et al., 2004), which will also correlate with other factors 
such as CMV seropositivity, as the likely hood of infection also increase with age. All 
of the individuals in this study were middle aged (between 23 and 58 years old), with 
variant and control individuals being age matched as closely as possible. Therefore any 
effects of age on the proportions of different cell subsets should be equivalent in each 
group, but may be an important factor in designing further studies.
The second part of this chapter involves the phenotypic characterisation of T cells from 
individuals with the exon 6 138G variant allele. As with the previously described C77G 
polymorphism, we have shown that variant allele expression does not have an effect on 
the proportions of the different cell types in the peripheral blood, or the total CD45 
expression level on T cells. Further to this we have demonstrated that the T cells from 
138G variant individuals are not lacking in their expression of any of the CD45 
isoforms. However, whilst there were no qualitative differences in isoform expression 
there is a quantitative difference in the proportion CD45R0 cells, both with and without 
CD45RA expression, in unstimulated T cells. Corresponding to this we have also
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observed a decrease in the proportion of T cells expressing CD45RA and CD45RC or 
CD45RA and CD45RB. Upon stimulation with PHA all of the T cells switched to 
expressing low molecular weight isoforms (CD45R0 and CD45RB).
Phenotypic analysis of both CD4 and CD8 cells shows an increased proportion of 
antigen experienced or activated cells in 138G variant individuals. Detailed analysis of 
the CD45R0+ subset suggests that it contains fewer effector type cells (CD45R0+ 
CCR7-) in 138G variant individuals, and an increased proportion of central memory 
cells (CD45R0+ CCR7+). This holds whether considering the subset as a proportion of 
CD8+ cells or as a proportion of the CD8+ CD45R0+ cells, suggesting that it is not just 
an artefact of the increased number of CD45R0+ cells.
Phenotype alone can not establish whether this is a true memory subset, and further 
functional studies are necessary. It is possible that this increased memory phenotype 
subset could actually contain highly diverse nai've cells. Alternatively it could contain 
more diverse expanded memory clones than those in 138A control individuals, or 
simply larger clones than are normally observed, which may not offer any kind of 
advantage. There is also a question as to whether these individuals are more susceptible 
to disease. To date the disease association studies have shown a protective effect of the 
138G variant allele against certain autoimmune and infectious diseases (as discussed in 
chapter 1). However if there is an increase in the memory cell repertoire, this may 
suggest an increased exposure to antigen, and therefore possibly an increased history of 
infection.
Whilst variant CD45 expression does not have an effect on the proportions of 
leukocytes, it does have a profound effect on the proportions of T cell subpopulations. 
In exon 4 C77G variant individuals there is an increased proportion and absolute 
number of CD8+CD45RA+ effector cells, whilst in the exon 6 138G variant 
individuals, there is an increased proportion of central memory cells (CD8+ 
CD45R0+CCR7+). The functional consequences of these phenotypic alterations will be 
investigated in the next chapter.
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Effects of variant CD45 expression on in vitro functional responses
4.1 Introduction
The phosphatase activity of the CD45 antigen is essential for efficient antigen receptor 
signalling, as has been demonstrated in CD45-negative cell lines (Pingel and Thomas, 
1989; Weaver et a l, 1991) , CD45-deficient mice (Kishihara et a l, 1993; Byth et al, 
1996) and humans (Kung et a l, 2000; Tchilian et al, 2001). Mice and humans lacking 
CD45 are severely immunodeficient, with few peripheral T cells and impaired T and B 
cell responses.
The main substrates of CD45 phosphatase activity have been shown to be members of 
the Src family of tyrosine kinases. CD45 can operate as both a positive and negative 
regulator of Src family kinases (Ostergaard et al, 1989; Shiroo et al, 1992). It has also 
been suggested that CD45 can function as a Janus kinase (JAK) phosphatase, negatively 
regulating cytokine receptor signalling which is involved in the differentiation, 
proliferation and anti-viral activity of haematopoietic cells (Irie-Sasaki et al, 2001). 
This would suggest that differential isoform expression has a role in the regulation of 
cytokine production and proliferative responses after stimulation of the T cell antigen 
receptor.
Several groups have investigated the proliferative responses of ‘naive’ CD45RA+ and 
‘memory’ CD45R0+ T cells to various stimuli. It has been demonstrated that 
alloantigens and mitogenic lectins can activate both CD45R0+ and CD45RA+ cells to 
the same extent. It has also been demonstrated that responses to recall antigens are 
markedly increased in the CD45R0+ subset (Merkenschlager et al, 1988; Plebanski et 
al, 1992), in terms of both magnitude and kinetics (Young et al, 1997).
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Robinson et al., (1993) showed an increase in proliferative response in the CD45R0+ 
subset after stimulation with anti-CD3 antibodies. This study measured CD3 antigen- 
induced calcium signals, diacylglycerol (DAG) production and protein kinase C (PKC) 
activation levels in both the CD45R0+ and CD45RA+ subsets. The CD3-induced rise in 
intracellular calcium was found to be higher in the CD45R0+ subset, as was the PKC 
activation level. The CD45R0+ cells were also found to have higher basal levels of 
DAG and PKC activity, suggesting that the signalling thresholds may be altered in these 
cells.
Kuiper et al., (1994) investigated the different responses of CD4+ CD45R0+ and CD4+ 
CD45RA+ cells to co-stimulation with CD3 and CD28. This study found that even in 
the presence of optimal CD28 co-stimulation, naive CD45RA+ cells are still less 
responsive to CD3 stimulation and required a higher level of both CD3 and CD28 cross- 
linking than memory cells. This supports the idea that whilst the signalling mechanisms 
are the same in both subsets, it is the signalling threshold that is critical for activation. It 
was further demonstrated by Schwinzer et al., (1994) that when CD3 stimulation was 
combined with activation of PKC by phorbol ester, the naive CD45RA+ cells responded 
equally as well as the CD45R0+ cells. They suggest that both subsets have the same 
potential for signalling through the TCR, and it is the co-stimulatory signals which 
ultimately determine the strength of the response.
These results are seemingly contradicted in a study of CD4 cells by Hall et al., (1999), 
in which the naive CD45RA+ cells were found to give the largest rise in intracellular 
calcium and greater inositol triphosphate generation. This suggests that antigen 
receptors on naive cells are able to signal more effectively, especially at an early stage. 
This disparity could be explained by the fact that in the study by Robinson et al., (1993) 
there were a proportion of recently activated cells in the CD45R0+ subset. These 
recently activated HLA-DR+ cells were excluded from the study of Hall et al., (1999), 
which would undoubtedly have an effect on the kinetics and magnitude of the observed 
response. Whilst HLA-DR is not the most reliable marker for activation status and 
others such as CD25, CD69 or CD54 (ICAM-1) are more commonly used, these studies 
do show the effect of including small subsets of activated cells.
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One of the major problems with comparing data from different proliferative studies is 
the comparison of slightly different subsets. This is dependant upon the separation 
protocols used, particularly whether double positive (CD45RA+CD45R0+) cells are 
completely excluded or are partially included in either subset. This can be further 
complicated, particularly in CD8+ cells by the presence of antigen experienced 
CD45RA+ cells, which may have altered proliferative responses compared to truly 
nai've cells.
A study by Sallusto et al., (1999) which investigated the responses of different subsets 
of CD8+ T cells, defined by CCR7 and CD45RA expression, showed that both effector 
memory (TEM, CCR7- CD45RA-) and central memory ( T c m , CCR7+ CD45RA-) cells 
respond better to stimulation with either CD3 alone, or co-stimulation with CD3 and 
CD28 than naive (CCR7+ CD45RA+) cells. They also demonstrated that the effector 
memory cells required lower doses of stimuli and responded quicker then the central 
memory cells.
This shows that there are phenotypic differences within both the CD45R0 and CD45RA 
populations, giving differences in the proliferative potential between and within the 
CD45R0 and CD45RA subsets. Both C77G and 138G variant individuals have altered 
isoform expression on their T cells, so it could be speculated that the proliferative 
responses particularly to TCR stimulation may also be altered.
As previously discussed in chapter one, upon activation of nai've CD4+ cells in the 
presence of IL-12, IFNy or TGFp, the ThO cells differentiate into Thl cells, which can 
release cytokines such as IFNy and TNFp. An important role of IFNy is in the 
activation of macrophages, increasing their antimicrobial efficiency and targeting 
bacterial infections. IFNy also acts to inhibit the polarisation of Th2 cells. In the 
presence of IL-4, ThO cells differentiate into a Th2 phenotype. Th2 cells can release IL- 
4 and IL-5 and also IL-6, 9, 10 and 13. Th2 cells can induce activation of mast cells and 
eosinophils. IL-4 and IL-5 can also provide T cell help to B cells to produce antibodies 
(Romagnani, 1992; Lehar and Bevan, 2004).
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Activation of naive CD8+ cells drives differentiation into Tel or Tc2 cells. Tel cells, 
often referred to cytolytic T cells (CTL) have direct cytolytic activity, release IL-2 and 
IFNy, and are essential in the clearance of intracellular pathogens. Tc2 cells have a 
helper function similar to CD4+ cells and release cytokines including IL-4, 5, 6 and 10 
(Seder et al., 1992). Upon re-stimulation both subsets of CD8 cells become cytotoxic 
(Cerwenka et al., 1998).
On stimulation with PMA and Ionomycin CD4+ cells produce more IL-2 and IL-4, 
whilst CD8+ cells produce more IFNy and TNFa. CD45R0+ cells secrete greater 
amounts of all of these cytokines and show different kinetics to the CD45RA+ cells 
(Conlon et al., 1995; Mascher et al., 1999). However there is a subset of CD8+ 
CD45RA+ antigen experienced cells (CDllahigh, CCR7 low) which have also been 
shown to be potent producers of IFNy (Faint et al., 2001). Given the complex and 
variable nature of cytokine production in different subsets, alterations in the proportions 
of effector and memory cells would have an effect on the balance of cytokines 
produced. Since CD45 variant individuals have altered proportions of activated and 
memory cells, it is possible that the cytokine profiles in these individuals are also 
altered.
4.2 Objectives
The aim of this chapter is to determine whether the altered proportions of naive and 
activated T cells observed in CD45 variant individuals alter their functional responses. 
Proliferative responses and cytokine production to different stimuli were investigated in 
both C77G and 138G variant individuals.
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4.3 Results
4.3.1 Proliferative responses of PBMC
4.3.1.1 The exon 4 C77G variant carriers
In the previous chapter we have shown that C77G variant individuals have increased 
proportions of primed CD8+ CD45RA+ T cells. The only study to describe the 
proliferative response of T cells in C77G variant individuals was by Schwinzer and 
Wonigeit (1990). In their study PMBC were stimulated with CD3 or PHA for 4 days 
and no significant differences were found between the 3 C77G variant and 4 control 
individuals in response to either stimulus.
To investigate the effect of the C77G variant allele on proliferation, we stimulated 
PBMC from variant and control individuals with PHA, CD3 and PMA and Ionomycin, 
determining dose dependency and time course of response. PHA-P is a lectin isolated 
from the red kidney bean Phaseolus vulgaris, which binds glycoproteins and has a 
variety of uses including mitogenic stimulation of lymphocytes. PMA has an analogous 
structure to Diacylglycerol (DAG), which is an allosteric activator of protein kinase C 
(PKC) so can activate T-cells and stimulate low-level production of IL-2. PMA was 
used in conjunction with Ionomycin, a calcium ionophore, which extracts Ca from 
aqueous to organic phase, raising free intracellular calcium and thus increasing T cell 
activation. Anti-CD3 antibody was used as a direct stimulator of the TCR. The UCHT1- 
2a clone was specifically chosen, as everybody should respond to it in the soluble form, 
whilst due to a polymorphism in the Fc receptor this is not the case for an IgGl or 
IgG2b antibody. Cells were also co-stimulated with anti-CD3 and anti-CD28 antibodies, 
as CD28 is a co-stimulatory molecule which with TCR stimulation can increase 
proliferative responses.
No differences were observed between the variant and control groups in response to 
stimulation with mitogen, either PHA-P or PMA and Ionomycin. Whilst PHA-P is T 
cell specific, PMA and Ionomycin elicits a broad response, stimulating most cell types 
in the culture. As this variant allele is found in healthy individuals, it is reasonable to 
assume that any differences in their responses would be minor, or easily compensated
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for. It is plausible that by using whole PBMC cultures any small differences in a 
particular cell type are being masked. We therefore focused on using TCR specific 
stimuli, culturing PBMC with varying doses of purified CD3 (UCHTl-2a) or co- 
stimulating with CD3 and CD28 (15E9).
Figure 4.1a shows the kinetics of the response to 0.25pg/ml CD3 of 5 individuals in 
each group. The variant and control individuals have similar kinetics, with the peak 
response occurring at 72 hours post-stimulation. Whilst the timing of the response is 
the same, there is a difference in magnitude, which is most evident at 72 hours. From 
figure 4.1b there appears to be a significant difference in the magnitude of the response 
to CD3 (p=0.04 using a two-tailed analysis of variance, ANOVA). This effect was 
found to be similar at all doses (p=0.91). The C77G variant samples have a slightly 
lower response which could mean that the variant individuals are not as efficient at 
signalling through the CD3 receptor.
Co-stimulating cells with CD3 and CD28 has a synergistic effect, with both control and 
variant samples showing a higher response than with CD3 alone, but neither responding 
to CD28 alone. Figure 4.2a shows the response to CD3 (0.25|ag/ml) and CD28 
(2.5p.g/ml) co-stimulation over time. The peak response observed is still at 72 hours, 
and the magnitude of the response appears to be identical in both groups. This is also 
evident in figure 4.2b, where given a reasonably large dose of CD28, there is no 
difference in the proliferative responses of the two groups, even at lower doses of CD3.
This might suggest that co-stimulation with CD28 has a greater effect on PBMC from 
C77G variant individuals than controls, as it brings a reduced response to CD3 alone, to 
one of the same magnitude. However, it is also possible that the effect of CD28 co­
stimulation is the same on both the variant and control samples, and it is simply that the 
control samples are already closer to their maximum proliferative rate.
In humans, memory T cells are generally cells which have switched to express CD45R0 
on their surface. As cells from C77G variant individuals are incapable of doing this, 
memory cells in these individuals would express both CD45R0 and CD45RA. To 
determine whether this differential expression confers an effect on memory cell
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Figure 4.1 Proliferative responses of PBMC from  5 heterozygous C77G and 5 common variant 
C77C individuals. Responses were assayed by thymidine incorporation. Results given are in counts 
per minute (cpm) with each sample being assayed in triplicate. Each line represents the mean of 5 
individuals, with the bars giving the standard error. Figures representative of 3 similar experiments. 
(A) Response to 0.25pg/ml of anti-CD3 (UCHTl-2a) at varying time points. Background less than 
lOOOcpm (data not shown). Analysis o f variance (ANOVA) was performed to determine the 
significance o f the observed difference between the responses o f the PBMC from C77G variant and 
C77C common variant individuals (p=0.08). (B) Response to varying doses of anti-CD3 (UCHT1- 
2a) at 72 hours. Proliferative responses o f the C77C common variant individuals were higher than 
that o f the C77G variant individuals (p=0.04).
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Figure 4.2 Proliferative responses of PBM C from  5 heterozygous C77G and 5 common variant 
C77C individuals. Responses were assayed by thymidine incorporation and results given in counts 
per minute (cpm) with each sample being assayed in triplicate. Each line on the graph represents the 
mean of 5 individuals, with the bars giving the standard error. Figures representative o f 3 similar 
experiments. (A) Response to co-stimulation with 0.25|ig/ml CD3 (UCHTI-2a) and 2.5 pg/ml 
CD28 (15E9) at varying time points. Background was less than 1500 cpm (Data not shown). (B) 
Response to co-stimulation with 2.5pg/ml CD28 (15E9) and varying does to CD3 (UCHTl-2a) at 72 
hours. (C) Response to co-stimulation with 0.25pg/ml CD3 (UCHTl-2a) and varying doses of CD28 
(15E9) at 72 hours.
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function, we investigated the in vitro response to recall antigens. PBMC from C77G 
variant and control individuals were stimulated with Tetanus toxoid or PPD (Purified 
Protein derivative from Mycobacterium Tuberculosis). As most people have previously 
been vaccinated with Tetanus or BCG, re-exposure to these antigens should elicit a 
recall memory response. In accordance with a previous study (Schwinzer and Wonigeit, 
1990) there were no differences in the response to Tetanus toxoid (figure 4.3) or PPD 
(data not shown) between the variant and control groups. Responses to recall antigens 
vary greatly between individuals, and although all individuals in this study gave 
measurable responses, nothing is known about vaccination status, either whether they 
have been vaccinated or how long ago, so further studies on a more defined sample 
group would be desirable. However, these results do suggest that the constitutive 
expression of the CD45RA isoform in C77G variant individuals does not have an effect 
on the memory cell recall response to specific antigens.
4.3.I.2. The exon 6 138G variant carriers
To determine if the increased proportion of CD45R0+ cells in 138G variant individuals 
(Chapter 3) has an effect on proliferative responses, PBMC from 138G variant and 
control individuals were stimulated with varying doses of CD3 (UCHTl-2a). The 138G 
variant allele does not appear to have any effect on the kinetics of the PBMC response 
to CD3 stimulation (Figure 4.4a). However there does appear to be a difference in the 
magnitude of the response with the G138G homozygous individuals showing reduced 
responses compared to both the A138G heterozygous and A138A control groups. Given 
that the phenotypic changes are more extreme in the G138G homozygous individuals, it 
is not a surprise that the biggest differences are found in this group. Analysis of variance 
(ANOVA) showed significant differences between the variant groups (p=0.001), and 
that the variance was different at each time point (p=0.019). Further analysis for each 
time point was carried out using Bumnett’s test for multiple comparison, and showed 
that the response of the G138G homozygous individuals was significantly different 
from both A138A control and A138G variant individuals at all time points (p<0.05). 
The magnitude of the proliferative response to CD3 is reduced in the G138G 
homozygous individuals compared to the A138A controls (P<0.05 for all doses). This 
suggests that the variant allele may have an effect on the efficiency of signalling
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through the CD3 receptor. Due to the lack of sample material available, this data is 
preliminary and has yet to be repeated, preferably on a larger sample group before any 
conclusions can be made.
131
Chapter 4
—■— C om m on variantC77C  
♦ Heterozygote C77G
10,000
9.000
8.000
7.000
6.000 
E 5,000 
« 4,000
3.000
2.000 
1,000
0 1 2 3 4 5 6 7
Time (Days)
Figure 43 Proliferative responses of PBM C from  10 heterozygous C77G and 10 common 
varian t C77C individuals to 5|ig/ml of Tetanus Toxoid at varying time points. Responses were 
assayed by thymidine incorporation. Results given are in counts per minute (cpm) with each sample 
being assayed in triplicate and background subtracted. Each line on the graph represents the mean of 
10 individuals, with bars giving the standard error. Figure representative of 2 similar experiments.
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Figure 4.4 Proliferative responses of PBMC from 4 G138G homozygous, 4 A138G heterozygous 
and 4 A138A common variant individuals. Responses were assayed by thymidine incorporation. 
Results given are in counts per minute (cpm) with each sample being assayed in triplicate. Each line 
on the graph represents the mean of 4 individuals, with bars giving the standard error. (A) Response 
to 0.05pg/ml o f anti-CD3 (UCHTl-2a) at varying time points. Background less than 2000cpm (data 
not shown). Analysis o f variance (ANOVA) showed significant differences between the variant 
groups (p=0.001), and that the variance was different at each time point (p=0.019). Further analysis for 
each time point was carried out using Bumnett’s test for multiple comparison; * p<0.05. (B) Response 
to varying doses o f anti-CD3 (UCHTl-2a) at 72 hours. Analysis o f variance (ANOVA) showed 
significant differences between the variant groups (p=0.001), and that the variance was dose 
dependant (p=0.029). Further analysis was carried out using Bumnett’s test for multiple comparison, 
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4.3.2 Cytokine production
4.3.2.1 The C77G Polymorphism
As previously discussed in section 4.1, different subsets of T cells have differing 
potentials for cytokine secretion. We have demonstrated that the proportions of different 
subsets of cells expressing CD45 isoforms are altered in the CD45 variant individuals 
and this could have an effect on their ability to produce different cytokines. Therefore 
various assays were carried out to determine if there are any differences in the ability of 
the PBMC from variant individuals to produce cytokines.
Elispot assays were performed to determine the proportions of cells which produce 
IFNy, IL-10 and IL-4 in response to stimulation with either CD3 or PHA. No significant 
differences were observed in the proportions of cells producing these cytokines in 
PBMC from C77G and C77C individuals (Figure 4.5). Elispots measure the number of 
cells producing the desired cytokine in response to a particular stimulus. As the Elipsot 
assays were carried out on whole PBMC, it does not give any indication of which cells 
are producing the cytokines. Therefore the ability for EFNy production by different 
subsets of T cells was determined by intracellular staining. It should be noted that 
intracellular staining measures the potential of a cell to produce cytokines, and this may 
not entirely correlate with the amount of cytokine that is actually released from the cell.
Figures 4.6a and 4.6b show that, in accordance with the Elispot data, there is no 
significant difference in the IFNy production by CD4 T cells between C77G and control 
individuals. The C77G CD8 cells, particularly the CD8+ CD45R0 + subset produce less 
IFNy, but this difference is not significant (Figure 4.6d). These results show there is no 
significant difference in the proportion of PBMC secreting cytokines (IFNy, IL-10, IL- 
4) or in the proportions of CD4 and CD8 T cells which have the capacity to produce 
IFNy. However, the total number of cells producing cytokines is not necessarily a 
reflection of the quantity of cytokine being secreted. The cytokine content of the 
supernatants was determined using the human Thl/2 Cytokine Bead Array (CBA) kit 
(BD Pharmingen) for IFNy, TNFa, IL-10, IL-5, IL-4 and IL-2. PBMC from CD45
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Figure 4.5 Cytokine production by PBMC from heterozygous C77G and common variant 
C77C individuals. Elispot assays were carried out to determine IFNy, IL-10 and IL-4 production. 
Results are given as the number o f spot forming cells (SFC) per 106 cells. Each point on the graph 
represents the mean of triplicate samples from one individual, with between 4 and 10 individuals 
assayed for each cytokine. The horizontal bars show the median value for each variant or control 
group. (A) Response to 5 jig/ml CD3 (UCHTl-2a) at 48 hours. (B) Response to lOpg/ml of PHA-P 
at 48 hours.
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Figure 4.6 Intracellular staining for IFNy production. PBMC were stimulated with 50ng/ml PMA 
and 500 ng/ml Ionomycin for 12 hours in the presence o f Golgiplug (BD Pharmingen). Each point on 
the graph represents one individual and the horizontal bars show the median value for each group. 
IFNy production in (A) CD4 cells and (B) CD8 cells from 6 C77G variant and 6 C77C control 
individuals. IFNy production in (C) CD4+CD45R0+ and CD4+ CD45R0- cells and (D) 
CD8+CD45R0+ and CD8+ CD45R0- cells from 6 C77G variant and 6 C77C control individuals.
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variant individuals and controls were stimulated with CD3 (UCHT1) or PMA and 
Ionomycin and cell culture supernatants were removed at 24, 48 and 72 hours post­
stimulation. No significant differences were observed between the C77G heterozygous 
and control individuals for any of the cytokines investigated. Figure 4.7 shows the 
quantities of cytokines detected in the cell culture supernatants 48 hours post­
stimulation. Although quantities varied slightly, similar patterns of cytokine expression 
were observed at 24 and 72 hours post-stimulation (data not shown). This is consistent 
with the previous data, given that the proportions of cytokine producing cells are the 
same in these two groups it is unlikely that the quantities of cytokines produced would 
differ greatly.
4.3.2.2 The 138G Polymorphism
Since CD45R0+ and CD45RA+ cells have different potentials for cytokine expression 
and we demonstrated that 138G variant individuals have an increased proportion of 
CD45R0+ cells, we next studied whether the altered isoform expression has an effect on 
cytokine production.
Elispot assays were performed to determine the proportions of PBMC which produce 
IFNy, IL-10 and IL-4 in response to stimulation with either CD3 or PHA. Although not 
statistically significant Figure 4.8 shows that there is a tendency for G138G 
homozygous individuals, with both CD3 and PHA stimulation, to have a slightly higher 
proportion of cells producing IFNy. No difference was detected in the production of IL- 
10 or IL-4 between these two groups, at least not in the presence of a mainly Thl 
stimuli.
To further analyse the differences in IFNy production between the PBMC from 138G 
and 138A individuals, IFNy production by different subsets of T cells was determined 
by intracellular staining. There is a significant difference in the percentage of both CD4 
and CD8 cells producing IFNy in G138G homozygous individuals, compared to A138A 
controls (Figure 4.9, p<0.05). As the phenotype of CD8 cells in CD45 variant
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Figure 4.7 Cytokine production by PBMC from 5 C77G heterozygous and 5 C77C common 
variant individuals as determined using the human Thl/2 Cytokine Bead Array (CBA) kit (BD 
Pharmingen). PBMC were stimulated with 50ng/ml PMA and 500 ng/ml Ionomycin, and 
supernatants removed at 24, 48 and 72 hours. Each point on the graph represents the mean o f 
triplicate samples from one individual. The horizontal bars show the median value for each variant or 
control group. Amount o f (A) IFNy, TN Fa and IL-2 and (B) IL-10, IL-5 and IL-4 present in cell 
culture supernatants after 48 hours stimulation with PMA and Ionomycin. Similar trends were 
observed at 24 and 72 hours (data not shown).
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Figure 4.8 Cytokine production by PBM C from  G138G homozygous and A138A common 
variant individuals. Elispot assays were carried out to determine IFNy, IL-10 and IL-4 production. 
Results are given as the number o f spot forming cells (SFC) per 106 cells. Each point on the graph 
represents the mean o f triplicate samples from one individual, with between 6 and 9 individuals 
assayed for each cytokine. The horizontal bars show the median value for each variant or control 
group. (A) Response to 5 pg/ml CD3 (UCHTl-2a) at 48 hours. (B) Response to lOpg/ml o f PHA-P at 
48 hours.
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Figure 4.9 Intracellular staining for IFNy production. PBMC were stimulated with 50ng/ml PMA 
and 500 ng/ml Ionomycin for 12 hours in the presence o f Golgiplug (BD Pharmingen). Each point on 
the graph represents one individual and the horizontal bars show the median value for each group. 
Differences between G138G or A138G individuals and A138A controls were analysed using the 
Mann-Whitney test: * p=0.030. IFNy production in (A) CD4 and (B) CD8 cells from A138G variant 
and A138A control individuals. IFNy production in (C) CD4+CD45R0+ and CD4+ CD45R0- cells 
and (D) CD8+CD45R0+ and CD8+ CD45R0- cells from A138G variant and A138A control 
individuals. Differences between A138G or G138G and A138A individuals was analysed using the 
Mann-Whitney test:* p = 0.030.
140
Chapter 4
individuals is always found to be more affected than the CD4 cells, it is not a surprise 
that the effects on IFNy production are more pronounced in the CD8 cells. The effects 
were be more dominant in the CD8+ CD45R0- subset (p<0.05, using the Mann- 
Whitney test).
The above data show that increased proportions of both CD4+ and CD8+ cells from 
138G variant individuals have the potential to produce IFNy. However, having 
increased proportions of cells capable of producing IFNy does not necessarily mean that 
they are actually secreting IFNy or that they are doing so in the same quantities. It is 
possible that these cells are less efficient at releasing IFNy and increasing the proportion 
of cells producing it could be a compensatory mechanism. Therefore an IFNy ELISA 
assay was set up to determine whether the increased proportion of IFNy producing cells 
correlated with an increased quantity of cytokine in the culture supernatants. Figure 
4.10 shows that after stimulation with PMA and Ionomycin, supernatants from G138G 
homozygous individuals contain more IFNy than those from the A138A controls after 
48 hours stimulation (p=0.030). This increase correlates with the increased proportions 
of cells producing the cytokine. Therefore it was important to determine whether the 
production of all cytokines is up-regulated, or that the cytokine response is skewed, 
toward a Thl bias.
To address these issues, the cytokine content of cell culture supernatants was 
determined using the human Thl/2 Cytokine Bead Array (CBA) kit (BD Pharmingen) 
to look at IFNy, TNFa, IL-10, IL-5, IL-4 and IL-2. PBMC from CD45 variant 
individuals and controls were stimulated (with CD3 (UCHT1) or PMA and Ionomycin) 
and cell culture supernatants were removed at 24, 48 and 72 hours post-stimulation. 
Although there are variations in the quantity of cytokine produced, the pattern of the 
produced cytokines was similar at 24, 48 and 72 hours and with CD3 stimulation (data 
not shown). Figure 4.11 shows the quantity of IFNy in the cell culture supernatants 48 
hours post-stimulation with PMA and Ionomycin. Although not statistically significant, 
there is still a consistent trend for an increased amount of IFNy produced after 
stimulation with PMA and Ionomycin, in G138G homozygous individuals. None of the 
other cytokines measured appeared to be different between the PBMC from G138G
141
Chapter 4
homozygote and A138G common variant individuals, suggesting a particular effect on 
IFNy production.
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Figure 4.10 IFNy production by PBM C from  4 G138G homozygous, 4 A138G heterozygous and 
4 A138A common varian t individuals determ ined by Eliza. PBMC were stimulated with 50ng/ml 
PMA and 500 ng/ml Ionomycin, and supernatants removed at 24 and 48 hours. Each point on the 
graph represents the mean of triplicate samples from one individual. The horizontal bars show the 
median value for each variant or control group. Differences between A138G or G138G and A138A 
individuals was analysed using the Mann-Whitney test:* p = 0.030.
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Figure 4.11 Cytokine production by PBMC from 4 G138G homozygous, 4 A138G heterozygous 
and 4 A138A common variant individuals as determined using the human Thl/2 Cytokine Bead 
Array (CBA) kit (BD Pharmingen). PBMC were stimulated with 50ng/ml PMA and 500 ng/ml 
Ionomycin, and supernatants removed at 24, 48 and 72 hours. Each point on the graph represents the 
mean o f triplicate samples from one individual. The horizontal bars show the median value for each 
variant or control group. Amount o f (A) IFNy, TN Fa and IL-2 and (B) IL-10, IL-5 and IL-4 present 
in cell culture supernatants after 48 hours stimulation with PMA and Ionomycin. Similar trends were 
observed at 24 and 72 hours (data not shown).
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4.4 Discussion
In this chapter we have investigated the proliferative responses, and cytokine production 
of PBMC from CD45 variant individuals to various stimuli. We have shown that for 
individuals with the C77G variant allele there are no differences in the proliferative 
responses to polyclonal stimuli such as PHA or PMA and Ionomycin or to recall 
antigens such as Tetanus toxoid or PPD. The responses to recall antigens are 
particularly interesting, as this would indicate that there are no functional differences in 
the CD4 memory cell population in C77G variant individuals, despite the lack of cells 
expressing the single CD45R0 isoform. It is plausible that either the double positive 
(CD45R0+ CD45RA+) cells can function equally well as memory cells, or that the 
increased proportion of antigen experienced CD45RA+ cells have a role in 
compensating for the lack of single CD45R0+ cells. As only CD4 specific stimuli been 
used in this study, the effects on the primed CD8+ CD45RA+ population remains to be 
established. This could be determined by looking at responses to either specific MHC-1 
binding peptides or infectious virus.
PBMC from C77G variant individuals show no difference in response to polyclonal 
stimuli such as PMA and Ionomycin. PMA is a polyfunctional diterpene phorbol ester, 
which is an analogous structure to DAG and so activates protein kinase C, and is not 
cell type specific. As this stimulus works on the signalling cascade down stream of the 
TCR, the role of CD45 in the regulation of the response is likely to be minimal. It 
should also be considered that these proliferation assays are being carried out on PBMC, 
so any effects on a single subset of cells, either in magnitude or kinetics of response, 
may be masked by the response of other cell types. It is therefore possible that either 
more T cell specific stimuli are needed or that separated subsets of cells should be used.
We have investigated the proliferative responses to CD3 stimulation in CD45 variant 
individuals. PBMC from C77G variant individuals show reduced proliferative responses 
to anti-CD3 stimulation (p=0.04). The fact that co-stimulation with CD3 and CD28 
appears to restore the proliferative responses completely in C77G variant cells would 
suggest that these cells do have the same capacity to respond, but are possibly less 
efficient in doing so, perhaps due to an alteration in signalling threshold. This would be
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further supported by the fact that higher doses of CD28 were required to restore the 
level of proliferative responses in PBMC from C77G variant individuals.
Given that primed CD8+ CD45RA+ cells have been shown to have a poor response to 
CD3 stimulation (Wills et al., 1999), and there is a significant increase in the proportion 
of the CD45RA+ cells in the C77G variant individuals, it would possibly be expected 
that the responses in these individuals would be reduced. Perhaps the increased 
proportion of primed or antigen experienced CD45RA+ cells in these individuals can 
help to compensate for the lack of more responsive CD45R0+ cells, although further 
analysis of individual subsets would be required to really establish this.
Given that CD45R0+ T cells have been shown to be more responsive to CD3 
stimulation (Robinson et al., 1993), it is surprising that this was not observed in the 
proliferative response of PBMC from G138G homozygous individuals despite the 
increased proportion of CD45R0+ cells. It is possible that any effect of the increased 
proportion of CD45R0+ T cells is being masked by the presence of other cell types in 
the culture. It is also plausible that these extra CD45R0+ cells are more recently 
activated, and may not be in the same state of differentiation, or are more prone to 
apoptosis. However, stimulation of these cells with PMA and Ionomycin appears to 
restore the proliferative response to the same level as the A138A controls samples (data 
not shown) this would indicate that the PBMC from G138G variant individuals do have 
the same potential to respond. This suggests that these cells are defective or at least less 
efficient in signalling through the TCR. Although given the preliminary nature of this 
data, further analysis would be required to confirm this observation and determine the 
true cause of the reduced response.
One major factor for consideration when interpreting all of the proliferation data is that 
all of the samples used in these experiments have been cryopreserved PBMC. 
Comparisons of fresh and cryopreseved cells from healthy non-variant CD45 donors 
have shown that whilst the proportion of different cell types is preserved with 
cryopreservation, the magnitude of the proliferative response is not. We have shown 
that whilst the hierarchy of individual responses is preserved, i.e. the individual with the 
highest response to stimulation of fresh PBMC still gave the highest response after 
cryopreservation, the magnitude of the response from the cryopreserved PBMC was
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significantly lower than that of the fresh samples (Figure 4.12). As all samples being 
compared in this study are cryopreserved this should not be a particular issue. However, 
it is not known if the effects of cryopreservation are the same in the CD45 variant cells, 
or even if a particular subset of cells is being selectively affected by the freezing 
process. It is possible that as the magnitude of the response is reduced the observed 
differences between the two groups are also reduced, making it harder to detect these at 
a significant level. Another consideration is the effect of cryopreservation on the 
cytokine production abilities of PMBC.
The data on cytokine production in cryopreserved PBMC is variable. In a series of 
studies on the effects of cryopreservation of cytokine secretion, Venkataraman showed 
that cryopreservation of PBMC induced enhanced production of IL-2 (1992), IL-6 
(1994), IFNy (1995), IL-10 (1996) and TNFa (1997) and decreased production of IL-12 
(1996). These studies further suggested that the increase in IL-6 and IL-10 are an 
indirect result of the increase in TNFa production and that the observed decrease in IL- 
12 production is a direct result of the increased IL-10 production. This highly complex 
regulatory system may be a reason for the variability in the results observed from 
different studies. In contrast, Wang et al., (1998) demonstrated that cryopreservation did 
not have an effect on the ability of PBMC to produce IFNy, GM-CSF, TNFa or IL-6 in 
response to PHA stimulation. A further study by Kreher et al., (2003) shows that 
cryopreservation of human PBMC does not have an effect on the production of IFNy, 
IL-2, IL-4 or IL-5 in antigen specific T cells responses as determined by Elispot assays. 
Further to this we have shown by intracellular staining of PBMC from non-variant 
CD45 donors that there is no difference in the percentage of IFNy producing cells after 
cryopreservation (data not shown).
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Figure 4.12 Proliferative responses of PBMC from the same individual to 0.25mg/ml anti-CD3 
(UCHTl-2a) before and after cryopreservation. Responses were assayed by thymidine 
incorporation. Results given are in counts per minute (cpm) with each sample being assayed in 
triplicate. Background was less than 500 cpm (Data not shown). Figure representative of results 
from 4 healthy CD45 common variant individuals. Analysis o f variance (ANOVA) was performed 
to determine the significance o f the observed differences between the sample treatments (p=0.021).
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However, the study of Wang et al., (1998) did indicate a possible increase in IL-2 
production in cryopreserved cells, which they suggest is caused by the DMSO used in 
cryopreservation. This may be particularly relevant as IL-2 is important in driving 
proliferation of cells. This may mean that in CD45 variant individuals rather than the 
altered proportions of cell subsets having a direct effect, the subtle effects observed are 
due to alterations in cytokine production. As all of the samples used in this study have 
been cryopreserved, any effects of cryopreservation should be the same in all of the 
sample groups. Whilst it is therefore fair to compare the different sample groups in this 
study, caution should be taken when trying to interpret the biological significance of any 
observed differences as it is possible that they are exaggerated by the freezing process.
We have demonstrated that there is no significant difference in the ability of PBMC 
from C77G variant and C77C control individuals to produce cytokines (IFNy, TNFa, 
IL-10, IL-5, IL-4 or IL-2). The only trend observed was a slight decrease in the 
proportion of cells producing and the amount of IFNy produced, but this was not found 
to be significant on this small sample group. However, PBMC from G138G variant 
individuals do have an increased proportion of cells, particularly CD8 cells, producing 
IFNy. We have also observed increased quantities of IFNy in cell culture supernatants 
after stimulation of PBMC from 138G variant individuals with either CD3 or PHA. 
Although this increase was consistent for the four individuals tested in this study, this is 
a small sample group, and caution should be taken when generalising such data. 
Interestingly no differences were found in any of the other cytokines tested, suggesting 
that it is not simply an up regulation of all cytokines but a specific up-regulation of 
IFNy in these variant individuals. It is also worth noting that there does not appear to be 
any difference in IL-2 production in PBMC from G138G homozygous individuals, 
suggesting that this is not a cause of the observed reduction in proliferative response. 
Taken together these results suggest that altered CD45 isoform expression can affect 
both the proliferative and cytokine responses of T lymphocytes.
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CD45 mRNA expression in CD45 variant individuals and analysis of 
splicing using minigenes
5.1 Introduction
Alternative splicing is an important mechanism for controlling the expression of genes 
which encode multiple protein isoforms, by utilising different RNA processing 
pathways. These products can be produced by the use of alternative splice donor or 
acceptor sites, the inclusion or exclusion of variant exons or failure to remove introns 
(Breitbart et al, 1987). Alternative splicing is regulated by both cis and trans-acting 
factors and the differential protein expression can be dependant on the tissue type (Laski 
et al, 1986), stage of development (Breitbart and Nadal-Ginard, 1987) or sex (Nagoshi 
et al., 1988).
Alternative splicing of CD45 exons 4, 5 and 6 (also referred to as exons isoforms A, B 
and C) at the N-terminus of the extracellular domain, could generate at least 8 different 
isoforms. Only 5 of these have been detected at the protein level in humans (Streuli et 
al, 1987). There is some evidence at the RNA level, that exons 7, 8 and 10 can be 
alternatively spliced in murine T cells and T cell lines (Chang et al, 1991; Virts et al, 
1998) although, protein expression has yet to be established. The exact function of the 
different CD45 isoforms remains obscure. The variable exons are heavily O- 
glycosylated, and alternative splicing of this region is a conserved feature of CD45 in a 
variety of species (Okumura et al, 1996). This would suggest that the length of the 
region and alterations in the glycosylation pattern may be important for the function of 
CD45 and its interaction with other molecules.
The expression of CD45 isoforms is highly regulated and dependent upon the activation 
and differentiation states of haematopoietic cells (Novak et al, 1994). In humans, it has
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been used to distinguish between different functional subsets of lymphocytes. B cells 
express the high molecular weight (220kD) isoform CD45RABC (also called B220), 
whilst immature CD4+CD8+ T cells express mainly the low molecular weight isoforms. 
Mature CD4+ and CD8+ thymocytes and peripheral T cells can express multiple 
isoforms (Akbar et al., 1988; Mackay, 1990; Ratech et al., 1997). Generally naive T 
cells express the highest molecular weight (CD45RABC) isoform, and switch to express 
the lower molecular weight (CD45R0) isoform upon activation.
Tissue specific splicing of different CD45 iso forms is thought to be controlled by 
negatively regulatory trans-acting factors (Rothstein et al., 1991) which allow the exons 
to be spliced out. However it has been shown that cis-elements within exons are also 
required for tissue specific alternative splicing (Streuli and Saito, 1989). Additionally it 
has been demonstrated that CD45 alternative splicing can be regulated by the 
antagonistic effects of SR protein splicing factors (ten Dam et al., 2000). The tissue 
specific and activation state dependant expression of CD45 isoforms necessitates a 
complex regulatory system, so it is likely to be the quantitative effect of a number of 
different mechanisms which ultimately determines expression.
The feasibility of using CD45 mingenes to examine alternative splicing in different cell 
lines has previously been established. Streuli and Saito (1989) used minigene 
constructs containing the variably sliced exons 4, 5 and 6 to show that the same primary 
transcript is alternatively spliced in B cells and thymocytes. To establish that the exon 4 
C77G point mutation was the cause of the abnormal splicing pattern observed in variant 
individuals, Zilch et al., (1998) introduced the point mutation into a minigene construct 
containing exons 2, 3, 4, 7 and 8. The presence of this single point mutation was 
enough to strongly diminish splicing towards CD45R0, suggesting that it is the cause of 
the variant splicing pattern.
Lynch and Weiss (2001) have described several splicing regulatory elements within 
exon 4, which increase (nucleotides 169-188) or decrease (nucleotides 89-108 and 149- 
168) the inclusion of exon 4 during splicing. The strongest of the regulatory elements 
was the exonic splice silencer (nucleotides 29-88) designated ESS1, which normally 
represses the inclusion of exon 4, by inhibiting the use of the weak 5’ splice site. Lynch
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and Weiss confirmed previous observations (Zilch et al., 1998) that the introduction of 
the C77G point mutation into a minigene containing exons 3, 4 and 7, almost 
completely abolishes the splicing out of exon 4. They associated this abnormal splicing 
with the disruption of the strong exonic splice silencer, ESS1.
Tsai et al., (1989) used a construct containing exons 2, 6 and 8 to investigate which 
portions of the exon 6 sequence are essential for tissue specific alternative splicing. 
Using a series of substitution mutations, they observed that altering the last lObp of the 
exon 6 sequence, lead to skipping of the exon 6 pre-mRNA and therefore the exon was 
always spliced out both in T and B cell lines. Considering these results in the light of 
the observation that individuals with the 138G variant allele, show an increase in the 
proportion of lower molecular weight isoforms expressed, it is plausible that the point 
mutation may promote the splicing out of exon 6.
Whilst several sequence elements have been described which are important in the basal 
level of splicing in resting cells, the sequences responsible for mediating activation- 
induced exon repression are largely unexplored. Rothrock et al., (2003) described a 
conserved signal-responsive sequence that mediates activation induced alternative 
splicing of CD45. This study found that the 60 nucleotide ESS1 sequence in exon 4 is 
sufficient to confer PMA-induced exon repression. Rothrock et al., (2003) showed that 
there is an imperfect repeat sequence which is conserved between ESS1, exon 5 and 
exon 6, and murine exon 7, called the activation-responsive sequence (ARS). It is 
unlikely that the ARS consensus sequence alone is sufficient to confer signal induced 
exon skipping in all contexts, although it is an important regularly element and has been 
found in other alternatively spliced exons, such as the transmembrane exon of CTLA-4. 
Interestingly this study also showed that the C77G point mutation does not have any 
effect on the ARS function of the ESS1 element. This means that whilst the C77G 
polymorphism reduces the basal splice silencing activity of ESS 1 (Lynch and Weiss, 
2001), it does not have an effect on ARS function, and therefore PMA-induced 
repression.
152
Chapter 5
5.2 Objectives
This chapter has two objectives, the first is to analyse CD45 mRNA expression in 
PBMC from CD45 variant individuals and determine if the altered isoform expression 
was due to an effect of the variant allele on splicing. The second objective is to use 
minigene constructs to determine if the introduction of the exon 6 138G mutation alters 
splicing, and thus CD45 isoform expression.
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5.3 Results
5.3.1 CD45 mRNA expression in C77G variant individuals
Individuals with the C77G variant allele constitutively express CD45RA on their T cells 
even after mitogen stimulation. Immunoprecipitation assays and RT-PCR analysis of 
stimulated T cells from variant individuals determined that whilst splicing of the 220kD 
CD45RABC isoform was unaffected, the 205kD CD45RAB isoform lacks proper 
regulation (Schwinzer et al., 1992). We performed RT-PCR analysis on unstimulated 
PBMC to determine the expression pattern of CD45 mRNA in individuals with the 
C77G polymorphism.
Total RNA was extracted from unstimulated PBMCs and after reverse transcription the 
cDNA was amplified with specific CD45 primers spanning exons 2 to 7. Interestingly a 
faint band corresponding to the CD45RA transcript (393bp) was observed in the C77G 
variant samples, which was undetectable in the controls (Figure 5.1). The presence of 
this band was observed in all 4 of the variant individuals tested.
The relative proportion of each transcript was determined by quantifying the size of 
each band as a percentage of the total bands in the sample. Figure 5.2 gives the mean 
values obtained from 4 C77G variant and 4 C77C common variant individuals. In 
agreement with previously published data (Schwinzer et al., 1992) there is a significant 
difference in the proportion of expressed message for the CD45RAB isoform, with 
increased transcript expression for the CD45RAB (26.5 +/- 3.7) and corresponding 
decrease in expression of CD45RB (20.5 +/- 4.9) transcript in C77G variant individuals 
(p=0.03).
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Figure 5.1 CD45 cDNA expression in PBM C from  C77G and C77C individuals. Total RNA was 
extracted from unstimulated PBMC. After reverse transcription, the cDNA was amplified with 
primers spanning exons 2-7 o f the CD45 gene. PBMC from individuals with the variant C77G or 
common C77C alleles contained mRNA for the CD45R0 (197bp), CD45RB (337bp), CD45RA 
(393bp), CD45RBC (480bp), CD45RAB (534bp), and CD45RABC (677bp) isoforms. The bands in 
each line were quantified and the corresponding densitograms shown above. Data shown is 
representative o f duplicate analysis o f 4 variant C77G and 4 control C77C individuals.
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Figure 5.2 CD45 RNA expression in PBM C from  heterozygous C77G and common variant 
C77C individuals. Total RNA was extracted from unstimulated PBMC’s. After reverse transcription, 
the cDNA was amplified with primers spanning exons 2-7 o f the CD45 gene. The bands in each line 
were quantified and graph above shows the expression o f each isoform as a percentage o f the bands 
present in each lane. The values are the mean and standard deviation o f 4 samples (p = 0.030 using 
Mann Whitney Test).
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5.3.2 CD45 mRNA expression in 138G variant individuals
As discussed previously in chapter 3, we have shown that individuals with the exon 6 
138G variant have a higher proportion of T cells expressing CD45R0, in either the 
presence or absence of CD45RA. To establish whether the alteration in CD45R0 
expression is a direct result of the variant 138G allele interfering with splicing, RT-PCR 
analysis was performed on PBMC before and after stimulation with PHA.
Cells from both common (138A) and variant (138G) individuals were stimulated for 10 
days with lOpg/ml PHA and showed complete switching to CD45R0 expression. No 
differences, either qualitative or quantitative, were observed between the samples by 
cell surface staining or RT-PCR analysis.
No qualitative differences were observed when RT-PCR analysis was performed on 
unstimulated PBMC from 138A and variant 138G individuals. Figure 5.3 is a 
representative gel image, showing RT-PCR with exon 2-7 primers for one common 
variant A138A and one homozygous G138G individual. The assay was performed in 
duplicate on four individuals of each genotype. Although there were no qualitative 
differences in terms of CD45 isoforms expressed, on quantifying the intensity of the 
bands a difference in the level of the CD45R0 transcripts was found. This can be clearly 
seen in the corresponding densitogram of the gel image.
Quantifying the size of each band as a percentage of the total bands in the sample, gives 
an indication of the relative proportion of each transcript (Figure 5.4). In PBMC from 
individuals with the A138A common variant, the ratio of the CD45RB to CD45R0 
transcripts is 0.93 (+/- 0.08) whilst for A138G heterozygous individuals it is 0.78 (+/- 
0.33) and for G138G homozygous individuals it is 0.47 (+/- 0.34). These results suggest 
that the 138G variant has a quantitative effect on splicing, with these individuals 
expressing more CD45R0 transcript than the controls.
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Figure 53 CD45 RNA expression in PBM C from  homozygous G138G and common variant 
A138A individuals. Total RNA was extracted from unstimulated PBMC. After reverse transcription, 
the cDNA was amplified with primers spanning exons 2-7 o f the CD45 gene. PBMC from individuals 
homozygous for the variant G138G or common A138A alleles contained mRNA for the CD45R0 
(197bp), CD45RB (337bp), CD45RA (393bp), CD45RBC (480bp), CD45RAB (534bp), and 
CD45RABC (677bp) isoforms. The bands in each line were quantified and the corresponding 
densitograms shown above. Data shown is representative o f duplicate analysis o f  4 A138A and 4 
G138G homozygous individuals.
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Figure 5.4 CD45 RNA expression in PBMC from homozygous G138G, heterozygous A138G 
and common variant A138A individuals. Total RNA was extracted from unstimulated PBMCs. 
After reverse transcription, the cDNA was amplified with primers spanning exons 2-7 of the CD45 
gene. The bands in each line were quantified and the expression o f each isoform is shown as a 
percentage o f the bands present in each lane. The values are the mean o f 4 samples, with error bars 
giving standard deviation. * p= 0.051 (comparison o f  G138G homozygous to A138A common 
variant individuals using Mann Whitney Test).
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5.3.3 Minigene analysis of the exon 6 138G variant allele
Both the phenotypic data (chapter 3) and analysis of mRNA level suggested an increase 
in CD45R0 expression in 138G variant individuals. Therefore we wanted to establish 
whether the 138G variant allele is the cause of this variant splicing.
The use of minigene constructs to study alternative splicing mechanisms offers a 
distinct advantage, they allow normally large genes to be manipulated and analysed by 
only including the parts of the gene that are directly of interest. In the case of CD45, the 
130Kb gene (Hall et al, 1988) consists of 34 exons which encode a mRNA of about 
5.2Kb in length (Ralph et al., 1987), which would be practically impossible to 
manipulate. Therefore minigene constructs have been created which contain various 
exons of interest, usually one or more of the variable exons flanked with at least one of 
the non-variable exons on either side and linked by part of the intron sequence.
We utilised the same minigene constructs used by Tsai et al, (1989) which contain the 
variably spliced exon 6 with part of the flanking intron regions on either side. The wild 
type construct pSV-mini-LCA30 contains exons 2, 6 and 8 of the human CD45 gene 
under the control of the simian virus (sv) 40 early promoter. The LS37 construct is 
identical to the pSV-mini-LCA30 construct except that it has lObp substitution 
mutations of nucleotides 134 to 144 at the 3’ end of exon 6 (Figure 5.5a). Both 
constructs were kindly provided by Dr H. Saito. The A138G point mutation was 
introduced into the pSV-mini-LCA30 construct by site directed mutagenesis using a 
high fidelity Pfu-PCR based method, to create the LSI38 construct.
The three constructs were transiently transfected by electroporation into COS-7 cells. 
After 48 hours the cells were harvested and total RNA extracted. After reverse 
transcription the cDNA was amplified using specific CD45 exon 2 and 8 primers and 
run out on a Visigel separation matrix (Figure 5.6). The two possible alternative splice 
products contain exons 2-6-8 (266bp) and exons 2-8 (122bp), as shown in figure 5.5b. 
Six separate transfections were carried out for each construct and Figures 5.7 shows one 
representative clone for each construct.
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As previously demonstrated by Tsai et al., the wild type pSV-mini-LCA30 construct 
was alternatively spliced in COS-7 cells to give two products, exon 2-6-8 and exon 2-8, 
with the larger exon 2-6-8 being predominant. The LS37 construct also gave the two 
splice products, but was extremely biased towards production of the smaller exon 2-8 
splice product. The observed exon 2-6-8 band for the LS37 construct is slightly smaller 
then for the wild type pSV-mini-LCA30 construct, this is likely due to shortening 
during construction of the linker substitution mutants (Tsai et al., 1989). Although 
attempts were made to confirm the sequence of this band, these were unsuccessful due 
to the small quantity of the PCR product.
The LSI38 construct produced both splice products, and whilst it was not completely 
biased as with the LS37 construct, there was an increase in the proportion of the exon 2- 
8 splice product compared to the controls. The ratio of the exon 2-6-8 to exon 2-8 
bands was calculated for each transfection and the mean of six calculated for each 
construct. The exon 2-6-8 to exon 2-8 ratio of the LSI 38 construct was 6.4 compared to
12.1 for the wild type construct and 0.6 for the LS37 construct. This indicates that 
although it does not cause the constitutive splicing out of exon 6, the 138G point 
mutation has a quantitative effect on the splicing pattern, with the ratio of the two splice 
products being almost half that observed with the wild type construct.
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Figure 5.5 The effect of the exon 6 138G mutation on splicing. (A) Schematic representation o f the 
minigene constructs used.The wild-type pSV-mini-LCA30 construct contains the variable exon 6 
flanked by the constitutive exons 2 and 8. The exons are represented by open boxes, and the introns 
are represented by lines (not drawn to scale). The mutant LS37 has a lObp substitution at nucleotides 
134-144 at the 3 ’ end o f exon 6 (Tsai et al., 1989). As indicated in the schematic, the mutant LS138 
was created by introducing a point mutation (A to G) at position 138 o f Exon 6. (B) The possible 
alternative splice products are indicated, with expected sizes.
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Transfection of COS-7 cells with CD45 minigenes
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2
CO 8
SV40 Promoter A>G 138 SV40 polyA pSP65
Electroporation
48 Hours
RNA
R everse Transcription
cDNA
PCR (CD45 Ex2/Ex8 primers) 
Visigel
Ex2-6-8 2 66bp  Ex2-8 122bp
Figure 5.6 Schematic representation of the CD45 minigene splicing assay. The L SI38 
minigene construct is represented as boxes (exons, with number specification inside) and lines 
(introns). One microgram o f the minigene construct was transiently transfected into COS-7 cells 
by electroporation. After 48hours, total RNA was extracted from the cells and reverse transcribed. 
The cDNA was amplified using CD45 Exon 2 and 8 specific primers. The amplified products were 
run out on a Visigel separation matrix and the bands quantified (See figure 5.7).
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Figure 5.7 RT-PCR analysis of three representative clones expressing the minigenes indicated.
The bands in each lane were quantified and the corresponding densitograms are shown above. The ratio 
between the intensity o f the exon 2-6-8 and exon 2-8 splice products is shown beside the gel and 
represents the mean o f six transfections for each minigene. The bands o f the expected size (266bp for 
exon 2-6-8 and 122bp for exon 2-8) were cloned and sequenced to confirm that they were the correctly 
spliced products. Larger than expected bands were also detected, these are most likely unspliced RNA.
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5.4 Discussion
In this chapter, the RNA expression of CD45 isoforms has been determined in PBMC 
from individuals with variant CD45 isoform expression. Individuals with the exon 4 
C77G polymorphism show constitutive expression of CD45RA containing isoforms. 
Upon mitogen stimulation PBMC from these individuals co-express both CD45RA and 
CD45R0 isoforms, being unable to completely splice the CD45RA containing isoform. 
To date, individuals that are homozygous for the C77G polymorphism have not been 
described, suggesting that this could be a detrimental mutation, not consistent with 
survival. Using RT-PCR analysis with exon 2 to 7 primers on unstimulated PBMC, we 
have demonstrated that there is a quantitative difference in the transcript level for the 
different isoforms.
Consistent with previous studies (Schwinzer et al., 1992), we observed that whilst 
message levels are increased for both the CD45RABC and CD45RAB isoforms, it is the 
CD45RAB isoform which is predominantly affected. There is also a corresponding 
decrease in the expression of CD45RB. Of the three variable exons, is has been shown 
that exon 5 (B) is the least tightly regulated (Streuli et al., 1987), so it is perhaps not that 
surprising that it is the CD45RAB transcript and not just the CD45RA transcript which 
is over-expressed in C77G individuals.
When interpreting data from this study it is important to remember that we are 
describing isoform expression on PBMC, and as isoform expression is known to be cell 
type specific the proportions of different cell types will have an effect on the observed 
transcript. In chapter 3 we demonstrated that the proportions of different cell types were 
not altered in CD45 variant individuals. Therefore it is highly unlikely that any 
differences observed are influenced by an alteration in the proportion of cells, but it is 
possible that either the expression pattern or ratios of different isoforms may be altered 
when describing a specific cell type. This is particularly relevant when considering T 
cells, where other factors such as age and health status can have an influence on isoform 
expression.
We have shown both by flow cytometry and RT-PCR analysis, that PBMC from 138G 
variant individuals have increased expression of CD45R0. Changes in this region of
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exon 6 have been shown to affect isoform expression, promoting the skipping of exon 6 
during splicing (Tsai et al., 1989). Therefore we would suggest that the A to G 
substitution in exon 6 of these variant individuals is the cause of the observed changes 
in isoform expression. To establish this, we utilised the minigene constructs used by 
Tsai et al., which contain exons 2, 6 and 8. We introduced the A138G point mutation 
into the wild type pSV-mini-LCA30 construct to create the LSI38 construct. These 
constructs, along with the previously described LS37 construct which contains the lObp 
substitution in exon 6, were transiently transfected into COS-7 cells. RT-PCR analysis 
produced two alternatively spliced products. Consistent with the previous study, the 
wild type construct gave both splice products, with the larger exon 2-6-8 product being 
predominant. The LS37 construct almost exclusively spliced to the exon 2-8 product, 
showing the preferential exclusion of exon 6. Introducing the A138G point mutation did 
have a quantitative effect on splicing, with the LSI38 construct showing an increase in 
the splicing out of exon 6 compared to the wild type control. This data provides direct 
evidence that it is the 138G mutation which is the cause of the observed alteration in 
splicing and therefore CD45R0 isoform expression in 138G variant individuals.
There are some disadvantages of using such an artificial system for studying splicing 
mechanisms. The first of these is that the exons used in the constructs are not always 
those which would be found adjacent to each other, and therefore they may not behave 
in exactly the same manner. This is also relevant as large portions of the intron 
sequences are omitted from the constructs, and it is possible that there are some 
regulatory elements found within the introns which have been removed.
The model proposed by Tsai et al., (1989) suggests that the lObp substation in exon 6 
reduces the overall similarity of the splice site to the consensus sequence, which would 
result in less efficient recognition by the spliceosome. It is plausible that the A138G 
polymorphism would work in a similar manner, with a slight reduction on the similarity 
of the sequence causing a slight decrease in efficiency. However it is also possible that 
the A138G polymorphism may disrupt an as yet unknown regulatory sequence within 
the exon, as with the disruption of the ESS1 sequence by the C77G polymorphism. 
Clearly further analysis would be needed to properly define the complex splicing 
mechanisms involved.
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CD45 isoform expression in individuals with ‘novel’ CD45 
polymorphisms
6.1 Introduction
The best characterised polymorphism in the PTPRC gene is the previously discussed 
C77G transversion in exon 4. This polymorphism disrupts a strong exonic splice 
silencer, preventing splicing of exon 4, leading to the expression of both high and low 
molecular weight CD45 isoforms on memory T cells. The C77G variant allele has been 
found at increased frequency in HIV-1 positive individuals in the UK (Tchilian et al,
2001), and there is a debated association of the variant allele with multiple sclerosis 
(Jacobsen et al., 2000; Vorechovsky et al., 2001; Ballerini et al., 2002; Miterski et al.,
2002). Jacobsen et al., (2002) described another transversion mutation in exon 4 
(C59A), which presents a similar T-cell phenotype to that observed in individuals with 
the C77G polymorphism. This appears to be extremely rare, being found in one of 311 
MS patients in the study and not elsewhere.
We recently identified the first common CD45 variant with an allele frequency of 
23.7% in the Japanese population and China (E.Tchilian, Personal communication). As 
discussed in chapters 3 and 5, the 138G variant allele promotes splicing on T cells to the 
low molecular weight CD45R0 isoform. In cohorts of Japanese patients, the 138G 
variant allele has a dominant protective effect in Graves’ disease, and G138G 
homozygous individuals were found to be protected against Hashimoto’s thyroiditis, 
both thyroid autoimmune diseases. We have also observed a protective effect against 
Hepatitis B infection (Boxall et al., 2004).
Other recently described polymorphisms in the PTPRC gene are C77T (Pro59Pro) in 
exon 4, G69C (Aspl21His) in exon 5, and T127A (Ilel87Asn) in exon 6 (Gomez-Lira 
et al., 2003). These new polymorphisms were found in Northern Italy at low frequencies
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(0-1%) and their effects on CD45 alternative splicing are currently unknown (Gomez- 
Lira et al., 2003). The main focus of this chapter will be the characterisation of two 
novel exon 4 polymorphisms: A54G (Stanton et al., 2004) and A32G (D.Pretorius, 
personal communication).
The A54G variant results in a semi-conservative amino acid substitution (Thr 19 Ala). 
This A54G variant has been identified in the Ugandan population, but is absent from 
Japanese, Korean, Malawian and UK populations. Given the previously described 
increased frequency of the C77G variant allele in HIV-infected individuals, the 
distribution of the A54G allele was investigated in a cohort of HIV seropositive and 
seronegative individuals in Entebbe, Uganda. There was an increased frequency of the 
A54G variant allele in HIV seropositive Ugandan individuals (6 out of 160 HIV 
seropositive individuals, compared to 1 out of 108 seronegative individuals) which is 
suggestive of it having an effect. However, because of the low sample numbers the 
difference was not statistically significant (p=0.25 by Fishers exact test). No detailed 
analysis of A32G distribution was performed. Since previously described exon 4 
polymorphisms (C77G and C59A) have been shown to have an effect on CD45 
alternative splicing, the aim of this chapter is to determine whether the A54G and A32G 
variant alleles also have an effect.
6.2 Objectives
Recently two novel polymorphisms have been described in the PTPRC gene; A54G in 
exon 4 (Stanton et al., 2004), and A32G in exon 4 (D.Pretorius, personal 
communication). The objective of this chapter is to characterise the CD45 expression on 
T cells from HIV seropositive individuals with these novel CD45 polymorphisms, to 
determine whether they alter CD45 splicing.
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6.3 Results
6.3.1 Phenotypic analysis of T cells from exon 4 A54G variant individuals
As with the C77G polymorphism, the A54G polymorphism is within the region of exon 
4 which has shown to be involved in the regulation of alternative splicing (Lynch and 
Weiss, 2001; Rothrock et al, 2003). To determine whether the A54G variant allele has 
an effect on alternative splicing of CD45, phenotypic analysis was carried out on PBMC 
from HIV seropositive Ugandan individuals. PBMC were obtained from three HIV 
seropositive individuals (one A54G variant and two A54A controls) as determined by 
sequencing (Figure 6.1). To determine the pattern of CD45 expression, the 
cryopreserved PBMC were stained with CD3, CD4 or CD8 against CD45R0 and 
CD45RA or CD45RB and CD45RA. Figure 6.2 shows the CD45 expression profiles of 
CD3+ T cells. Unlike individuals with the C77G variant allele, both the A54G and 
A54A HIV seropositive individuals show the presence of both single and double 
positive CD45R0+ cells (Figure 6.2a). The individual with the A54G variant allele does 
appear to have an increased proportion of CD45R0+ CD45RA+ double positive cells, 
with around 20% of double positive cells compared to around 5% in the two control 
individuals. Whilst this could be an indication of altered CD45 expression, it could also 
be a result of the viral infection as both the disease status and viral load will have an 
effect on the proportions of and phenotype of T cells. Similar patterns of expression 
were observed in both CD4 and CD8 T cells (data not shown). No statistically 
significant differences were observed in the CD45RA CD45RB expression profiles 
(Figure 6.2b). Further analysis on PBMC from healthy HIV seronegative individuals 
with the A54G variant allele will be necessary to determine whether this polymorphism 
has a real effect on the alternative splicing of CD45.
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Figure 6.1 The presence of the A54G polym orphism  was confirmed by sequencing. The box
indicates the A to G transversion at position 54 o f exon 4.
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Figure 6.2. Expression of CD45 isoforms in peripheral T cells in HIV seronegative European 
caucasoids w ith and w ithout the C77G varian t allele and Ugandan HIV seropositive individuals 
w ith and w ithout the A54G varian t allele. PBMC samples were gated on CD3+ cells and 
expression o f (A) CD45RA and CD45R0 and (B) CD45RA and CD45RB was analysed.
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6.3.2 Phenotypic analysis of T cells from exon 4 A32G variant individuals
The exon 4 A32G polymorphism has been identified in HIV seropositive individuals in 
South Africa (collaboration with D.Pretorius, University of Stellenbosch, Tygerberg, 
South Africa). Little is know about this novel polymorphism, so phenotypic analysis 
was carried out to determine whether the A32G variant allele has an effect on 
alternative splicing of CD45. PBMC were obtained from three HIV seropositive 
individuals, two A32G variant and one A32A common variant individuals. To 
determine the pattern of CD45 expression, the cryopreserved PBMC were stained with 
CD4 or CD8 against CD45R0 and CD45RA.
There are obvious differences in the proportions of CD45R0+ CD45RA- CD4+ T cells 
in the A32G individuals, with this subset being twice the size of that in the common 
variant individual (Figure 6.3). Although HIV is known to infect CD4+ T cells, so it is 
probable that these differences are due to differences in the disease progression in these 
individuals. Conversely, in the CD8+ T cells of A32G variant individuals, there is a 
two-fold decrease in the CD45RA- CD45R0+ subset. This is particularly interesting as 
we have previously observed that the C77G polymorphism has a greater effect on CD8+ 
T cells than CD4 cells. It is possible that these altered proportions of cells indicate a role 
for the A32G variant allele in altered CD45 splicing. However, viral infections are 
known to have an effect on the phenotype of CD8+ T cells (Appay et al., 2002) so the 
alterations in the proportions of different subsets may also be due to differences in the 
viral load or stage of disease in these individuals.
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Figure 6 3  Expression of CD45 isoforms in peripheral T cells in Ugandan HIV seropositive 
individuals w ith the A32G varian t allele and A32A control. PBMC samples were gated on (A) 
CD4+ helper cells or (B) CD8+ cytotoxic T cells and expression o f CD45RA and CD45R0 was 
analysed.
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6.4 Discussion
Given this preliminary data it appears unlikely that the A54G variant allele has a 
significant effect on splicing, and there is no abolition of a particular subset as is seen 
with the C77G polymorphism. It is possible that there are subtle alterations in the 
proportions of the different subsets, as is the case with the A138G polymorphism, but 
this would be difficult to distinguish due to the HIV seropositive status of the 
individuals in this study.
The A32G polymorphism does appear to potentially have a greater effect on alternative 
splicing. This polymorphism does not result in the complete loss of any subset, but 
rather appears to have an effect on the proportions of different subsets. It is striking that 
the CD45RA- CD45R0+ subsets of cells is reduced in CD8+ T cells in A32G variant 
individuals. This would be consistent with the expression pattern observed on T cells of 
C77G variant individuals, a particularly relevant comparison as these polymorphisms 
both are within the same regulatory region for splicing of exon 4. However, there is 
little consistency between the expression patterns of the CD4 and CD 8 cells in the 
A54G variant individuals. It is known that HIV infection can have an effect on the 
proportions of different subsets. This makes it difficult to interpret whether the observed 
differences are due to the presence of the variant allele or a simply linked to the viral 
status of the individuals.
To determine the effect of both the A54G and A32G variant alleles on splicing, further 
analysis needs to be carried out on PBMC from healthy HIV-seronegative individuals 
with these polymorphisms. However, to determine the effect and exact mechanism of 
these polymorphisms, molecular studies utilising RT-PCR analysis or minigene 
constructs containing the mutation may be required.
It is interesting that both of these rare polymorphisms have been detected in HIV 
seropositive individuals. Whilst not statistically significant it is notable that the A54G 
variant allele was found at a higher frequency in the HIV seropositive sample group. It 
would be interesting to determine whether the frequency of the A32G allele is also 
altered in HIV seropositive individuals, or other viral infections. Further disease 
association studies will undoubtedly give insights into the subtle effects of these rare
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polymorphisms and may give us a better understanding of the function of the CD45 
isoforms.
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CD45 transgenic mouse models
7.1 Introduction
In humans, naive T cells express high molecular weight exon A containing isoforms, 
but following activation switch to the expression of low molecular weight isoforms 
(CD45R0, and CD45RB low). A majority of memory cells maintain expression of 
CD45R0. CD45 isoform expression in mice is different, with few thymocytes or 
peripheral T cells expressing high molecular weight (CD45RABC) isoforms, whilst 
most express isoforms containing exon B. It is the level of CD45RB isoform expression, 
which separates functionally distinct T cells in mice and rats, with primed cells being 
CD45RB low, whilst CD45RB high cells are a mixture of both naive and primed cells. 
B cells in both humans and rodents predominantly express high molecular weight 
(CD45RA containing) isoforms.
The simultaneous expression of multiple CD45 isoforms on leukocytes makes analysis 
of isoform function difficult. To overcome this issue several studies were carried out in 
which transformed cell lines were transfected with specific isoforms. These studies 
suggest that CD45 phosphatase activity is independent of the extracellular splice 
variant, with the cyoplamsic tail being sufficient to restore TCR signalling (Trowbridge, 
1991; Hovis et al., 1993; Volarevic et al., 1993; Desai et al., 1994). However, other 
studies have given contradictory results with either CD45RABC or CD45R0 being 
found to be more efficient at restoring TCR signalling (Novak et al., 1994; Onodera et 
al., 1996; Doman et al., 2002). This inconsistency is likely due to differences in the 
CD45 negative cell lines, stimuli and assays used. The interpretation of this data is 
further complicated in many studies by an inability to obtain physiological levels of 
isoform expression. This means that effects of the altered expression level may obscure 
any effects of isoform expression. Such limitations with cell line studies have lead to the 
production of CD45 knockout and transgenic mice.
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Kishihara et al., (1993) generated CD45 deficient mice by gene targeting of exon 6. B 
cell development appeared normal in these mice, although they failed to proliferate in 
response to IgM cross-linking. T cell development was blocked at the double positive 
stage, with the few mature T cells detected in the periphery unable to mount a CTL 
response to viral challenge. Whilst these mice suggested a role for CD45 in the 
development and function of T and B cells, endogenous CD45 expression was not 
completely abolished, making the effects difficult to interpret. To overcome this issue, 
Byth et al., (1996) targeted exon 9 to create complete CD45 gene knockout mice. T cell 
development in these CD45-null mice was inhibited at both the double positive and 
single positive stages, leading to reduced numbers of mature T cells in the periphery and 
suggesting a role for CD45 in the regulation of signals through both the pre-TCR and 
TCR. These mice were also found to have increased numbers of IgM high splenic B 
cells and impaired B cell functional activity.
To determine the function of single CD45 isoforms, CD45 transgenic mice were 
created. These mice expressed single CD45RABC and CD45R0 isoforms under the 
control of the proximinal p56lck promoter (Kozieradzki et al., 1997). This gave good 
expression in the thymus, and showed that both isoforms could restore thymic 
development. However, these CD45 trangenic mice were backcrossed onto exon 6 
targeted knockout mice, which express some endogenous CD45 isoforms containing 
exons 4 and 5, and there was a ten fold difference in expression level between the 
CD45R0 and CD45RABC isoforms, making the isoform function difficult to interpret. 
To overcome this issue, Ogilvy et al., (2003) created transgenic mice expressing single 
CD45RB and CD45R0 isoforms, backcrossed onto exon-9 targeted CD45-null mice. In 
this study the transgenes were under the control of vavl gene transcriptional regulatory 
elements, so were expressed specifically throughout the hemopoietic compartment. 
Both isoforms were found to restore thymocyte development and peripheral T cells 
function in the CD45-null mice, with the expression level appearing to be the critical 
factor. However, even at high expression levels neither isoform was capable of fully 
restoring peripheral B cell maturation, suggesting that the role of the CD45 isoforms 
may differ between B and T cells.
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To study the role of CD45 isoforms on peripheral T and B cells we introduced murine 
CD45RABC and CD45R0 cDNA trangenes (Tg) under the control of the human CD2 
promotor into exon-9 targeted CD45 knockout (CD45-/-) mice (Figure 7.1). This 
generated CD45RABC Tg+ CD45-/- (CD45RABC/KO) and CD45R0 Tg+ CD45-/- 
(CD45RO/KO) mice (Tchilian et a l , 2004). These mice show that high-level transgene 
expression of either isoform can restore thymic differentiation, peripheral T cell 
function and immune responses to influenza virus and LCMV. However, as with the 
previous study, it is the expression level, which is critical for these processes.
Measuring T and B cell turnover shows increased CD8 cell proliferation and a block in 
B cell development in both the CD45RABC/KO and CD45RO/KO mice. Despite high 
CD45 expression levels entry to or survival of T cells in the spleen also appears to be 
compromised, resulting in reduced numbers and suggesting that either combinations of 
isoforms or even higher expression of a single isoform may be required. Peripheral T 
cells from these CD45 Tg mice have been found to have an activated phenotype, with 
higher CD44 and CD lla and lower CD62L expression. Whilst numbers and 
proliferation of peripheral B cells appears normal, they are found to have an immature 
phenotype in both CD45RABC/KO and CD45RO/KO mice. This would suggest that 
normal T and B cell differentiation and homeostasis requires not only a certain level of 
CD45 expression, but may also require the expression of particular combinations of 
isoforms.
From our human data we have observed that individuals with either the exon 4 C77G or 
exon 6 138G polymorphism have increased proportions of T cells with a memory / 
activated phenotype. Because of the striking observation that both humans with CD45 
polymorphisms and CD45 Tg mice have increased proportions of activated/memory T 
cells in the periphery, we decided to use the transgenic mice as a model for the C77G 
human polymorphism. C77G heterozygous individuals have one CD45 allele capable of 
normal splicing, but the second allele is unable to splice to the low molecular weight 
isoforms. This results in constitutive CD45RA expression on T cells from variant 
individuals, even after stimulation. To model this situation we crossed CD45RABC/KO 
mice (CD45RABC Tg+ CD45-/-) with wild type (CD45+/+) mice, creating 
CD45RABC/WT mice, which have one fixed and one normally spliced allele. These
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Figure 7.1 T ransgenic constructs. The VAhCD2 cassette was used to generate CD45RABC and 
CD45R0 mice. The CD45cDNAs were inserted into the second exon o f the hCD2 minigene, leaving 
the promoter and first hCD2 exon (depicted by shading) intact. As a poly A signal a 500 bp fragment 
from the 3 ’ untranslated region o f  the hCD2 gene was used (shaded box). The expression cassette 
was separated from the plasmid with Sal I and Not I for microinjection.
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mice were then used, in parallel with the human studies to investigate the effect of 
variant high molecular weight isoform expression on T cell phenotype and function.
7.2 Objectives
To use CD45 transgenic mice expressing one fixed CD45RABC and one wild type 
allele, as a model for the human C77G polymorphism, and analyse the effect of variant 
isoform expression on T cell phenotype and function.
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7.3 Results
The data presented in this chapter is part of an ongoing collaborative project with Dr E. 
Tchilian and Mrs R. Dawes.
One of the major limitations in comparing the transgenic mouse data with that obtained 
from human studies is the difference in total CD45 expression level. In C77G variant 
individuals, total CD45 expression on T cells, monocytes and B cells was found to be 
equivalent to or slightly higher than that of the C77C controls. Despite having high and 
low expressing lines of CD45RABC/KO mice, even in high expressing lines the total 
CD45 expression is 3 to 5 times lower than that of the wild type mice.
As crossing CD45RABC/KO mice with wild type mice created the CD45RABC/WT Tg 
mice, it follows that the total CD45 expression in these mice is not equivalent to wild 
type mice. Therefore, to determine that any effects are due to the difference in isoform 
expression and not expression level, hemizygous (CD45+/-) mice were created as a 
control, by crossing wild type and CD45 knockout mice. In the following experiments 
these mice were also compared to wild type (CD45+/+), CD45 exon-9 targeted 
knockout (CD45-/-) and CD45RABC/KO (CD45RABC Tg+ CD45-/-) mice. To 
establish total CD45 expression level thymus, lymph node and spleen cells were stained 
with a murine panCD45 antibody, an antibody against an epitope present on all CD45 
isoforms (Figure 7.2). Despite having theoretically higher total CD45 expression levels 
than the hemizygous controls, the CD45RABC/WT mice actually appear to have lower 
levels, particularly on lymph node T and B cells, likely due to an effect of the transgene 
and antibody reactivity.
The CD45 knockout mice have a partial block in thymic development, both in the 
transition from double negative to CD4+ CD8+ double positive cells and in the 
maturation of double positive to single positive CD4+ and CD8+ thymocytes. 
Introduction of the CD45RABC Tg (CD45RABC/KO) restores CD4+ thymocyte 
development to near normal levels. In hemizygous (CD45+/-) and CD45RABC/WT 
mice, thymocyte development is completely restored, with normal proportions and 
numbers of both CD4 and CD8 cells in the periphery (Figure 7.3). This shows that not
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Figure 7.2 Total CD45 expression on T and B cells in the thymus, lymph node and spleen from wild type (CD45+/+), CD45RABCAVT and 
hemizygous (CD45+/-) mice. Flow cytometric analysis showing the surface expression of CD45 detected with a pan specific anti-CD45 
monoclonal antibody on CD4, CD8 and CD 19 gated cells from wild type (filled histogram), CD45RABC/WT (red line) and hemizygous (black 
line) mice. Data representative of three similar analyses.
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Figure 7.3 Flow cytometric analysis of thymus, lymph node and spleen cells from wild type (CD45+/+), CD45RABC/WT, hemizygous 
(CD45+/-), CD45RABC/KO and CD45-/- mice. Lymphocytes from the thymus, lymph nodes and spleen were double stained with anti-CD4 and 
anti-CD8 monoclonal antibodies. Data shown is representative o f four similar analyses.
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only is expression level important, but that increased expression of the high molecular 
weight isoforms does not have an effect on the proportions of peripheral T cells.
T cells (CD4 and CD8) from the spleen and lymph node of CD45RABC/KO mice were 
found to have reduced CD3 expression. This expression is restored in both the 
hemizygous and CD45RABC/WT mice, suggesting that this may also be related to level 
rather than isoform expression (Figure 7.4a). Peripheral T cells from CD45RABC mice 
were also found to have an activated phenotype compared to those of wild type mice, 
with up-regulation of CD44 and CD lla and down-regulation of CD62L on CD4 and 
CD8 cells, and up-regulation of Ly6C and CD 122 on CD8 cells. Although further 
characterisation of other markers is still required, both CD45RABC/WT and 
hemizygous (CD45+/-) mice have up-regulated CD44 expression on their peripheral T 
cells compared to wild type mice, particularly in lymph node T cells (Figure 7.4b). 
However, the effect is more pronounced in CD45RABC/WT mice (E.Tchilain, personal 
communication).
CD45 is essential for efficient TCR signal transduction. Lymph node T cells from 
CD45RABC/KO mice were found to proliferate in response to lectins (such as ConA), 
but failed to respond to plate bound anti-CD3s. Comparing lymph node cells from wild 
type and hemizygous mice shows that the magnitude of the response to anti-CD3 is 
reduced in the hemizygous mice (Figure 7.5a). Interestingly at 72 hours post­
stimulation, lymph node cells from CD45RABC/WT mice are actually proliferating as 
well, if not better than the wild type mice. Further analysis shows an alteration in the 
kinetics of this response, with the T cells from these mice responding more rapidly. 
Figure 7.5b shows the proliferative response to 1 pg/ml anti-CD3s, with an initial rapid 
response from the CD45RABC/WT mice after 24 hours and a swifter decline by 96 
hours. The speed and decline of the response also varies with dose of anti-CD3 (data not 
shown). This suggests that both the expression level and isoform expression have an 
effect on T cell proliferative responses.
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Figure 7.4 Characterisation of T cells from the lymph node and spleen of wild type (CD45+/+), 
CD45RABC/WT and hemizygous (CD45+/-) mice. Lymphocytes from the lymph nodes and spleen 
from wild type (filled histogram), CD45RABC/WT (red line) and hemizygous (black line) mice were 
stained with (A) anti-CD3 and (B) anti-CD4 or anti-CD8 and anti-CD44 monoclonal antibodies. Data 
shown is representative o f four similar analyses.
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Figure 7.5 Proliferative responses of lymph node cells from  3 wild type (CD45+/+), 3 
CD45RABC/W T and 3 hemizygous (CD45+/-) mice. Lymph node cells from CD45+/+, 
CD45RABC/WT and CD45+/- mice were stimulated with plate bound anti-CD3 antibody. 
Responsees were assayed by thymidine incorporation. Results are given in counts per minute (cpm) 
with each sample being assayed in triplicate. Each line represents the mean o f three mice, corrected 
for background, with bars giving the standard deviation. (A) Response to varying doses of anti-CD3 
at 72 hours. (B) Response to lpg/ml anti-CD3 at varying time points. Data provided by Mrs R. 
Dawes.
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7.4 Discussion
Studies with transgenic mice expressing single CD45 isofoims clearly show that the 
total level of expression is important. High level expression of either high or low 
molecular weight isoforms restores the development, activation and distribution of 
lymphocytes (Tchilian et a l , 2004). However, even in mice with high levels of 
transgene expression, entry to or survival of T cells in the spleen may be compromised, 
and peripheral T cells have an activated phenotype. The introduction of a single CD45 
wild type allele completely restores T cell development in the thymus and numbers of T 
cells in the spleen, as shown in the CD45+/- and CD45RABC/WT mice.
Despite having restored numbers of T cells, both hemizygous and CD45RABC/WT 
mice have increased proportions of activated T cells (as measured by CD44 expression) 
compared to wild type mice. This effect appears to be more significant in the 
CD45RABC/WT mice. We have previously described that in humans, T cells from 
C77G variant individuals have increased proportions of activated effector type cells. As 
the CD45 expression level on T cells from C77G variant individuals is comparable to 
that of C77C control individuals, the altered phenotype is likely to be caused by the 
altered isoform expression. Given these two observations in mice and humans it is likely 
that both expression level and the balance of expressed isoforms are important, but that 
the effects of one are being masked by those of the other.
The most interesting observation with the CD45RABC/WT mice is the altered 
proliferative response to CD3 stimulation. The hemizygous (CD45+/-) mice show 
reduced proliferative responses to CD3 stimulation at 72 and 96 hours compared to wild 
type mice. The CD45RABC/WT mice respond more rapidly, followed by a rapid 
decline or exhaustion. This response of the hemizygous mice shows that altered 
expression level does have an effect on the proliferative response. The CD45 expression 
level of the CD45RABC/WT and hemizygous mice is not identical, but the slight 
difference would not be expected to cause the observed alteration in kinetics of the 
response of the CD45RABC/WT mice, particularly as the proportions of T cells and 
CD3 expression levels are found to be the same in these mice. This indicates that the 
expression of the high molecular weight isoform is having an effect. Further analysis of 
the CD45RABC/WT mice would be required to determine the cause of this altered
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proliferative response to CD3 stimulation, particularly whether these mice have 
increased numbers of activated cells, or if these T cells have a lower activation 
threshold, so accounting for the rapid initial response. It would be interesting to 
investigate the effect of the altered isoform expression on apoptosis, and to determine if 
this accounts for the rapid decline of the proliferative response.
Preliminary experiments have so far shown no significant difference in the cytokine 
production of whole lymph node cells from wild type (CD45+/+), hemizygous 
(CD45+/-) and CD45RABC/WT mice in response to PMA and Ionomycin stimulation 
(data not shown). Given the altered proliferative responses to CD3, T cell cytokine 
production after CD3 stimulation is an interesting area for further study. Given that B 
cell maturation has previously been suggested to be dependant upon both expression 
level and the combinations of isoforms expressed (Tchilian et al., 2004), this would 
present an interesting area to investigate further, both in the CD45RABC/WT mice and 
humans with CD45 variant alleles.
Presently the mechanisms underlying the altered phenotype and function of 
lymphocytes of both humans with variant CD45 alleles and transgenic mice with altered 
expression of CD45 isoforms at the cell surface remain obscure. The CD45RABC/WT 
mice clearly show that both the expression level and isoform expression have an effect, 
but with the present model it is difficult to separate the effects of these two factors. The 
creation of mice with normal levels of CD45 surface expression, but an altered balance 
of different isoforms (such as single CD45RABC or CD45R0 expression) will provide a 
model to investigate the biochemical events leading to the observed altered phenotype 
and function of lymphocytes. Such a model would also provide an invaluable method of 
determining the immunological mechanisms underlying the disease associations of 
CD45 variant alleles in humans.
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Discussion
CD45 is a haemopoietic cell specific tyrosine phosphatase essential for efficient antigen 
receptor signal transduction in lymphocytes. CD45 is expressed in multiple isoforms in 
a cell type, differentiation and activation-specific manner. However the exact function 
of the different isoforms and the mechanism linking their expression to different 
leucocyte functions remains unclear. In spite of this lack of understanding of CD45 
isoform function, it is clear that altered CD45 expression has major effects in humans. 
Lack of CD45 expression is a cause of severe combined immunodeficiency (SCID) and 
several point mutations of CD45 that cause altered splicing have been described and 
shown to be associated with infectious and autoimmune diseases.
The main objective of this project was to determine how the altered expression of 
alternatively spliced CD45 isoforms affects the function of lymphocytes. Utilising the 
existence of human CD45 polymorphisms (exon 4 C77G and exon 6 138G) we have 
studied the effect of altered CD45 isoform expression on T cell phenotype and function.
The exon 4 C77G polymorphism
The C77G polymorphism is a point mutation in an exonic splice silencer which prevents 
splicing out of exon 4 (Thude et al., 1995). T cells from variant individuals 
constitutively express high molecular weight CD45RA containing isoforms, even after 
stimulation. C77G heterozygous individuals are relatively rare (allele frequency of 0- 
2.3% in Europe, Asia and North America) and no homozygous individuals have been 
described. We have shown that whilst these individuals have normal proportions of 
different cell types, they have altered proportions of different T cell subsets, 
predominantly an increase in the proportion of CD8+ CD45RA+ effector cells. Such 
primed CD45RA+ cells are usually viral specific cells, often associated with CMV 
seroconversion, and are activated cells which have re-expressed CD45RA (Appay et al.,
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2002; Kuijpers et a l, 2003). The increased size of this subset in C77G individuals may 
reflect a failure to efficiently deal with chronic viral infections. As this primed 
CD45RA+ population also increases with age (Hong et al, 2004), the variant and 
control individuals used in this study were age matched where possible, but larger 
matched sample groups should ideally be used.
Given the postulated association of the C77G polymorphism with viral infections and 
autoimmune diseases such as MS, HIV, HCV, autoimmune hepatitis and systemic 
sclerosis, it has been suggested that these individuals may be more susceptible to or less 
efficient at clearing certain viral infections (Jacobsen et al, 2000; Tchilian et a l, 2001; 
Ballerini et a l, 2002; Schwinzer et al, 2003; Vogel et al, 2003). Another striking 
example of this is the increased frequency of C77G variant individuals who were unable 
to clear the hepatitis C virus. This inability to clear chronic viral infection raises some 
interesting questions, particularly with regard to the altered T cell phenotype in variant 
individuals. It is unclear whether it is the presence of the variant allele which affects the 
T cell phenotype, or if the altered phenotype is a result of the infection.
This would make virus specific responses a key area of further study to establish 
whether the larger primed CD8+CD45RA subset is a revertant cell population and if it 
is CMV specific. Tetramers could be used to determine whether these are primed cells 
specific to dominant CMV epitopes, and heteroduplex analysis could be used to detect 
expanded clones within the subset (Maini et a l, 1998; Wills et a l, 2002). However, 
susceptibility to or inability to clear viral infection is unlikely to be purely due to an 
alteration in the proportions of T cell subsets, so other cell types, such as B cells, NK 
cells or APCs should also be analysed. Given the increased total CD45 expression 
observed on monocytes from C77G variant compared to control individuals, this may be 
a particularly relevant cell type for further analysis. Furthermore NK cells have recently 
been shown to have a role in anti-HCV immune responses (Khakoo et al, 2004), 
making NK cell cytotoxicity another potential area of further investigation.
T cells from C77G variant individuals were found to have reduced proliferative 
response to CD3, whilst their responses to soluble recall antigens such as tetanus toxoid 
and PPD appear normal. As primed CD45RA+ cells have been shown to respond poorly 
to CD3 (Appay et a l, 2002), the reduction in the proliferative response may be a
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reflection of the increased proportion of these cells in C77G variant individuals. To date 
all of the proliferative responses have been measured in PBMC cultures. Therefore the 
mitogenic responses of specific T cell subsets could be further dissected using CSFE 
labelling. As CD45 isoform expression alters with time following mitogenic 
stimulation, thymidine incorporation assays using purified cell subsets (CD45RA+ or 
CD45R0+ cells) may also be required to follow the proliferative responses at later time 
points.
As the increased proportion of CD45RA+ primed cells is predominantly observed in the 
CD8 population, the antigen specific responses of this subset also needs to be 
investigated. Possible areas of study could include alio, influenza and EBV-specific 
CTL responses, to determine whether the function of the CD8+ CD45RA+ cells have 
been altered in C77G variant individuals. In addition to assays for general immune 
competence it would also be interesting to determine whether CD45 variant individuals 
have altered responses to disease antigens, with both HBV and HCV being likely 
candidates for study.
The exon 6 138G polymorphism
The second polymorphism analysed in this study is the exon 6 138G polymorphism. 
This is the first common CD45 variant to be described in humans, with nearly 40% of 
the Japanese population being heterozygous and 5.1% homozygous for the G allele 
(Stanton et al., 2003). This polymorphism results in an amino acid substitution 
(Threonine 47 to Alanine) and interferes with alternative splicing. By analysing CD45 
mRNA expression in PBMC from CD45 variant individuals and using minigene 
constructs transfected in COS-7 cells, we have demonstrated that the 138G variant allele 
promotes splicing towards the low molecular weight isoforms. The 138G variant 
individuals therefore have increased proportion of CD45R0+ T cells. We have shown 
that T cells from these individuals contain increased proportions of the highly 
differentiated central memory subset (CD8+ CD45R0+ CCR7-).
Cohorts of patients with Graves’ disease (an autoimmune thyroiditis) or HBV infection 
have reduced number of 138G variant individuals compared to controls, suggesting a
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strong protective effect of the 138G allele (Boxall et al., 2004). The underlying 
mechanisms of this effect are unknown. However, compared to A138A common variant 
individuals, both A138G heterozygous and G138G homozygous individuals have 
increased proportions of T cells capable of producing IFNy in vitro. In Graves’ disease 
there is a shift towards a Th2 cytokine response, which could be counteracted by the 
increased IFNy production in 138G variant individuals (Uchimura et al., 2002). 
Similarly the anti-viral effects of IFNy have also been shown to be a protective 
mechanism in HBV infection (Guidotti and Chisari, 2001).
The high frequency of the 138G variant allele in Japanese, Chinese, Thai and 
Cambodian populations (unpublished data) suggest that it may also affect susceptibility 
and pathogenesis in other autoimmune or infectious disease and could have an 
important effect on disease incidence in a large proportion of the human population. The 
increased proportion of IFNy producing T cells in 138G variant individuals and the 
apparent protective effect of the variant allele in Graves’ disease, a type 2 autoimmune 
thyroiditis, suggest that the variant allele may have an influence in diseases where the 
Thl/Th2 balance is important. This might include conditions such as allergy and 
helminth infections.
The presence of increased proportions of IFNy producing T cells in 138G variant 
individuals raises an interesting question, as to whether this is a specific effect on IFNy 
or whether the expression of other cytokines is also affected. If it is a general effect, 
then is there an up-regulation of all Thl and Th2 cytokines or it is there a bias towards 
production of Thl type cytokines, such as IFNy ? We were not able to detect differences 
in the amount of other cytokines (IL-2, IL-4, IL-5, IL-10, TNFa) produced by T cells 
from 138G variant and A138A control individuals, suggesting that this is a specific 
effect on IFNy production. However, as there can be a difference between the 
proportions of cells capable of producing cytokines and the amount produced may be 
dependant upon the stimulus used, more detailed analyses are required. Polarisation of 
naive cells to Thl or Th2 could be investigated using cytokine blocking antibodies, to 
determine if cells from 138G variant individuals are more easily biased towards a Thl 
response (Messi et al., 2003). Quantification of expression levels of fate-determining T-
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bet and GATA-3 transcription factors could also be used as an indication of T cell 
commitment to either the Thl or Th2 lineage.
CD45 regulates antigen receptor signalling by dephosphorylation of Src kinases and can 
modulate cytokine receptor signalling via Janus Kinases (Jaks) (Irie-Sasaki et al., 2001; 
Hermiston et al., 2003). Given the altered proliferative response to CD3 stimulation 
observed in both CD45 variant individuals and transgenic mice, it would be logical to 
investigate any possible alterations in TCR signalling. Such studies may include Ca 
mobilisation assays and measuring the phosphorylation status and kinase activities of 
p561ck and p59fyn. Since 138G variant individuals show increased IFNy production and 
CD45 knockout mice have been shown to have increased cytokine production, with 
corresponding hyperphosphorylations of Jak 2, Stat 3 and Stat 5 in different cell types 
(Irie-Sasaki et al., 2001), future studies should also determine the kinetics and 
magnitude of phosphorylation events downstream of the cytokine receptors. The basal 
phosphorylation status of Jaks should be measured in various subsets of cells from 
138G variant and A138A control individuals, whilst Stat3 and Stat5 phosphorylation 
should be assessed following activation with cytokines.
Other CD45 polymorphisms
Several other rare CD45 polymorphisms have been described at frequencies of 0-1%, 
but no information is currently available as to their effects on alternative splicing or 
associations with disease (Gomez-Lira et al., 2003). The exon 4 C59A mutation has 
been shown to cause abnormal CD45 splicing, but has so far only been described in one 
MS patient and not elsewhere (Jacobsen et al., 2002). Although not fully characterised 
at present, the novel exon 4 (A54G) polymorphism described in African Ugandan 
populations, is present with increased frequency in HIV seropositive individuals 
(Stanton et al., 2004). Screening for novel polymorphisms in other regions of the CD45 
molecule and ethnic distribution studies of the different polymorphisms may provide a 
basis for future and more detailed disease association studies.
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CD45 transgenic mice
Transgenic mice have previously been constructed which express single high 
(CD45RABC) or low (CD45R0) molecular weight isoforms on a CD45 knockout 
background under the control of the human CD2 promoter (Tchilian et al., 2004). 
Phenotypic analysis and in vivo challenge of these mice with influenza and LCMV 
shows that T cell differentiation and peripheral T cell function are related to the level of 
total CD45 expression rather than isoform. These mice were found to have an increased 
proportion of activated cells and altered proliferative and cytokine responses. It is 
interesting that both in individuals with the C77G and A138G polymorphisms and 
CD45 transgenic mice, CD8 cells appear to be more affected by abnormal CD45 
expression than CD4 cells. This could be indicative of differential requirements of 
CD45 isoform expression during the development of and signalling events in CD4 and 
CD8 cells. Furthermore mice expressing high levels of transgene were found to have a 
block in B cell maturation (Ogilvy et al., 2003; Hong et al., 2004) suggesting a role for 
the expression of combinations of isoforms. As there are a number of parallels in the 
data from the transgenic mice and CD45 variant individuals, further characterisation of 
B cells in CD45 variant individuals may prove an interesting area of further study.
We created a Tg mouse model for the human C77G polymorphism, by crossing 
transgenic mice expressing single CD45RABC isoform on a CD45 knockout 
background with wild type mice. These CD45RABC/WT mice have one normally 
spliced allele and one high molecular weight allele which can not be spliced, so 
mimicking the pattern of CD45 isoform expression observed on T cells from C77G 
variant individuals. Data from the CD45RABC/WT mice suggests that both expression 
level and isoform expression are important in T cell phenotype and function. These 
mice have increased proportions of activated (CD44 high) T cells and altered 
proliferative response to CD3 stimulation. There is a distinct shift in the kinetics of the 
CD3 response, with cells from CD45RABC/WT mice responding faster and declining 
quicker than either the wild type or hemizygous (CD45+/-) mice.
The CD45RABC/WT mice show that both the expression level and isoform expression 
have an effect on T cell phenotype and function, but at present it is difficult to separate 
the effects of these two interrelated factors. Generation of Tg mice with normal levels of
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CD45 surface expression, but an altered balance of different isoforms will provide a 
model to investigate the underlying mechanisms of altered phenotype and function of 
lymphocytes, and of disease associations. Such Tg mice would be an invaluable model 
for investigating the in vivo effects of variant CD45 isoform expression on viral 
infection and autoimmune disease.
In summary, in this study we have shown that altered CD45 isoform expression affects 
T cell phenotype and function. Two different human CD45 variants with contrasting 
phenotypes and disease associations were analysed. The exon 4 C77G polymorphism 
leads to constitutive CD45RA expression, with increased proportions of primed CD8+ 
CD45RA+ cells, and reduced proliferative responses to CD3 stimulation. This 
polymorphism is found at higher frequencies in some autoimmune and infectious 
diseases. In contrast the exon 6, 138G variant allele, promotes splicing towards low 
molecular weight CD45R0 isoforms, with variant individuals having increased 
proportions of central memory and IFNy producing T cells. The 138G variant allele is 
associated with protection against Graves’ disease and hepatitis B.
Although we still do not completely understand how the expression of the alternatively 
spliced isoforms affects lymphocyte functions, we have clearly shown that altered 
isoform expression both in CD45 variant humans and CD45 Tg mice can have profound 
effects on immune functions and diseases. Understanding how the expression of CD45 
isoforms affects immune function is important, as it could lead to the development of 
therapeutic agents targeting CD45 and the signalling pathways that it modulates. It 
could also provide insights into the function of naive and memory cells, leading to new 
strategies for vaccination or immunomodulation.
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